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Abstract
Investigating the Molecular Mechanisms of the Metabolic Syndrome
by Tiffany Jaye Morris
This thesis aims to highlight molecular mechanisms that have been altered by
prenatal undernutrition and may be involved in the metabolic syndrome. Two sepa-
rate studies were conducted both using a rat model developed through manipulation
of the maternal diet to provoke the key features of the metabolic syndrome in adult
offspring. Microarray technology was used to detect changes in gene expression in tar-
get tissues between offspring of control (normally fed, AD) and undernourished (UN)
mothers to obtain a broader picture of the cellular functions and genetic pathways
that may be implicated in the metabolic syndrome.
The first study compared gene expression differences in liver, skeletal muscle, and
white adipose tissue between 55 day old male offspring of AD and UN mothers. No
significant changes were found in muscle or adipose tissue; however, the differences
in the liver suggested the UN animals had been metabolically programmed to favour
fat as an energy source.
To investigate whether DNA methylation might be responsible for the observed
transcriptional changes, pooled liver samples from the first study were used with
the McrBC restriction enzyme assay to determine full, partial, incomplete, or no
methylation between AD and UN. Two differentially expressed genes (Zfand2a and
Mapk4 ) showed methylation changes.
The same liver samples were hybridised to a miRNA array. Two miRNAs showed
a nearly 2-fold upregulation in the UN livers. Both were found to be either directly
or indirectly associated with the metabolic syndrome. MiR-335 has been shown to
be upregulated in the livers of obese/diabetic mice. By association with miR-27a,
miR-451 might be involved in aspects of lipid metabolism in adipose tissue.
A second study used microarray to analyse the liver tissues of day 170 female off-
spring of the same rat model with additional insults (neonatal leptin treatment and
post-weaning high-fat (HF) diet). Leptin has been shown to reverse the programming
effects of the restricted maternal diet and this study aimed to highlight mechanisms
that could be involved in this reversal. The results revealed the importance of the in-
teraction between treatments. Significant gene expression changes were only present
when two or more treatments were combined. This study revealed significantly, dif-
ferentially expressed genes involved in immune function, regulation of the circadian
rhythm, and metabolism.
These findings provide a number of interesting genes and pathways for further
studies and also highlight the need to conduct a thorough study in multiple tissues
at different time-points to pinpoint the window of developmental plasticity.
‘. . .Two roads diverged in a wood, and I I took the one less traveled by, And that
has made all the difference.’ Robert Frost, 1920.
This thesis is dedicated to my family: Scott, Deborah, Crystal and Heather
(and Shelby too!)
Acknowledgements
I would like to begin by acknowledging my supervisor, Professor Nabeel Affara
for his guidance throughout my PhD. My life would be very different right now if it
was not for him. When I arrived in England with my 6-month work visa, he gave me
the opportunity to work in his lab, offered me a PhD studentship, and helped me to
find funding. This has been the experience of a lifetime and it would not have been
possible without his support.
It was nothing less than serendipitous that I ended up in Cambridge, England
working with Prof. Affara. I owe that to Dr. Robert Erickson, from the University of
Arizona. I worked in his lab as an undergraduate. He introduced me to Bioinformatics
and encouraged me to pursue it in my graduate studies. I arrived in Cambridge hoping
to work at the Sanger Institute, but naive to UK work laws, I searched in vain for
a lab that would give me a temporary position on such short notice. Suddenly,
I remembered the box of chocolates that said, ‘To: Tiffany From: England’ and
immediately emailed Dr. Erickson to find out if he knew of a lab in Cambridge...the
rest is history!!
An important thank you goes to my PhD mentor, Professor Stewart Gilmour, for
his help in getting me through my crash course in biochemistry. His contribution to
my work with his ideas and discussion was immensely important.
I would like to thank the many members of the lab that have helped me throughout
my studies: Dr. Carole Sargent and Dr. Anthony Brown for their advice and training,
particularly when I first joined the lab; Julien Bauer for his help and advice on the
analyses in this thesis; Dr. Oriane Chausiaux for her constant support, advice, and
willingness to travel; Dr. Emily Clemente, Dr. Gina Oliver, Claire Wyllie, Sharon
Morris, Kerry Cline, Dr. Alexandra Lopes, Chris Reitter, Dr. Claire Quilter, Dr.
2
Lydia Ferguson, Dr. Peter Ellis and Meena Bagga are all past or present members of
the lab that impacted my experience. It is with pleasure that I will always remember
the tea breaks in the canteen.
Anytime not spent in the lab was usually spent on the river. Thank you to
the girls that took my mind off work and rowed with me in the cold early winter
mornings: Ailsa Benton, Catherine Blake, Ciara Metcalfe, Emma Smith, and many
more through the years!
My PhD was funded by the University of Auckland Liggins Institute because of
Dr. Peter Gluckman whom I am indebted to for giving me this opportunity. I spent a
total of six months in New Zealand on two separate occasions, which was an amazing
experience. I loved working at the Liggins Institute and am especially thankful to:
Dr. Mark Vickers for his help in my understanding of the physiological side of my
project; Dr. Deborah Sloboda for her advice and support; and Dr. Alice Coveny for
the coffee breaks, the chats, the mountain biking and the fun we had at the Perth
Zoo!
I am also appreciative to Dr. Jonathan Hayes for his latex troubleshooting skills
that proved to be very useful as I was writing this thesis. Also his support, advice,
friendship and spaghetti carbonara!!
I am grateful to have completed this writing process in the Vicarage; a special
place full of special people (Nelsy, Ultan, Charm, Nick, Scott, Sandra, and Kaushik).
I have known them only a short time yet they have made an impact. It has been the
perfect place to end this journey and look forward to a new one.
Finally, a big thank you to my supportive and loving family: my sisters Crystal
(especially for her thorough proofreading) and Heather; my parents Scott and Debbie.
Their constant belief in me carried me through the most difficult times in this process.
I have talked about getting a PhD since I was eleven and they are as relieved as I am
that it is finally complete.
This thesis was created using the LATEX typesetting system (MiKTeX 2.8 package for
Microsoft Windows). The figures were prepared with CorelDraw 10.0 software.
3
Author’s Declaration This dissertation is the result of my own work that was
performed between October 2006 and October 2009. It contains nothing which is
the outcome of work done in collaboration with others, except as specified in the
text. The results presented in this thesis have not been submitted for any other
degree or diploma. The thesis does not exceed the prescribed word limit of 60,000
words as set by the School of the Biological Sciences.
Tiffany Jaye Morris MSc
Contents
Table of Contents i
List of Tables vii
List of Figures xi
Abbreviations xii
1 Introduction 1
1.1 The Metabolic Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.1.2 Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2 Developmental Plasticity . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.3 DoHaD and Maternal Nutrition . . . . . . . . . . . . . . . . . . . . . 5
1.4 An Evolutionary Perspective . . . . . . . . . . . . . . . . . . . . . . . 5
1.4.1 Thrifty Genotype/Thrifty Phenotype . . . . . . . . . . . . . . 6
1.4.2 Predation Release Hypothesis and Genetic Drift . . . . . . . . 7
1.4.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
1.5 Epidemiological Data . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.5.1 Dutch Hunger Winter . . . . . . . . . . . . . . . . . . . . . . 9
1.5.2 Pima Indians . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.5.3 Cohort Studies . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.6 Animal Models of the Metabolic Syndrome . . . . . . . . . . . . . . . 12
1.6.1 Maternal Diets . . . . . . . . . . . . . . . . . . . . . . . . . . 13
i
1.6.2 Postnatal Diets . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.6.3 Hormonal Insults . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.6.4 Surgical Interventions (Reduced Placental Transfer by Uterine
Artery Ligation) . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.6.5 Genetic Models . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.6.6 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
1.7 Mechanisms of Nutritional Programming . . . . . . . . . . . . . . . . 19
1.8 Microarray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
1.8.1 microRNA Arrays . . . . . . . . . . . . . . . . . . . . . . . . . 22
1.8.2 Microarray Applied to Developmental Plasticity . . . . . . . . 22
1.9 Structure and Aims of the Thesis . . . . . . . . . . . . . . . . . . . . 23
2 General Methods 25
2.1 Animal Care/Sample Collection . . . . . . . . . . . . . . . . . . . . . 25
2.2 RNA Extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.2.1 For Oligonucleotide Expression Array (Undernutrition Study
and Leptin Study) . . . . . . . . . . . . . . . . . . . . . . . . 25
2.2.2 For microRNA Expression Array . . . . . . . . . . . . . . . . 26
2.2.3 Quality Assessment . . . . . . . . . . . . . . . . . . . . . . . . 26
2.3 Microarray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3.1 Experimental Design . . . . . . . . . . . . . . . . . . . . . . . 27
2.3.2 Quality Control . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3.3 Reducing Error . . . . . . . . . . . . . . . . . . . . . . . . . . 29
2.3.4 Data Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.3.5 Validation of Microarray Data: Quantitative Real Time PCR . 30
2.3.6 Mouse Exonic Evidence Based Oligonucleotide Expression Array 30
2.3.7 Illumina BeadArray . . . . . . . . . . . . . . . . . . . . . . . . 34
2.3.8 microRNA Expression Array . . . . . . . . . . . . . . . . . . . 37
2.3.9 Filtering, Data Visualisation and Normalisation . . . . . . . . 38
2.3.10 Selection of Differentially Expressed Genes . . . . . . . . . . . 40
ii
2.3.11 Gene Ontology Analysis . . . . . . . . . . . . . . . . . . . . . 42
2.4 Polymerase Chain Reaction . . . . . . . . . . . . . . . . . . . . . . . 43
2.4.1 Genomic PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
2.4.2 Comparative Quantitative Real Time RT-PCR . . . . . . . . . 43
2.5 DNA Extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
2.5.1 From Tissue (Undernutrition Study) . . . . . . . . . . . . . . 44
2.5.2 Following RNA extraction . . . . . . . . . . . . . . . . . . . . 44
2.6 Methylation PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2.7 Bisulphite Sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3 Expression Study of rats undernourished in utero 47
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3.1.1 Energy Balance and Starvation . . . . . . . . . . . . . . . . . 48
3.1.2 Genes/Pathways Highlighted in Other Studies . . . . . . . . . 56
3.1.3 Initial Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.2.1 Previous Findings: Phenotypic Assessment . . . . . . . . . . . 58
3.2.2 Microarray . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.2.3 QRT-PCR for Microarray Verification . . . . . . . . . . . . . . 87
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
3.3.1 Glucose Metabolism . . . . . . . . . . . . . . . . . . . . . . . 92
3.3.2 Insulin and IGF-1 Signalling . . . . . . . . . . . . . . . . . . . 93
3.3.3 Mitochondrial Activity . . . . . . . . . . . . . . . . . . . . . . 93
3.3.4 Fat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
3.3.5 Ribosomal Proteins and Protein Turnover . . . . . . . . . . . 95
3.3.6 Effects on Gene Transcription . . . . . . . . . . . . . . . . . . 96
3.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
4 Leptin Reversal Study 108
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.1.1 Leptin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
iii
4.1.2 Leptin Receptor . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.1.3 Genetics of Obesity . . . . . . . . . . . . . . . . . . . . . . . . 111
4.1.4 Energy Balance: Interactions of Leptin and the Brain . . . . . 112
4.1.5 Leptin and the Circadian Rhythm . . . . . . . . . . . . . . . . 115
4.1.6 Leptin During Pregnancy, Lactation and Puberty . . . . . . . 119
4.1.7 Leptin Differences in the Sexes . . . . . . . . . . . . . . . . . 119
4.1.8 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.1.9 Initial Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 126
4.2.1 Illumina Microarray . . . . . . . . . . . . . . . . . . . . . . . 126
4.2.2 qRT-PCR for Microarray Validation . . . . . . . . . . . . . . 158
4.2.3 Comparison of Treatment Groups . . . . . . . . . . . . . . . . 158
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
4.3.1 Cluster 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
4.3.2 Genes Involved in the Immune Response . . . . . . . . . . . . 175
4.3.3 Relevant Genes in Other Clusters . . . . . . . . . . . . . . . . 176
4.3.4 Candidate Genes . . . . . . . . . . . . . . . . . . . . . . . . . 176
4.3.5 Adipose Tissue . . . . . . . . . . . . . . . . . . . . . . . . . . 177
4.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
5 Methylation Study 179
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 179
5.1.1 Epigenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . 180
5.1.2 Epigenetic Change, Developmental Programming, and the Metabolic
Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 183
5.1.3 Available Techniques for Methylation Analysis . . . . . . . . . 185
5.1.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
5.1.5 Study Design . . . . . . . . . . . . . . . . . . . . . . . . . . . 187
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
iv
5.3.1 Zfand2a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
5.3.2 Mapk4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
5.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
6 microRNA Expression Study 200
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
6.1.1 microRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
6.1.2 Study Design . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
6.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 207
6.2.1 Data Quality Control . . . . . . . . . . . . . . . . . . . . . . . 207
6.2.2 Normalisation . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
6.2.3 Differential Expression . . . . . . . . . . . . . . . . . . . . . . 218
6.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225
6.3.1 miR-335 Implicated in Lipid Metabolism . . . . . . . . . . . . 226
6.3.2 miR-451 Expression in Human Cancer Cells and Possible As-
sociation with Adipocyte Differentiation . . . . . . . . . . . . 227
6.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 229
7 General Discussion and Future Work 230
7.1 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 230
7.1.1 Gene Expression Profiling Male 55 day old Rats Exposed to
Maternal Undernutrition in utero . . . . . . . . . . . . . . . . 231
7.1.2 Gene Expression Profiling Female 170 day old Rats Exposed to
Maternal Undernutrition in utero, Postnatal Leptin and post-
weaning High Fat Diet . . . . . . . . . . . . . . . . . . . . . . 231
7.1.3 Methylation Assay on Male 55 day old Rats Exposed to Ma-
ternal Undernutrition in utero . . . . . . . . . . . . . . . . . . 232
7.1.4 MiRNA Expression Profiling of Male 55 day old Rats Exposed
to Maternal Undernutrition in utero . . . . . . . . . . . . . . 233
7.2 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
v
A Primer Lists 235
B Publications and Presentations 241
C Supplementary Data 242
References 243
vi
List of Tables
3.1 Day 55 Phenotype Data . . . . . . . . . . . . . . . . . . . . . . . . . 59
3.2 Day 110 Phenotype Data . . . . . . . . . . . . . . . . . . . . . . . . . 60
3.3 Illumina Gene List . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
3.4 Fold Change Values Comparing Microarray and QRT-PCR . . . . . . 89
3.5 Functional Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
4.1 Day 170 Phenotype Data . . . . . . . . . . . . . . . . . . . . . . . . . 125
4.2 Biological Processes of Clusters . . . . . . . . . . . . . . . . . . . . . 149
4.3 Leptin Gene List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
4.4 Leptin Gene Biofunctions . . . . . . . . . . . . . . . . . . . . . . . . 170
5.1 Methylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
6.1 miRNA Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 225
A.1 Expression Primers1 . . . . . . . . . . . . . . . . . . . . . . . . . . . 235
A.2 Expression Primers2 . . . . . . . . . . . . . . . . . . . . . . . . . . . 236
A.3 Lillycrop Expression Primers . . . . . . . . . . . . . . . . . . . . . . . 236
A.4 Methylation Primers2 . . . . . . . . . . . . . . . . . . . . . . . . . . . 237
A.5 Methylation Primers3 . . . . . . . . . . . . . . . . . . . . . . . . . . . 238
A.6 Methylation Primers5 . . . . . . . . . . . . . . . . . . . . . . . . . . . 239
A.7 Lillycrop Methylation Primers . . . . . . . . . . . . . . . . . . . . . . 239
A.8 Bisulphite Primers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 240
vii
List of Figures
2.1 Rat Samples on Mouse MEEBO . . . . . . . . . . . . . . . . . . . . . 31
2.2 Bead Array Image . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.1 Major Sites of Insulin Action . . . . . . . . . . . . . . . . . . . . . . 49
3.2 Major Sites of Glucagon Action . . . . . . . . . . . . . . . . . . . . . 49
3.3 Basal State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.4 Gluconeogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
3.5 Tissue Interrelationships During Fasting . . . . . . . . . . . . . . . . 54
3.6 Starved State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.7 Effects of Maternal Nutrition on Lipid Metabolism . . . . . . . . . . 56
3.8 Study Design of Rats Undernourished in Utero . . . . . . . . . . . . . 58
3.9 MEEBO Dye Swap . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.10 Pre-Normalisation MEEBO Density Plot . . . . . . . . . . . . . . . . 62
3.11 Amplitude in Red Channel . . . . . . . . . . . . . . . . . . . . . . . . 62
3.12 Amplitude in Green Channel . . . . . . . . . . . . . . . . . . . . . . . 63
3.13 MEEBO MA plot . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.14 Illumina Microarray Study Design . . . . . . . . . . . . . . . . . . . . 66
3.15 Illumina Internal Controls. . . . . . . . . . . . . . . . . . . . . . . . . 68
3.16 Hierarchical Clustering of All Tissues Before Normalisation. . . . . . 69
3.17 Pairwise Comparison of AD Liver Samples Before Normalisation. . . 70
3.18 Pairwise Comparison of UN Liver Samples Before Normalisation. . . 71
3.19 Pairwise Comparison of AD Muscle Samples Before Normalisation. . 72
3.20 Pairwise Comparison of UN Muscle Samples Before Normalisation. . 73
viii
3.21 Pairwise Comparison of AD WAT Samples Before Normalisation. . . 74
3.22 Pairwise Comparison of UN WAT Samples Before Normalisation. . . 75
3.23 Boxplot Before Normalisation . . . . . . . . . . . . . . . . . . . . . . 77
3.24 Density Plot Before Normalisation . . . . . . . . . . . . . . . . . . . . 77
3.25 Boxplot After Quantile Normalisation. . . . . . . . . . . . . . . . . . 78
3.26 Density Plot After Quantile Normalisation. . . . . . . . . . . . . . . . 78
3.27 Microarray Validation by qRT-PCR . . . . . . . . . . . . . . . . . . . 88
3.28 Microarray Validation by qRT-PCR . . . . . . . . . . . . . . . . . . . 88
3.29 Genes that Influence Glucose, Fat and Energy Metabolism Pathways
and IGF-1 and PI3 Signalling Pathways. . . . . . . . . . . . . . . . . 91
4.1 Leptin and the Starvation Response . . . . . . . . . . . . . . . . . . . 115
4.2 Leptin and the Homeostatic Pathway . . . . . . . . . . . . . . . . . . 116
4.3 Leptin Receptor Expressing Neurons . . . . . . . . . . . . . . . . . . 117
4.4 Insulin Leptin Reward . . . . . . . . . . . . . . . . . . . . . . . . . . 118
4.5 Design of Leptin Reversal Study . . . . . . . . . . . . . . . . . . . . . 122
4.6 Results From Vickers 2005 et al. . . . . . . . . . . . . . . . . . . . . . 124
4.7 Microarray Design for Leptin Reversal Study . . . . . . . . . . . . . . 126
4.8 Hierarchical Clustering of Raw Leptin Array Data . . . . . . . . . . . 128
4.9 Summary of Leptin Internal Controls . . . . . . . . . . . . . . . . . . 129
4.10 Pairwise Comparison of ADSALCHOW Samples Before Normalisation. 130
4.11 Pairwise Comparison of UNSALCHOW Samples Before Normalisation. 131
4.12 Pairwise Comparison of ADLEPCHOW Samples Before Normalisation. 132
4.13 Pairwise Comparison of UNLEPCHOW Samples Before Normalisation. 133
4.14 Pairwise Comparison of ADSALHF Samples Before Normalisation. . . 134
4.15 Pairwise Comparison of UNSALHF Samples Before Normalisation. . . 135
4.16 Pairwise Comparison of ADLEPHF Samples Before Normalisation. . 136
4.17 Pairwise Comparison of UNLEPHF Samples Before Normalisation. . 137
4.18 Boxplot before Normalisation . . . . . . . . . . . . . . . . . . . . . . 138
4.19 Density Plot Before Normalisation . . . . . . . . . . . . . . . . . . . . 138
ix
4.20 Boxplot After Quantile Normalisation . . . . . . . . . . . . . . . . . . 139
4.21 Density Plot After Quantile Normalisation . . . . . . . . . . . . . . . 139
4.22 Venn Diagram of Overlap Between FSPMA Gene Lists . . . . . . . . 140
4.23 Genes Present in Pairwise Comparisons . . . . . . . . . . . . . . . . . 141
4.24 Hierarchical Clustering of Data Analysed by One-Way ANOVA . . . 144
4.25 Biological Processes Found by FSPMA . . . . . . . . . . . . . . . . . 145
4.26 Molecular Functions Found by FSPMA . . . . . . . . . . . . . . . . . 146
4.27 Cellular Components Found by FSPMA . . . . . . . . . . . . . . . . 147
4.28 qRT-PCR Data for Cyclophilin Control . . . . . . . . . . . . . . . . . 159
4.29 Microarray Expression Data 1 . . . . . . . . . . . . . . . . . . . . . . 160
4.30 Microarray Validation by qRT-PCR 1 . . . . . . . . . . . . . . . . . . 161
4.31 Microarray Expression Data 2 . . . . . . . . . . . . . . . . . . . . . . 162
4.32 Microarray Validation by qRT-PCR 2 . . . . . . . . . . . . . . . . . . 163
4.33 Comparison of Treatment Effects for Gck and Per2 . . . . . . . . . . 164
4.34 Comparison of Treatment Effects for Igfbp2 and Igfbp4 . . . . . . . . 164
4.35 Comparison of Treatment Effects for Rt1-ba and Rt1-149 . . . . . . . 165
4.36 Comparison of Treatment Effects for Rt1-m6-2 and Ca3 . . . . . . . 165
4.37 Gluckman et al. qRT-PCR Comparison . . . . . . . . . . . . . . . . . 166
4.38 Effect of Treatment on Array Signals for Candidate Genes . . . . . . 167
4.39 Differentially Expressed Genes for Two Studies. . . . . . . . . . . . . 168
4.40 Comparison of Treatment Effects for Klf15 and Enpp2 . . . . . . . . 175
5.1 Methylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181
5.2 Diet and Methylation . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
5.3 Methylation Techniques . . . . . . . . . . . . . . . . . . . . . . . . . 188
5.4 Methylation Analysis Pipeline . . . . . . . . . . . . . . . . . . . . . . 189
5.5 PCR of McrBC Methylation Assay 1 . . . . . . . . . . . . . . . . . . 194
5.6 PCR of McrBC Methylation Assay 2 . . . . . . . . . . . . . . . . . . 195
6.1 miRNA Biogenesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
6.2 miRNA Processes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
x
6.3 miRNA Internal Controls . . . . . . . . . . . . . . . . . . . . . . . . . 209
6.4 Hierarchical Clustering of Raw miRNA Data . . . . . . . . . . . . . . 210
6.5 MA Plot of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . . . 211
6.6 MA Plot 2 of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . . 212
6.7 MA Plot 3 of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . . 213
6.8 Boxplot of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . . . 214
6.9 Density Plot of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . 215
6.10 Heatmap of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . . . 216
6.11 Mean SD of Raw miRNA Data . . . . . . . . . . . . . . . . . . . . . 217
6.12 Pairwise Comparison of AD Liver miRNA Samples After Normalisation219
6.13 Pairwise Comparison of UN Liver miRNA Samples After Normalisation220
6.14 Boxplot miRNA Samples After Quantile Normalisation. . . . . . . . . 221
6.15 Density Plot of AD miRNA Samples After Quantile Normalisation. . 222
6.16 Density Plot of UN miRNA Samples After Quantile Normalisation. . 223
6.17 miR335 Expression in WT Tissues . . . . . . . . . . . . . . . . . . . 228
6.18 miR335 Liver Expression in Diabetes/Obesity Mouse Models . . . . . 228
xi
List of Abbreviations
AD ad-libitum fed
ALSPAC Avon Longitudinal Study of Parents and Children
ANOVA analysis of variance
ATP adenosine triphosphate
BLAST Basic Local Alignment Search Tool
cDNA complementary deoxyribonucleic acid
CHOW post-weaning normal chow diet
CpG areas of sequence rich in C’s and G’s
Ct threshold cycle value
Cy3/Cy5 cyanine fluorescent dyes (cyanine 3/5)
DAVID Database for Analysis, Visualization, Integrated Discovery
DNA deoxyribosenucleic acid
dNTP deoxyribosenucleic triphosphate
DoHaD developmental origins of health and disease
EDTA ethylenediamine tetra acetic acid
EST expressed sequence tag
FDR false discovery rate
FSPMA Friendly Statistical Package for Microarray Analysis
g grams
HF post-weaning high fat
KDE Knowledge Discovery Environment Software
LEP leptin treatment
log2 base-2 logarithmic
MEEBO Mouse Exonic Evidence Based Oligonucleotide
mg/kg milligrams/kilograms
Milli Q Milli Q grade water
miRNA micro RNA
ml milli litre
mM milli molar
mRNA messenger ribonucleic acid
µg micro gram
µl micro litre
MgCl2 magnesium chloride
Na2 sodium
NaCl sodium chloride
NCBI National Centre for Biotechnology Information
ng nanograms
xii
nm wavelength
PAR predictive adaptive response
PCR polymerase chain reaction
PolyA poly deoxyadenosine
p-value probability value
qRT-PCR quantitative reverse transcription polymerase chain reaction
RNA ribonucleic acid
rpm revolutions per minute
SAL saline treatment
SD standard deviation
SSC saline sodium citrate
ssDNA single stranded DNA
TAE tris-acetate albumin
TCA cycle The Citric Acid Cycle
Tm melting temperature
Tris tris(hydroxymethyl)aminomethane
tRNA transfer ribonucleic acid
UN undernourished
UTR untranslated region
VST variance-stabilising transformation
xiii
Chapter 1
Introduction
This thesis aims to investigate the molecular mechanisms behind the rising inci-
dence of metabolic syndrome related disorders. The work included here investigates
the metabolic effects of the nutritional environment by comparing the genetic makeup
of different phenotypes and considering this in light of the evolution of diet. The in-
tended outcome of this research is to enable us to gain a better understanding of
the molecular mechanisms that signal the body to utilise nutrients, store fat, and feel
hunger. This introduction provides the background on the theories behind the process
of development, the selection for our current biological makeup, and the evolution
of diet that has driven humans to develop this way. The background on microarray
will give details of the technique that is most important to the data presented in
this thesis. Each chapter in this thesis will begin with an introduction of its own to
present more detailed background on relevant topics.
1.1 The Metabolic Syndrome
In the 1920s, observations revealed that risk factors including obesity, hyperlipi-
daemia, and hypertension tended to occur together. This was termed ‘syndrome X’
and it was proposed that insulin resistance might be the underlying mechanism [1].
Today, this clustering of metabolic abnormalities is referred to as the metabolic syn-
drome. It occurs when several risk factors occur together in a single person. These
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risk factors include: obesity, insulin resistance or intolerance to glucose, proinflamma-
tory state, prothrombotic state, atherogenic dyslipidemia, and higher blood pressure.
Metabolic syndrome was defined in 2006 by the International Diabetes Federation
(IDF) as central obesity and two of the following: raised triglycerides, reduced HDL
cholesterol, elevated blood pressure, and elevated plasma glucose.
Understanding the metabolic syndrome has become important as studies have
shown that individuals with the metabolic syndrome are six times more likely to
develop diabetes, 2-3 times more likely to develop cardiovascular disease, and are
likely to suffer from obesity, particularly visceral obesity [2].
1.1.1 Obesity
The rate of obesity is quickly increasing worldwide. Before the 20th century
obesity was rare, but in 2005 it was estimated that 9.8% of adults are obese with
rates in the United States, Australia, and Canada increasing rapidly compared to the
overall rate (WHO organisation fact sheet). The growing obesity problem is impact-
ing human morbidity, mortality and quality of life, and results in costly healthcare.
With the increasing number of young obese women, obesity during pregnancy is also
a problem. This can have negative maternal health effects, can cause risks during
pregnancy, and can lead to persistent problems in the developing child. Type-2 dia-
betes is also becoming more common and affects particular groups of people with a
higher frequency.
1.1.2 Diabetes
Type-2 diabetes mellitus is characterised by high blood glucose associated with
insulin resistance and relative insulin deficiency. It is related to the inability to make
or respond to insulin. Fat and muscle cells require insulin to absorb glucose. If these
cells fail to respond to insulin, blood glucose levels will rise. The liver helps regulate
glucose levels by reducing the secretion of glucose in the presence of insulin. However,
if an individual is insulin resistant the liver’s production of glucose will not decrease.
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Insulin resistance normally refers to the reduced ability of insulin to lower glucose.
Other functions of insulin can also be affected: insulin resistance in adipocytes re-
duces uptake of circulating lipids and increased mobilisation of stored lipids in these
cells elevates free fatty acids in the blood plasma. The elevated blood fatty-acid con-
centrations, reduced muscle glucose uptake, and increased liver glucose production
all contribute to elevated blood glucose levels. A major component of the metabolic
syndrome is the high plasma levels of insulin and glucose due to insulin resistance.
If an individual is insulin resistant they can develop hyperglycemia (excessive blood
glucose) after a meal. The inability of the pancreatic β-cells to produce sufficient in-
sulin to maintain normal blood sugar levels is what causes the transition from insulin
resistance to type-2 diabetes [3].
The occurrence of diabetes often coincides with obesity and other symptoms of
the metabolic syndrome. Diabetes has been correlated with low birth weight and has
also been tied to poor maternal nutrition [4]. A better understanding of the cause of
metabolic syndrome and the metabolic pathways that have been altered could lead
to better treatment and hopefully prevention.
1.2 Developmental Plasticity
Developmental plasticity describes the time during development when organs and
body systems are sensitive to the environment and can change structure and func-
tion [5]. Intrauterine life is a critical point in development. Environmental factors
can have a large impact on fetal growth. Gestation is considered a time of develop-
mental plasticity because it is a period when organs and body systems are plastic
and particularly sensitive to developmental cues. The changes that occur during
these sensitive developmental windows are often irreversible. This permits a range
of phenotypes to develop from a single genotype depending on environmental con-
ditions [6, 7]. Different environments can directly induce changes in an individual’s
behaviour, morphology and physiology. This plasticity is adaptive, in that individu-
als that show a plastic response have higher fitness (potential to reach reproduction)
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than those that do not [8]. The responses can be immediate and short term or they
can be expressed in the offspring rather than the parent. Many organisms are known
to express specific predictive adaptive responses (PAR) to their environment. A PAR
is specifically defined as a type of developmental plasticity that evolved as an adap-
tive response to an environmental cue acting early in the life cycle, but where the
advantage of the induced phenotype is primarily manifest in a later phase of the life
cycle [9].
There are a plethora of examples of this concept in nature. One example is
the freshwater crustacean Daphnia. If the mother is exposed to chemical traces
left behind by a predator then the offspring will be born with a defensive ‘helmet’
that offers protection against the predator. However, the helmet takes considerable
resources during development and therefore, it can be detrimental to the success of
the organism in a predator-free environment where it is unnecessary [10]. A second
example is present in the plague locust Schistocerca gregaria. This locust can develop
into two very different phenotypes: the migratory form or the solitary form. These
phenotypes are so different that they could be mistaken for two different species. The
migratory form has bigger wings, different mouthparts, a different camouflage colour,
and a different metabolism. They also display different behaviours, as the migratory
form does not hide but congregates in large swarms. The selection for one phenotype
over the other depends on the population density. The signal comes from the mother
who secretes a chemical on the eggs that she lays [11]. In this example, the migratory
form takes more resources to develop. Therefore, it only develops when there are not
enough resources to support the solitary form. A higher initial investment must be
made to raise the chances of survival to reproduction. These examples, like others,
occur because of a cue during development that predicts the environment that the
offspring will encounter. The primary purpose of this type of adaptive response is
to increase the likelihood that an individual will survive to reproduction. These
examples are of major changes in morphology, but differences could also be much
more subtle with the effects magnified in later life. These are examples of trade-
offs. One phenotype takes more resources but allows for a chance of survival in a
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harsher environment, whereas the other takes less resources and is likely to result in
a longer life span. In humans, longevity runs in a family which indicates a genetic
component. It is also possible to select animals artificially for longevity. In mice,
prenatal undernutrition leads to reduced longevity [12], and postnatal undernutrition
leads to a marked prolongation of the lifespan [13].
1.3 DoHaD and Maternal Nutrition
DoHaD (developmental origins of health and disease) is an emerging field of study
investigating the concept that insults during development and early life can lead to
certain adult diseases (type-2 diabetes, obesity, hypertension). Studies in this field
have focussed on nutritional changes (low protein, caloric restriction) at different
windows during gestation. The developing foetus is completely dependent on its
mother, and so it follows that maternal nutrition during pregnancy in particular has
a strong influence on the intrauterine environment. The developing foetus responds
to undernutrition by changing the trajectory of development and slowing growth. It
is proposed that development is being induced by cues in the environment that are
preparing the developing organism for the type of environment into which it will likely
be born [10]. Thus the cue is acting as a predictor of the nature of this environment.
The DOHaD hypothesis proposes that the metabolic syndrome originates through
developmental plasticity in response to undernutrition during fetal life and infancy
[6]. Two common explanations for how this occurs have been developed: the thrifty
phenotype hypothesis proposed by Hales and Barker [14] and the predation release
hypothesis proposed by Speakman [15].
1.4 An Evolutionary Perspective
The thrifty phenotype hypothesis and the predation release hypothesis are two
attempts to explain this relationship between poor fetal and infant growth and the
increased risk of metabolic syndrome in later life. The thrifty phenotype hypothesis
5
proposes that undernutrition during development leads to physiological and metabolic
changes that promote survival at the expense of health later in life [14]. Human dis-
eases are increasingly correlated with growth patterns early in life implicating early-
life nutrition as the underlying mechanism [16]. The predation-release hypothesis
suggests that the genes responsible for increased susceptibility to obesity were not
selected for but have been the result of random drift. Now that western lifestyles
have changed drastically in a short period of time the potential of these genes is
being realised [17].
1.4.1 Thrifty Genotype/Thrifty Phenotype
In 1962, James Neel [18] proposed the thrifty genotype hypothesis. This theory
proposed that ‘thrifty genes’ were selected during times of famine that enhanced
an individual’s ability to store fat. The theory hypothesises that in the current
environment these genes now predispose those individuals to the metabolic syndrome.
In 1992, Hales and Barker [14] proposed another hypothesis, the thrifty pheno-
type hypothesis. The theory is sometimes called ‘Barker’s hypothesis’ after David
J.P. Barker at the University of Southampton who published the theory in 1997 [19].
The theory proposed that early-life metabolic adaptations promote survival, with
the developing organism responding to cues of environmental quality by selecting an
appropriate trajectory of growth. If the fetal environmental is poor (i.e. undernutri-
tion), there may be an adaptive response, which optimises the growth of important
body organs sacrificing the health of others [20]. This enhances postnatal survival
under similar poor conditions but becomes detrimental when nutrition is more abun-
dant in the postnatal environment than it had been in the prenatal environment [21].
This theory is also used to explain insulin resistance. If individuals that are under-
nourished prenatally continue to be poorly nourished and remain thin and insulin
sensitive, the poor functional capacity for insulin secretion would not be detrimental;
however, increased food intake and decreased energy expenditure trigger glucose intol-
erance and lead to obesity [20]. The offspring can be said to have been ‘programmed’
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for the environment that the mother was living in at the time of pregnancy. The term
programming was chosen to describe the link between patterns of infant feeding and
later changes in physiology and disease risk. It now includes broader early life events
that contribute to altered growth patterns and altered risk of metabolic disease later
in life.
1.4.2 Predation Release Hypothesis and Genetic Drift
Speakman et al. [15, 17] states that the thrifty genotype hypothesis does not
account for the large number of thin people in western societies. The thrifty gene
hypothesis suggests that obesity was selected for as being beneficial for fecundity after
times of famine. Speakman argues that the frequency of alleles does not support that
interpretation. He presents an alternative hypothesis which he calls the ‘predation
release hypothesis’ or when combining it with similar theories involving genetic drift,
he calls them the ‘drifty gene’ hypotheses.
Speakman’s predation release hypothesis considers the evolutionary history of
humans to understand and put into context the way the body utilises and stores nu-
trients. For many centuries, there was evolutionary pressure to select against the very
lean as those that could store fat most effectively were more likely to survive until the
next meal could be found. In this hunter gatherer society, physical work and exercise
was an unavoidable part of daily life. This would put an additional selective pressure
against excessively lean people that would be too weak, but would also prevent people
from putting on excess weight. In early societies, although excessive fat and sugar
intake were not part of the diet, there was still a selective pressure against an ability
to store too much fat which would have led to decreased ability to move quickly and
escape predators. This balance was maintained by establishing upper and lower set-
limits. The lower limit was set by the risk of starvation and the upper limit by the
risk of predation. These set-limits evolved over many thousands of years until the
skill of fire-starting was acquired. This ‘release from predation’ relaxed the selection
against a fatter phenotype. This relaxation in the set-point allowed the upper weight
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limit to be affected by genetic drift (the change in allele frequencies in a population).
Even though this upper weight limit was not under selective pressure the lifestyle
required a significant amount of physical activity and so those individuals with a
higher set-point would be unlikely to reach that potential and become overweight
or obese. Now very recently (the last 50-100 years) the abundance, palatability, and
cheapness of food have changed the way food is consumed. Westerners consume more
calories than are required to maintain their health and have reduced physical activity
at work. So those people with a higher set point are able to reach that potential and
those are the people more prone to obesity. Today, lifestyle is very different to the
one that our bodies adapted to over the millennia [17, 22]. This hypothesis gives one
potential explanation for the variation in susceptibility to obesity seen in the human
population. This variation in set-point (described in more detail in Chapter 4 in re-
lation to leptin) may provide an explanation for the difficulty particular individuals
have in avoiding obesity and for the tendency for obesity to run in families.
1.4.3 Summary
It is likely that the rapid rise in obesity, diabetes, and metabolic syndrome involves
both of these theories. As discussed in more detail in Chapter 4, humans do have
varying set-points at which the feedback mechanism controlling obesity will function
properly. Speakman has shown that the rate of obesity in human society is not high
enough to indicate it has been selected for; however, the predicative adaptive response
has been observed in many species. The metabolic syndrome is a complex syndrome
that involves many disorders. It is likely that some aspects have been selected for
and others are the result of genetic drift. Several epidemiological studies have been
done showing the effect of maternal nutrition on the future health of the offspring
and the knock-down effects this has on generations to come.
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1.5 Epidemiological Data
The idea that maternal health may influence the future health of the baby has been
around since Victorian times [23]. Epidemiological data supports the hypothesis that
poor growth in fetal life and infancy is associated with type-2 diabetes, coronary heart
disease, stroke, hypertension and obesity [24]. Epidemiological studies by Forsdahl et
al. in Norway, first showed a causative link between early life environmental factors
and subsequent disease [25]. In 1986, David Barker and colleagues suggested that
poverty, poor nutrition, and general health of mothers produced high rates of infant
mortality, and also a lifelong risk of coronary heart disease. Epidemiological data from
several human populations have provided human data on the importance of maternal
nutrition during pregnancy and its influence on disease in the adult offspring.
1.5.1 Dutch Hunger Winter
The Dutch Hunger Winter was a short-term famine that occurred from 1944-
1945. Toward the end of the Second World War, the German occupation forces
in the Netherlands cut off the food supplies coming into the northern part of the
country. The population of much of the Netherlands suffered severe food shortages
for six months. The epidemiological data from women pregnant during this famine
shows that babies born to mothers who suffered severe starvation during the last three
months of their pregnancies grew up to have a dramatically reduced ability to deal
with high levels of sugar. These offspring often grew up nutritionally richer in the
post-war environment and experienced an increased risk of developing diabetes [26].
This indicates that undernutrition in the last trimester of pregnancy may programme
later obesity in men and women [27, 28]. These studies suggest that perturbations
of central endocrine regulatory systems established in early gestation may contribute
to the development of obesity in later life.
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1.5.2 Pima Indians
The Pima Indians, of the Gila River Indian community in Arizona, lived suc-
cessfully in the desert environment by maintaining the 2,000 year old tradition of
irrigation and agriculture. This was disrupted in the late 19th century when their
water supply was diverted. This disruption caused poverty, malnutrition and even
starvation. The community was forced to survive on the lard, sugar and white flour
provided by the U.S government for survival [29]. By 1929, irrigation was gradually
reintroduced and now agriculture is once again a major source of food, but the type
of farming has changed. The Pima Indians are now the subject of numerous studies
into the population’s high prevalence of obesity and particular chronic diseases. The
high risk of diabetes can largely be explained by the presence of maternal diabetes
during pregnancy [30]. In the Pima Indians, higher instances of diabetes have been
correlated with both high and low birth weight. This is in contrast to studies in the
USA, Sweden, France, Norway and Finland that demonstrate a significant correlation
between low birth weight and the later development of adult diseases [31]. McCance
et al. proposed that the population may have developed a genetic predisposition for
insulin resistance as it provided a survival advantage in their previous environment.
1.5.3 Cohort Studies
In addition to these retrospective studies, prospective studies are being conducted
worldwide. Here is a summary of one that was conducted in the UK.
Southampton Women’s Survey
The Southampton Women’s Survey (SWS) is a large study in Southampton, Eng-
land. The study began out the University of Southampton, where David Barker
developed the thrifty phenotype hypothesis, to investigate the diet and lifestyle fac-
tors that affect women’s health and the health of their children. It was established
to measure characteristics of women living in the city that are aged 20-34 before
pregnancy. The survey recruited 12,500 women and followed them through their sub-
10
sequent pregnancies. The study includes 3,000 live-born infants that will be followed
throughout childhood. The objectives of the project are twofold. First, to characterise
the influence of a mother’s own fetal growth on her dietary balance, body composi-
tion, and endocrine profile before and during pregnancy on: (i)the early trajectory
of fetal growth; (ii)the maintenance of this growth trajectory in late gestation; and
(iii)placental and fetal adaptive responses, including altered regional blood flow and
body composition of the foetus. Second, to examine how maternal and intrauterine
influences interact with the offspring’s genes and postnatal environment to determine:
(i) weight gain, head growth and linear catch-up growth in infancy; (ii) the pathways
of growth and development during childhood that lead to poor adult health; and (iii)
cardio-respiratory function and asthma in childhood, as well as levels of risk factors
for adult coronary heart disease, type 2 diabetes mellitus and osteoporosis.
The studies in Southampton have demonstrated that the balance between carbo-
hydrate intake in the first trimester and animal protein intake in the last trimester
influences placental growth and neonatal body composition. Furthermore, studies of
early pregnancy, assisted reproductive technology and animal experiments, indicate
that maternal body composition, endocrine profile, diet and physical activity around
the time of conception, are important in establishing both the fetal growth trajectory
and the fetal supply line.
ALSPAC-Avon Longitudinal Study of Parents and Children
The ALSPAC study is a longitudinal population-based birth cohort study that
recruited 14,541 pregnant women in 1991-92, with 14,062 live-born children. These
women were residents of one of three former (Avon) Health Districts in the UK. The
women represented 85% of the eligible population. The goal was to understand the
ways in which the physical and social environments interact with the genotype to
affect, health, behaviour and development [32]. The study recorded information for
growth, onset of obesity, respiratory function, traits relevant to adult-onset diseases,
infections, motor and mental ability, educational achievements, sexual development,
accidents and injuries, and atopic diseases (i.e. asthma, eczema, allergies, mood
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behaviour, and temperament). Also, from late adolescence into adult life the study
will monitor the development of type-2 diabetes, markers of coronary heart disease,
schizophrenia and other psychotic disorders, criminal behaviour, ability to hold down
a job, onset of drug and alcohol abuse, and reproductive success and failure.
1.6 Animal Models of the Metabolic Syndrome
Animal models are very important in the study of the metabolic syndrome. The
metabolic syndrome involves the interaction of many factors (genetics, fetal program-
ming, eating habits, energy expenditure, age, and gender) that would be impossible to
manipulate and control in a human population. Several models have been developed
to investigate the metabolic syndrome. These models have been done in a variety of
different organisms including mice, rats, guinea pigs, rabbits, hamsters, pigs, sheep,
primates, horses, dogs, and frogs. The most common models utilise a maternal diet
manipulation during pregnancy (low protein and general calorie restriction, or high
fat/junk food diet). In addition, models given genetic or surgical manipulations, hor-
monal insults, or a particular postnatal diet can also be informative. Several studies
on the impact of severe undernutrition have been done by our collaborators using
small animal species (rats) as well as larger mammals (sheep). Cost, size, time, and
ethical issues are major reasons for choosing particular animal models over others.
Also, popularity can be a good reason for choosing a model. If many other studies
have been done on a particular model then animals will be easier to obtain and there
will be more data for comparison. The difference in gestation time and variation in
timing of the insult makes it possible to gain more information regarding the crucial
‘windows’ for fetal programming. A recent review by Warner and Ozanne [33] de-
tails the importance of animal models in studying fetal programming. Many of the
different models and the major findings associated with each are summarised here.
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1.6.1 Maternal Diets
Rodents are a useful model in maternal diet manipulation studies as the shorter
gestation time and lifespan. The development of the brain involved in regulating
feeding and energy expenditure develops in the early postnatal period in rodents,
whereas in humans it develops in the third trimester of pregnancy [34]. A guinea pig
would be a slightly better model as they are born with a well-developed endocrine,
cardiovascular, and central nervous systems [35]. Sheep are also a good model as
their pregnancies are usually singleton or twin so nutrient allocation between offspring
during pregnancy is more analogous to human. The examples listed below will focus
on rodent animal models, particularly rats, as that is the model used in this thesis.
Protein Restriction
The maternal low protein model is extensively studied due to the similarities found
between studies using this model and studies of individuals with type-2 diabetes
and/or the metabolic syndrome. Studies have shown that amino acids found in a
protein diet are key to normal fetal growth, but can also be detrimental at high
concentrations [33]. The commonly used low protein rat model involves feeding the
rats a low (5-8%) protein diet during pregnancy [36]. This mimics the nutritional
situation in many underdeveloped countries and results in growth restriction of the
offspring. If these offspring are suckled by the same protein-restricted mothers they
remain permanently growth restricted even when weaned to a normal chow diet (20%
protein). Cross-fostering to mothers being fed a normal chow diet during lactation
until weaning causes rapid catch up growth. Catch up growth is the rapid growth after
birth that brings a low-birth weight offspring up to the weight of control offspring. In
rats, catch up growth affects longevity by causing accelerated loss of kidney telomeric
DNA. Maternal protein restriction has long-term effects on insulin-sensitive tissues
[37] and causes reductions in pancreatic β-cell mass, skeletal muscle mass and central
adipose tissue weights. Offspring subjected to a low-protein diet during gestation
demonstrate improved glucose tolerance at a young age (6 weeks to 3 months) [38, 39].
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However, males undergo a gradual loss in glucose tolerance and by 17-months develop
Type 2 diabetes and insulin resistance [40]. The female offspring experience a more
gradual loss in glucose tolerance and do not develop Type 2 diabetes and insulin
resistance until 21 months [41].
Caloric Restriction
A calorie restricted rat model is utilised in this thesis (see Chapter 3 and Chapter
4). This involves feeding rats 30-50% of their normal diet during pregnancy. This
maternal dietary restriction during pregnancy in rats results in offspring that suffer
severe growth restriction and show endocrine and metabolic abnormalities. Studies
have shown that the timing of the restricted diet during development is critical in the
programming of metabolic disorders [33]. Work done by Garofano et al. has shown
that a 50% restriction of a normal chow diet in the last week of pregnancy results in
low birthweight offspring with decreased β-cell mass. The rat offspring demonstrate
this reduced β-cell mass and insulin content in adulthood [42] even after returning to
a normal diet and normal body and pancreatic weight. In addition, extended nutrient
restriction into the nursing period results in more permanent metabolic abnormali-
ties (permanent β-cell mass and loss of glucose tolerance [43, 44]) in offspring. The
model used in this thesis was more severely restricted (30% ad libitum) during preg-
nancy. Vickers et al. has shown that rats exposed to this level of maternal restriction
and then switched to a normal postnatal diet gain weight quickly and develop the
metabolic syndrome (obesity, hyperphagia, hypertension etc.) [45]. This effect is ex-
acerbated by a postnatal high fat diet. Even a restricted diet after birth (3-6 weeks)
will result in impaired insulin secretary response at 12 weeks of age [37]. Many stud-
ies have been done using caloric restriction. Diets differ between laboratories using
different proportions of macronutrients, which can help elucidate the importance of
different nutrients in fetal programming.
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Iron Restriction
Iron deficiency is a very common nutritional disorder and pregnant woman are
among the most susceptible. In the study by Gambling et al., rats were given 7.5
mg/kg compared to the control rats that were given 50 mg/kg. This mild iron
deficiency in utero caused a significant increase in the blood pressures of both male
and female offspring [46]. In addition, the offspring have decreased iron concentrations
in brain tissue and behavioural differences have been observed [47].
Overnutrition
High fat diets aim to imitate westernised diets. Relatively few studies have focused
on the long-term consequences of a maternal high-fat diet and maternal obesity during
pregnancy or lactation compared to other nutritional studies. Studies have revealed
effects on adiposity, cannibalism (presumably related to failure of lactation), and an
increased body weight and visceral fat depot [2]. In a study by Gorski et al. [48], rat
offspring of normally fed mothers were cross-fostered onto obese dams, which resulted
in increased obesity later in life suggesting the suckling period is still an important
developmental window in rats.
Maternal High-Fat Diet Offspring that experience maternal overnutrition during
pregnancy have been shown to have increased risk of developing Type 2 diabetes and
cardiovascular disease later in life [49]. These offspring develop abnormal cholesterol
and lipid metabolism, hyperinsulinaemia, insulin resistance and have an increased
risk of hypertension and cardiovascular disease [49, 50, 51]. Bayol et al. [52] de-
veloped a rat model using a ‘junk food’ diet with processed, palatable food items
developed for human consumption. The diet contained high levels of fat, sugar, and
salt with low protein levels and thus resembled a low protein model. The study found
that the diet influenced muscle development, feeding behaviour, and adiposity. This
preliminary study suggested that the observed changes in the muscles of the offspring
whose mothers had been on the junk food diet may have a decreased ability to move
effectively (i.e. exercise) and may therefore be more prone to obesity.
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Maternal Obesity Increase rates of obesity in western countries have led to an
increased prevalence of maternal obesity, which can lead to high-risk pregnancies and
complications at birth and in later life [2]. Animal models of maternal obesity can
help us understand the mechanisms that may transfer this susceptibility to obesity
and features of the metabolic syndrome from mother to offspring and into later life.
Offspring of obese mouse mothers have been shown to have an increased fat-to-lean-
mass ratio and hyperphagic behaviour. In addition, they were insulin resistant at
3 months and males had developed impaired glucose tolerance by 6 months. An
increase susceptibility to cardiovascular disease was demonstrated by hypertension
and signs of endothelial cell dysfunction [53]. Another study showed that both male
and female offspring of obese mothers developed metabolic syndrome phenotypes
and increase adiposity. Males also demonstrated insulin resistance and poor glucose
tolerance [54].
1.6.2 Postnatal Diets
High fat postnatal diets are often used in conjunction with undernutrition during
pregnancy (as done in the study described in Chapter 4. This is done to create a
mismatch between pre- and postnatal life that is often associated with the metabolic
syndrome as described by the thrifty phenotype hypothesis. Vickers et al. [45] has
shown that the postnatal high fat diet exacerbates the effects caused by the maternal
undernutrition diet.
1.6.3 Hormonal Insults
Glucocorticoid Treatment
It is established that glucocorticoid treatment during pregnancy in animals and
humans leads to reduced birth weight, and it is more recently being realised that
this has long-term effects on the offspring [37]. Exposing pregnant females to glu-
cocorticoids is another treatment used to induce the metabolic syndrome. A recent
study using the nonhuman primate marmoset, revealed that glucocorticoid exposure
16
resulted in increased expression of 11β-hsd1 in liver, pancreas, and subcutaneous fat.
The increase in 11β-hsd1 occurred before the onset of obesity [55].
Adrenalectomy
Gardner et al. [56] conducted a study combining adrenalectomy (the removal of
one or both adrenal glands) in the rat with a glucocorticoid treatment and a low pro-
tein diet to confirm that maternal glucocorticoids are involved in the programming
of hypertension in the offspring. The maternal diet-induced hypertension is depen-
dent on an intact adrenal gland postnatally and glucocorticoids are key nutrients
responsible for maintaining high blood pressure.
Leptin Treatment
Leptin functions to sense and regulate body energy stores in humans and in ani-
mals. Leptin administration after birth has been used to investigate it as a possible
treatment to prevent obesity or to reverse the programming effects of maternal un-
dernutrition during pregnancy. Vickers et al. conducted a study utilising a leptin
treatment that reversed the effects of prenatal undernutrition in female rats [57] (these
samples are used in Chapter 4. However, the same protocol showed no significant
effect in male rats [58]. Yura et al. [59] conducted a similar study in mice that did
not result in a reversal of the programming effects, but rather caused a growth surge
in the mice that received normal maternal nutrition during gestation.
Growth Hormone
Growth hormone treatment was tested as a possible treatment for fetal program-
ming. Vickers et al. found that GH treatment after weaning in male rats that were
exposed to maternal undernourishment during gestation resulted in increased body
weight, but significantly reduced fat pad weight. Systolic blood pressure was markedly
decreased and the rats had an increased heart-to-body weight ratio indicating GH
treatment reduces hypertension and improves cardiovascular function.
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1.6.4 Surgical Interventions (Reduced Placental Transfer by
Uterine Artery Ligation)
A common cause of intrauterine growth restriction (IUGR) is due to placental
disease particularly in developing countries. The sheep is an ideal placental insuffi-
ciency model as the foetus can be monitored throughout gestation. However, these
studies usually only focus on fetal development as cost prohibits taking the offspring
to adult life. There is also a problem of the confounding of the factors of reduced ma-
ternal and fetal blood flow, nutrient restriction and hypoxaemia that vary in severity
between species (i.e. sheep, rodents and humans) [35].
1.6.5 Genetic Models
The ability to introduce or eliminate genes from the genome of rodents has made
rats and mice excellent complex, genetic models. Rodents are especially useful be-
cause of their large family size and easy measurement of phenotypic parameters.
There are several mouse models with knock-out genes that are useful for investigat-
ing the metabolic syndrome. Two genetic models that will be described in detail in
Chapter 4 are the ob/ob leptin deficient mouse and the db/db leptin-receptor defi-
cient mouse. Also mentioned briefly in Chapter 6 is the KKAy lethal agouti gene
mouse model. A recent publication by Artinano et al. [60] reviewed nine genetic
rat models of the metabolic syndrome that develop a number of disorders including
obesity, hypertension, hyperphagia, fatty liver, etc. The most common rat men-
tioned is the Zucker rat that has a mutation in the leptin-receptor similar to that
of the db/db mouse. A few of the other genetic models available for investigating
the metabolic syndrome include: IGF-I knockout mice, IGF-II transgenic mice and
IRS-I disrupted mice. The IGF-II transgenic mouse highly over-expresses IGF-II re-
sulting in increased fetal size, organ overgrowth, and has been used to investigate the
development of the endocrine pancreas [61].
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1.6.6 Summary
This is a broad overview of the many animal models available for the investigation
of the metabolic syndrome. Of course none of these models manifest the disease in
the same way humans do, the combination of models helps to understand the role of
fetal programming in utero as a cause of adult disease [62].
1.7 Mechanisms of Nutritional Programming
Either in the introduction or in chapter 5 you need to include much more detail
about the proposed mechanisms of nutritional programming. This should include
a general introduction to epigenetics, how methylation blocks gene transcription,
histone modification, the reciprocal relationship between methylation and histone
modification and the evidence that early life environment can alter epigenetics pro-
cesses (in vitro culture, IUGR, maternal behaviour and the now wealth of evidence
that nutrition can alter DNA methylation and the fact that methylation changes have
been seen in your model).
The molecular mechanisms behind the developmental programming of disease in
response to insults during gestation are unclear. Waterland et al. [63] came up with
three criteria for considering possible mechanisms: 1) Nutritional programming is
an adaptive process, so only mechanisms consistent with an adaptive response are
considered; 2) Programming occurs during critical windows of development, so only
mechanisms that act in these windows can be considered and 3) The potential mech-
anism must explain a programming process and not be a reflection of the outcome of
the process.
The mechanisms that have been proposed and generally meet this criteria are:
organ structure, altered cell number, clonal selection, cell type, metabolic differenti-
ation, autoregulatory pattern of DNA binding proteins, precocious activation of the
HPA axis, increased local glucocorticoid axis and endocrine sensitivity, epigenetic
regulation of gene expression via altered chromatic structure or DNA methylation,
hepatocyte polyploidisation, impaired mitochondrial function, and reduced oxidative
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capacity [64, 63]. More than one mechanism is likely to be involved. These mech-
anisms may vary between tissues and depending on the duration and timing of the
insult. One mechanism that has gained significant support is the epigenetic regulation
of gene expression via DNA methylation. The understanding of how, when, and what
changes are made to the epigenome could have significant clinical implications. The
identification of methylation patterns that increase disease susceptibility could lead
to identification of individuals with these patterns and allow advanced preventative
treatment or lifestyle adjustments [65].
This thesis aims to take an exploratory look into whether DNA methylation may
be involved in any of the gene expression changes highlighted by the microarray
studies.
1.8 Microarray
Since the sequencing of the human genome the field of molecular biology has
been transformed. This has led to a new field of biology referred to as genome
biology or genomics. New technology combined with our growing knowledge enables
scientists to probe the genome investigating the structure and function of a very
large number of genes simultaneously. The types of investigations performed can
be grouped into subfields including structural genomics, comparative genomics and
functional genomics. Structural genomics includes the genetic mapping, physical
mapping and sequencing of genes in the genomes of various organisms. Comparative
genomics aims to make inferences based on the comparison of the genomes of different
organisms. Finally, functional genomics involves investigating the role that individual
genes or subsets of genes play in the development and life of an organism [66]. The
work in this thesis would fall in the subfield of functional genomics.
Many high-throughput techniques have been developed to investigate properties
of the genome. Microarray is a technique that enables the user to probe thousands
of genes simultaneously to look for changes in expression levels, methylation or SNPs
(single nucleotide polymorphisms).
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This thesis utilises microarray technology to probe the rat genome expression
profile for novel genes that are affected by the nutritional insult during pregnancy.
Microarray enables this large scale screening of gene expression by detecting the
presence and abundance of labelled nucleic acids. It makes it possible to measure
the expression of thousands of genes simultaneously. It also makes it possible to
compare the expression in different cell types (i.e. tissues) and to compare the effects
of different treatments.
An array is a glass slide on which single stranded DNAs (ssDNA) with various
sequences, referred to as the probe, have been placed or synthesised in a grid-like
pattern. This can be done using a variety of techniques including spotting, pho-
tolithographic synthesis, inkjet synthesis, or most recently, BeadArray technology.
The array is washed in a solution containing ssDNA that is generated from a particu-
lar biological sample that is being studied and is referred to as the target. The DNA
in the solution contains sequences complementary to the sequences of DNA on the
surface of the array and will hybridise to those complementary sequences. The solu-
tion is labelled with a fluorescent dye so that the hybridisation spot can be detected
and quantified easily.
The DNA target hybridised on the array is obtained by a reverse transcriptase
reaction from the mRNA extracted from a tissue sample. This DNA is fluorescently
labelled with a dye and a subsequent illumination with an appropriate source of light
will provide an image of the array of features (set of spots). The intensity of each
spot or the average difference between matches and mismatches can be related to
the amount of mRNA present in the tissue and in turn, with the amount of protein
produced by the gene corresponding to the given feature. The array is then used to
answer a specific question regarding the printed DNAs.
A number of microarray platforms have been developed using the different tech-
niques mentioned above; with different formats (one-channel/ two-channel, in-house/
commercial, cDNA/ oligonucleotide); by different companies (Affymetrix, Illumina,
Agilent and Nimblegen); with a different number of probes; for different species (most
common human, rat and mouse). To choose a particular platform considerations have
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to be made concerning the organism of study, the number of samples to hybridise, the
cost and the amount of extracted RNA available. One channel arrays are becoming
more common and are largely preferable because there is less variation introduced due
to dye bias. Homemade arrays allow for total flexibility and are low cost if enough of
them will be produced; however, they do not offer standardised protocols and tested
analysis methods that the commercial arrays offer[66].
In this thesis, two different types of mRNA arrays were used. The MEEBO
oligonucleotide array is a printed array that was made in-house by the Department
of Pathology Centre for Microarray Resources. The Illumina array is a BeadChip
that uses a bead coated in ssDNA inserted into the glass slide. Both are described in
more detail in Chapter 2.
1.8.1 microRNA Arrays
In addition to the mRNA arrays, this thesis also utilised microRNA (miRNA)
arrays. miRNAs are small noncoding RNAs that regulate gene expression by targeting
mRNAs for cleavage or translational repression. Recent developments in microarray
technology have included the manufacture of arrays with miRNA targets. Illumina
briefly released a miRNA expression array that had 380 sequences from the mouse
genome (described in more detail in Chapter 2). The miRNA array was used for
this thesis in Chapter 6 to investigate the effects of maternal undernutrition on the
miRNA expression levels in the livers of 55 day old male offspring.
1.8.2 Microarray Applied to Developmental Plasticity
By using microarray to find gene expression changes, it is possible to take a global
gene approach to investigating which genes/mechanism might be involved in program-
ming. Previous studies have used a candidate gene approach. By approaching the
problem with less bias, it may be possible to identify novel genes and pathways im-
portant in programming. In this study, genes will initially be identified by microarray
and then the methylation status of the promoter regions of these genes of interest
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will be analysed.
1.9 Structure and Aims of the Thesis
This thesis aims to pinpoint potential molecular mechanisms that underpin the
development of the metabolic syndrome. The thesis utilises microarray technology
and epigenetic assays to probe the genome for information. All the techniques and
materials used are introduced and described in Chapter 2.
Chapter 3 utilises samples from a previous study (Vickers unpublished study) to
compare the gene expression profiles of offspring of rats that were undernourished
during pregnancy (UN) to those whose mothers ate a normal chow diet during preg-
nancy (AD). Liver, white adipose, and skeletal muscle tissue samples are examined
from male animals that were 55 days old, before the development of the metabolic
syndrome phenotype. The chapter gives the background on metabolism and relevant
metabolic pathways. The chapter also summarises the results of the initial pheno-
typic study before detailing the results of the expression profiling and the associated
pathway analysis. The aim of the study presented in this chapter was to highlight
genes differentially expressed between AD and UN rats that may be involved in pre-
disposing the UN animals to the development of the metabolic syndrome in later
life.
Chapter 4 utilises the samples from a previous study [57] to compare the gene
expression profiles of rats subjected to three different treatments: undernourishment
during pregnancy (AD/UN); leptin treatment (SAL/LEP); and postnatal high-fat
diet (CHOW/HF). Liver samples were from female animals that were 170 days old
and had already developed metabolic syndrome in particular treatment groups. The
chapter introduces leptin and its role in appetite signalling and energy homeostasis.
The results of the initial phenotypic study are described to put the results of the ex-
pression profiling study in context. The results of the phenotypic study had suggested
that leptin treatment in UN animals resulted in a reversal of programming that made
these animals susceptible to the metabolic syndrome. This chapter aims to highlight
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genes differentially expressed between treatment groups and potentially involved in
the metabolic programming and the reversal of the programmed phenotype.
Chapter 5 introduces the hypothesis that epigenetic mechanisms are responsible
for the fetal programming. The preliminarily investigation presented here deter-
mined the methylation status of particular genes by conducting a restriction enzyme
methylation assay (McrBC) on samples that were highlighted in a preliminary anal-
ysis of the results presented in Chapter 3. This chapter aims to investigate whether
epigenetic effects through methylation at CpG dinucleotides in promoter sequences
are responsible for gene expression changes and could in turn be responsible for the
resulting phenotypic changes.
Chapter 6 utilises a newly developed miRNA microarray to investigate the effect
of maternal undernutrition on the microRNA (miRNA) expression levels using the
liver samples of male rats that were 55 days old (the same samples as utilised in the
study in Chapter 3). This chapter aims to highlight miRNAs involved in differentially
regulating genes as a consequence of maternal undernutrition during pregnancy.
Chapter 7 summarises the results of the work presented in this thesis and discusses
the implications of these results. This chapter aims to outline the general conclusions
and to state plans for future work.
24
Chapter 2
General Methods
2.1 Animal Care/Sample Collection
Tissues (liver, retroperitoneal white adipose fat, and biceps femoris skeletal mus-
cle) for the data in Chapter 3 were collected and snap-frozen in liquid nitrogen by
collaborators at the Liggins Institute, University of Auckland. They were stored at
-80 ◦C until being shipped to the University of Cambridge on dry ice. Liver tissue for
the data in Chapter 4 was collected and snap-frozen in liquid nitrogen by collabora-
tors at the Liggins Institute, University of Auckland. All tissue was stored at -80 ◦C
until RNA extraction was done at the Liggins Institute. RNA was shipped to the
University of Cambridge on dry ice. All animal manipulations were performed under
the ethics and approval protocol number CR328 from the Animal Ethics Committee
of the University of Auckland.
2.2 RNA Extraction
2.2.1 For Oligonucleotide Expression Array (Undernutrition
Study and Leptin Study)
Total RNA was isolated from tissue using TRIzol reagent (Invitrogen, Paisley,
Scotland, UK). For each sample, 25 mg of frozen tissue was dropped in 1 ml of
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TRIzol solution. The tissue was homogenised at maximum speed for 30 seconds.
The homogeniser head was thoroughly cleaned between each sample. Muscle and
fat tissue was then centrifuged at 11,500 g (12,000 rpm) for 10 minutes at 4 ◦C.
This caused the extracellular membranes, polysaccharides, and high-molecular weight
DNA to form a pellet at the bottom of the tube with the RNA in the supernatant. In
fat samples, an excess of fat will collect in the top layer which can be removed. The
cleared homogenate solution can then be moved to a fresh tube. These samples along
with liver samples, were then left at room temperature for 5 minutes to promote the
dissociation of the nucleoprotein complexes. In the fume hood, 200 µl of chloroform
was added and the sample was mixed with a vortex on high speed for 15 seconds,
then incubated at room temperature for 3 minutes. Tubes were then spun at 11,500 g
(12,000 rpm) for 15 minutes at 4 ◦C. The aqueous phase was carefully transferred to
a new tube. Equal volume of 70% ethanol (50% for liver samples) was added to the
aqueous phase for total RNA precipitation. The subsequent steps were all preformed
at room temperature using the RNeasy Mini Column purification kit (Qiagen, UK)
following the manufactures instructions.
2.2.2 For microRNA Expression Array
Purification of total RNA and a separate miRNA-Enriched Fraction from 25 mg
of frozen liver tissue was performed using the miRNeasy kit (Qiagen, UK) following
the manufacturer’s protocol. This protocol also utilises Qiagen’s RNeasy MinElute
Cleanup Kit.
2.2.3 Quality Assessment
Total RNA quality was assessed by running 100–500 ng of the RNA sample on the
Nano Lab-on-a-chip system (Agilent, Palo Alto, CA.) to check for RNA degradation.
MicroRNA quality was assessed using the Small Lab-on-chip system. The Agilent
Bioanalyser 2100 separates the total RNA sample such that 18s and 28s ribosomal
RNA will dominate the electropherogram. When good quality RNA is analysed the
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ratio between the two peaks ranges from 1.5–2.0. The ND-1000 spectrophotome-
ter (Nanodrop) was used to measure the total RNA concentration and purity. A
280/260 nm (ratio of absorbance) of 1.98 was used as the quality threshold, as values
less than this would indicate protein contamination. A 260/230 nm of 1.8 threshold
was used to avoid samples with organic contamination.
2.3 Microarray
2.3.1 Experimental Design
An important aspect of a microarray experiment is the experimental design. A de-
signed experiment involves a series of tests in which purposeful changes can be made
to the input variables of a process or a system, so that the results can be observed
and the reasons for the changes in the output can be identified. Factors that may
contribute to noise in an experiment must be identified and if possible, controlled.
The appropriate statistical analyses should be chosen in advance. The three main
principles of experimental design are replication, randomisation, and blocking. Repli-
cation is the repetition of an experiment which allows an estimate of the experimental
error. In microarray, there are two types of replication: biological and technical. Bi-
ological replication involves the repetition of an experiment using different biological
samples that have gone through the same experimental conditions. This will reveal
biological variation between individuals in the population being studied. Technical
replication is an exact repetition of an experiment using the same biological sample.
This will reveal differences noise introduced in the experiment based on differences
in equipment or experimental conditions [66]. Randomisation requires the random
choice for every factor (nuisance factors) that is not of interest but might influence
the outcome of the experiment. Examples of this involve the placement of spots or
beads on an array, and the use of control and treatment samples on the same slide
of batch of slides. Randomisation can control for the confounding of factors. If all
treatment samples were run on one batch of slides and all the control samples on a
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different batch then the variation introduced by the experiment and that introduced
by the slides would be impossible to separate [66].
Blocking is a technique for experimental design that aims to increase the accuracy
with which the influences of the nuisance factors are assessed in a given experiment. A
block is a subset of experimental conditions that are expected to be more similar than
other conditions. Blocking is used to eliminate the variability due to the difference
between blocks. An example of a block is the chip itself. All spots in an array or
on a slide are subject to the same factors during slide processing; it is expected that
the spots on a single chip will have less variance than the measurements across the
entire experiment. The two channel array process deals with this by hybridising the
treatment and control samples on the same array; however, it introduces the nuisance
factor of the dyes, which in this experiment is dealt with by running replicates that
are dye swapped. This means that the same experiment is run twice with the control
and treatment hybridised with each dye. The BeadArray deals with blocking by
having more than one array on a single slide [66].
2.3.2 Quality Control
As the image analysis is fully automated, it is important to have good quality
assessment methods. With the spotted arrays, this is very crucial as spotting errors
can cause problems with spot shape regularity, spot area to perimeter ratio, displace-
ment, spot uniformity, and spot signal area to spot area ratio. With spotted arrays,
it is useful to visually inspect slides and images to check for any obvious problems
with the printing or hybridisation.
Many of these problems are overcome with BeadArray Technology. However, with
both methods there are still a variety of other potential problems that can be detected
using visualisation tools. BlueFuse R© performs a quality control assessment and uses
a flagging system to highlight potentially unreliable data, while Illumina uses a set
of internal controls for the same purpose. Visualisation tools are then used to look
for differences in slides or outlying samples, or to assess the information provided by
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BlueFuse R© or Illumina.
2.3.3 Reducing Error
Choosing the right statistical methods is an essential part of microarray analysis.
It is important to identify the potential sources of variability during the quality
control step and then choose normalisation methods that will correct for this without
covering the biological variability of interest. There is a large potential for error when
using microarray as cost restraints reduce the number of replicates that can be done
while the number of variables remains large. Data normalisation aims to remove the
external noise to reveal biologically relevant differences in gene expression. A lack
of statistical significance may indicate low experimental sensitivity rather than an
absence of biological effect. Low sensitivity may be caused by an inadequate number
of replicates and/or a failure to control noise that contributes to random error [67].
Data Filtering
Following the quality control analysis, it is important to remove samples that are
extreme outliers. If the experimental design has incorporated enough biological and
technical replicates, it should be possible to detect outliers that may negatively affect
the results.
Between Array Normalisation
The characteristics of each array should be similar. Proper experimental design
should have randomised samples in such a way that any sources of error will be dif-
fused when replicates are combined. If it is assumed that these precautions have been
successful and that filtering has removed samples that are extreme outliers, then the
within-array-normalisation step should centre all arrays on the same mean/median.
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2.3.4 Data Analysis
Once data has been filtered and normalised it is analysed to determine which
genes differ significantly in expression level between the treatment and the control.
In this thesis, a linear model is used to compare samples. This method requires
two matrices: one is the design matrix, which indicates what RNA samples have
been applied to the array and the second, is the contrast matrix, which specifies what
comparisons should be made between the samples. The differential expression is then
determined by calculating a p-value using an analysis of variance method (ANOVA)
or a pairwise comparison.
2.3.5 Validation of Microarray Data: Quantitative Real Time
PCR
The goal of microarray is to explore a large subset of the genome to find genes that
might be involved in a particular biological process related to the test sample utilised.
A list of genes with a chosen level of statistical significance will be revealed, but it
is absolutely essential to test the validity of these results by testing the expression
of that gene individually with an alternate method. RT-PCR and northern blotting
are two methods often used at this step. Quantitative RT-PCR is the method of
choice for validation of microarray experiments, as it has been shown to be the most
sensitive method for quantifying changes in expression. Comparative quantitative
RT-PCR has been used for validation in this thesis.
2.3.6 Mouse Exonic Evidence Based Oligonucleotide Expres-
sion Array
Initially, the samples were hybridised to a spotted array, specifically the Mouse
Exonic Evidence Based Oligonucleotide (MEEBO) array. This array is comprised
of DNA oligonucleotides representing the mouse genome that are pre-spotted to the
array using robotic spotting. This chip probes approximately 25,000 genes in the
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Rat hyb onto mouse chip gives signal in most spots (62%)
Figure 2.1: Rat embryo DNA hybridised to the mouse MEEBO chip. The rat DNA
gave signal in approximately 62% of the features and scatter plots of data revealed a
R2 value of 0.993. This work was done by Peter Ellis.
mouse genome and uses a dual colour hybridisation protocol. Dual-colour hybridisa-
tion is used in a two-channel experiment by labelling the target and the probe with
Cy3 and Cy5 dyes. By using this chip, we were cross hybridising rat samples to a
chip with mouse oligonucleotides. To test the accuracy of hybridising rat samples to
a mouse chip, we performed several test hybridisations. Rat embryo DNA was am-
plified, labelled and self-self hybridised to the MEEBO chips. The rat embryo DNA
gave signal in approximately 62% of the features and scatter plots of data revealed a
R2 value of 0.993 as shown in figure 2.1 (work done by Peter Ellis). These are very
good results, but not as ideal as having an actual rat chip. For this reason, once the
technology was available, samples were also hybridised to the Illumina Bead Array
described below.
Smart PCR amplification, Klenow Labelling and Array Hybridisation
Extracted RNA samples were run on the Agilent to ensure RNA quality. Reverse
transcription was performed using Powerscript (Clontech), from 1 µg of total mRNA
mixed with 1 µl of cDNA synthesis primer (10 µM), and 1 µl of template switching
primer and RNase-free water up to 5 µl. This mix was incubated for 2 minutes
at 72 ◦C. To this mixture 2 µl of 5x First Strand Buffer, 1 µl DTT (20 µM), 1 µl
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dNTPs (10 µM), and 1 µl Powerscript RT were added and this mix was incubated for
60 minutes at 42 ◦C . The cDNA amplification used the SMART PCR amplification
protocol. A mix containing 75 µl of RNase-free water, 10 µl 10x PCR Buffer II, 2 µl
10 mM dNTPs, 4 µl IIA Primer, 5 µl 25 mM MgCl2, and 2 µl AmpliTaq (5 U/µl) was
made and added to 2 µl of product from the 1st Strand synthesis. Amplification was
performed at 95 ◦C for 1 minute in order to activate the enzyme, then for 14 cycles,
95 ◦C for 5 seconds, 65 ◦C for 5 seconds, and 68 ◦C for 6 minutes. Labelling was
performed using the Klenow Labelling kit (BioPrime) following the manufacturer’s
instructions. 20 µl of 2.5x Random Primer Buffer and 1 µl Klenow (40 U/µl) was
added to 22 µl of amplified DNA. The mix was incubated at 95 ◦C for 5 minutes.
This mix was placed on ice while 5 µl 10x Low-C dNTPs and 1 µl cyanine dye (Cy3 or
Cy5) was added and the mix was incubated for 2 hours at 37 ◦C. 5 µl of STOP Buffer
was added to stop the reaction. Labelled cDNA was purified using G50 Columns.
Labelling and synthesis was checked using the Nanodrop and purified Cy3 and Cy5
labelled products were combined. The sample was then pooled with 1 µl Cot1DNA,
1 µl yeast tRNA (Invitrogen), and 1 µl of poly-dA (Sigma) as blocking reagents.
Ethanol precipitation was performed by adding 250 µl of 100% Ethanol and 10 µl
3M NaAcetate (pH 5.2), inverting the mix, placing on dry ice for a 10 minutes, and
spinning at 11,500 g (12,000 rpm) for 15 minutes at 4 ◦C . The pellet was washed
with 500 µl of 75% Ethanol and spun for 5 minutes at 11,500 g (12,000 rpm). The
supernatant was discarded and the excess Ethanol was tapped away. The pellet
was immediately resuspended in 50 µl of hybridisation buffer (40% formamide, 5x
Denhardt’s solution, 5x SSC, 1.65 mM sodium pyrophosphate, 50 mM Tris-Cl pH 7.4,
and 0.1% SDS) at 50 ◦C for 10 minutes. The samples were denatured at 95 ◦C for
5 minutes, quickly pipetted onto slides, and covered with lifter-slips. The slides were
placed in hybridisation boxes containing tissues soaked with 50 µl of water to ensure
constant humidity, but not so much moisture that cover slips slide off. The boxes
were placed in a water bath at 48 ◦C and hybridised for 17 hours. After incubation,
the cover slip was separated from the array by immersing it into a solution of 1x SSC.
The labelled array was washed with agitation for 5 minutes each in baths of 1x SSC,
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followed by 0.5x SSC, and finally 0.1x SSC. The array was rinsed quickly in water
(no more than a few seconds to avoid denaturation) and in ethanol, and spun at 3000
x g to dry. Slides were then stored desiccated in a dark box until scanning and were
stable for at least a week. When possible, the arrays are scanned on the same day
as the washing step to avoid differential degradation of the dyes and accumulation of
dust.
Image Capture, Quantification and Quality Control
The MEEBO microarray image was captured using an optical scanner, the ArrayWorx R©
biochip reader (Applied Precision). The preliminary scan was performed at the mini-
mum exposure time in each channel (0.06 seconds), and the optimum exposure calcu-
lated to bring the brightest features on the array to the saturation limit of the scanner,
thus, increasing the sensitivity of the image analysis for the less bright pixels. The
final scan was performed with the new exposure times. The array was scanned to
produce a digital record of the red and green fluorescence emissions at each point
on the array. This digital record typically takes the form of a pair of 16-bit TIFF
images. Images must be analysed to extract numerical foreground and background
intensity for the red and green channels for each spot on the array. The localisation
of each spot on the array was done automatically by the software Bluefuse R© using
the basic array layout and the number of spots on the array. Bluefuse R© averages
intra-slide replicate spots to assess the reproducibility of the duplicates and provide
a confidence score. The setting of time-exposures for Cy3 and Cy5 is a way of ad-
justing, therefore, correcting for intensity variances between both channels. Images
were analysed with the Bluefuse R© software. Bluefuse R© performs a quality control
assessment of the data and allocates flags accordingly (A: highly reliable, E:highly
unreliable). This information can be used to filter bad data. For some analyses, a
balanced design is required and therefore flagged data was not filtered. However, the
flag was considered once the list of significant genes was obtained and genes with
E flags were considered unreliable. Data files were then imported into excel, where
relevant pieces of information could be cut out and transferred to an analysis software
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program.
2.3.7 Illumina BeadArray
The Illumina Bead Array technology is based on the random self-assembly of an
array of beads onto a patterned substrate. The 3-micron silica beads self assemble
in microwells on planar silica slides (see Figure 2.2). Each bead is covered with hun-
dreds of thousands of copies of a specific oligonucleotide that act as probe sequences.
The random loading of beads and subsequent decoding allows extreme miniaturisa-
tion and high-density packing which increases the redundancy of each element on the
array. The DNA-decoding method utilises sequential hybridisations of dye-labelled
oligonucleotides to create a combinatorial decoding method. By using an error check-
ing scheme, the median random error rate for the decoding algorithm was estimated
to be <1 x 10−4. This has negligible impact on the results of the hybridisations
which give the >20-fold redundancy and the five-fold minimum redundancy of each
bead type [68]. This system has a specific rat chip. The specific Illumina chip we
use in our hybridisation is the Rat-Ref12 chip, as shown in Figure 2.2. This chip was
designed from the NCBI RefSeq database and contains 12 arrays, each comprised of
22,500 oligonucleotide 50-mers and probes 21,910 genes covering almost the entire
rat transcriptome.
Each array has up to 1,536 different bead types. Each bead type is represented
by an average of ≈30 copies in any array. This means that each array is unique. Due
to the ≈30–fold oversampling (50,000 beads/1,536 bead types), it is insured that
decoded arrays have greater than or equal to five beads of each type in the array,
all sequences are represented. Each bead type has ≈700,000 copies of a particular
oligonucleotide probe covalently attached to the bead by the sequence’s 5′ end. These
chimeric oligonucleotides are approximately 75–nucleotides in length, comprising a
≈25–nucleotide identifier sequence and a 50–nucleotide gene-specific probe. Because
the population of beads in an array is a random sampling of a starting bead pool
containing 1,536 bead types, the representation of the bead types in the array follows
34
Figure 2.2: Bead Array Image
the Poisson distribution. That is, there is a variable number of each of the 1,536 bead
types both within and between arrays. This randomness and redundancy provides two
important advantages. The randomness minimises the effects of spatially localised
artefacts and the redundancy increases measurement precision and robustness. These
factors combine to increase measurement accuracy [69].
It is also important that the identifier sequence of the oligonucleotide does not
interfere with the hybridisation. This is done by screening the sequences to avoid sim-
ilarity that would lead to cross-hybridisation. In addition, the identifier sequences are
half the length of gene-specific probes and have lower Tm’s (melting temperatures).
It is estimated that the signal provided by the identifier sequences is not enough to
affect the analysis [69].
RNA Amplification, Labelling and Array Hybridisation
The RNA samples were amplified following the Illumina TotalPrep RNA am-
plification protocol. This process begins with reverse transcription using the T7
Oligo(dT) Primer to synthesise first strand cDNA containing a T7 promoter se-
quence. Second strand cDNA synthesis converts the single-stranded cDNA into a
double-stranded DNA (dsDNA) template for transcription. The reaction uses DNA
polymerase and RNase H to simultaneously degrade the RNA and synthesize the sec-
ond strand cDNA. cDNA purification removes RNA, primers, enzymes, and salts that
would inhibit in vitro transcription. In vitro transcription generates multiple copies
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of biotinylated cRNA from the double-stranded cDNA templates; this is the ampli-
fication and labelling step. cRNA purification removes unincorporated NTPs, salts,
enzymes, and inorganic phosphate. After purification, cRNA is ready for use with
Illumina’s direct hybridisation array kits. The samples were hybridised overnight at
55◦C to the RatRef-12 expression chip available from Illumina (sampling 21,290 genes
from the rat transcriptome).
Image Capture, Quantification and Quality Control
The BeadArray Reader and associated BeadStudio software was used for the
image analysis of the Illumina BeadArrays. The scanner uses a confocal-type imaging
system with -0.8–µm resolution and 532 and 635 nm laser illumination. Scans were
performed in the 532–nm channel [69]. The scanner completes the following steps
during the scanning of the BeadArrays: (i) All pixel intensities are altered using a
sharpening transformation. The intensity of a particular pixel is made higher/lower
if its intensity is high/low in comparison to the intensities of the pixels surrounding
it. (ii) Foreground intensities are calculated as a weighted average of signals obtained
using the four pixels nearest to each bead centre as a virtual bead centre. Sharpened
pixel intensities are used in the calculation. (iii) The local background, an average of
the five dimmest pixels (unsharpened intensities) within the 17x17 pixel area around
each bead centre, is subtracted.
It is essential to upload the slide specific decode file before scanning the slide,
as this gives the software the details of the location of the bead types on the slide.
Once the scan is complete, the files are transported to BeadStudio for the quality
assessment.
The Illumina Bead Studio software was used for the initial quality control as-
sessment. Bead Studio includes a spectrum of internal controls for determining data
quality. These check for consistency in signal intensity, expected background and
noise levels, mismatches versus perfect matches, and signal in housekeeping genes.
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2.3.8 microRNA Expression Array
RNA Amplification, Labelling and Array Hybridisation
DNA samples were run with the Illumina MicroRNA Profiling Assay using the
Mouse microRNA Panel which contains 380 sequences. The manufacturer provides
a detailed protocol for the assay which is an extension of the proven DASL (cDNA-
mediated Annealing, Selection, Extension, and Ligation) Assay. First, a stretch of
polyA tail was added to the 3′ end of each sequence in the RNA sample. Then
sufficient RNA from each sample was reverse-transcribed. The biotinylated cDNAs
were combined with microRNA-specific oligos (MSOs), hybridisation reagents, and
paramagnetic particles in an Assay Specific Extension (ASE) plate. The plate was
heated to allow the MSOs for each sequence target of interest to anneal to the bi-
otinylated cDNA samples. The cDNA was simultaneously captured by paramagnetic
particles. After the oligos were hybridised to the cDNA, mis-hybridised and excess
oligos are washed away. Next, an extension and ligation master mix (consisting of
extension and ligation enzymes) was added to each cDNA sample. The extension
and ligation reaction occurs at 45 ◦C . The DNA polymerase and the Uracil DNA
Glycosylase were added to the master mix for PCR. The PCR reaction used three
universal primers. Two were labelled with fluorescent dyes and the third was bi-
otinylated. The biotinylated primer captures the PCR product and allows the strand
containing the fluorescent signal to be eluted. The PCR plate was thermal cycled to
fluorescently label and amplify the templates generated in the Pre-PCR process. The
double-stranded PCR products were immobilised by binding the biotinylated strand
to paramagnetic particles. The solution was transferred to a filter plate and incu-
bated at room temperature so that the PCR product could bind to the paramagnetic
particles. The single-stranded fluor-labelled PCR product from the filter plate was
washed and then eluted into an intermediate (INT) plate. The product from this
plate was hybridised to the BeadChip. The BeadChips were hybridised overnight
using the Illumina Hyb Chamber with a temperature ramp from 60 ◦C to 45 ◦C .
The BeadChips were then removed from the Hyb Chamber and washed three times
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with UB2 and XC4 reagents.
Image Capture and Quantification
The Illumina BeadArray scanner was used to capture and quantify the hybridisa-
tion signals as described for the expression arrays. The Illumina Bead Studio software
was used for the initial quality control assessment. Subsequent analysis was done us-
ing the R package Limma as previously described for the expression arrays.
2.3.9 Filtering, Data Visualisation and Normalisation
Once the data has been captured and quantified, the raw data was imported into
an analysis software program. Most of the analysis done in this thesis utilised R. R
is an open source language and environment for statistical computing and graphics.
R provides a variety of statistical (linear and nonlinear modelling, classical statistical
tests, time-series analysis, classification, clustering, etc.) and graphical techniques,
and is highly extensible. Bioconductor is an add-on package for R that was developed
for Computational Biology and Bioinformatics [70]. As Bioconductor is commonly
used for microarray analysis, additional add-on packages are frequently being de-
veloped by users. These packages can be platform or analysis specific. The two
packages utilised most for analysis in this thesis are Limma and Lumi, which are
described later.
Inforsense Knowledge Discovery Environment 4.2 (KDE; www.inforsense.com)
was also occasionally used for data manipulation and analysis. KDE is a statisti-
cal package with a unique interface that appears as a pipeline of tasks. Although
less flexible than R, it is useful for visually manipulating datasets. The software
also includes a wide variety of normalisation methods, classifications, clustering, and
graphical options.
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Filtering
Illumina data was filtered in R for those showing expression on at least one array.
Filtering out only those that were not detected at all is the least stringent filtering
available. A detect call was used to include a count of how many slides showed an
expression value for each gene. This information was useful in analysing the data to
see the robustness of the results for a particular gene.
Data Visualisation
Data visualisation is important to assess the success of the experiment, the quality
of the data, and to choose an appropriate normalisation method. Plots comparing the
arrays are useful to determine that all arrays performed in a similar way. A selection
of graphs including MA plots, pariwise comparisons, box plots, density plots and
hierarchical clustering were produced for all datasets.
Normalisation Methods
Normalisation was performed in R (Bioconductor) using the Limma [71] and Lumi
[72] Bioconductor packages for microarray analysis. Limma is a package that was
designed for the analysis of gene expression microarray data using linear models to
assess differential expression. Lumi is a package that was designed especially for
Illumina BeadArray Data. It includes algorithms specific to the unique aspects of
the Illumina BeadArray system. In particular, the variance-stabilising transformation
(VST) algorithm takes advantage of multiple technical replicates (on average 20–30
per array) unique to the Illumina BeadArray system [73]. It is therefore, better suited
to the analysis of Illumina data than a base-2 logarithmic (log2) transformation,
which is traditionally used in microarray analysis. Variance stabilisation is one of the
primary reasons for log2 transformation of microarray data. Larger intensities tend
to have larger variances when repeatedly measured and can cause a problem when
data is subsequently analysed using ANOVA models. The VST algorithm utilises the
within-array technical replicates to model the mean-variance relationship directly.
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This allows the direct calculation of parameters for optimal data transformation from
each array.
This was followed by quantile normalisation which was chosen to remove any
remaining technical variability between arrays. Quantile normalisation [74] method
transforms the distribution of intensities from one distribution to another.
Multiple Testing Correction
Due to the large number of genes being tested simultaneously it is important
to perform a multiple testing correction to correct for the chance of obtaining false
positives. Here, we have chosen the false discovery rate (FDR) to correct for false
positives. The FDR method orders genes in increasing order of the p-values provided
from the independent tests. The p-values are then compared to a threshold value
related to the genes position in the list. The null hypothesis is rejected for genes that
have a p-value less than their corresponding threshold. The FDR correction is not
one of the most stringent and is a good choice because it does not assume all genes
are independent.
2.3.10 Selection of Differentially Expressed Genes
Pairwise Comparison-Linear Modelling
Limma was used for pairwise comparisons between treatment groups using a linear
model to compute p-values, which were adjusted using the Benjamini and Hochberg
multiple testing correction. The derivation of the p-value reflects the degree of vari-
ance between biological replicates and thus, is a measure of the confidence in assigning
significance of small fold changes in gene expression. Genes with a p-value < 0.05
were considered to be significantly differentially expressed.
Mixed Model ANOVA
The Leptin Reversal Study (Chapter 4) involved three separate treatments. To
analyse the data effectively, it was necessary to find a method that could separate
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the effects of each treatment and provide a separate gene list for each. ANOVA
based methods are particularly suited to estimating variance in studies with several
experimental steps. The appropriate model for this experiment is a Mixed Model
ANOVA, which allows random and fixed effects and estimates the variability by
variance components. Peter Sykacek, previously at University of Cambridge, wrote
a software package for R called FSPMA: Friendly Statistical Package for Microarray
Analysis [75] that relies on another mixed model ANOVA package for R, YASMA: Yet
Another Statistical Microarray Analysis [76], which allows the precise specification of
nested effects. FSPMA requires a balanced study design and is run by entering the
specifics of the experimental design into a definition file specifically designed for one
channel microarray experiments. In this particular experiment, the fixed effects were
the three treatments (preg, the AD (normal) or UN (undernourished) diet during
pregnancy; lepsal, the leptin (LEP) or saline (SAL) injection at days 3-13 of life;
and diet, the normal (CHOW) or high-fat (HF) postweaning diet) and the random
effect was the biological replicates for each treatment group. The technical replicates
were taken into account during the normalisation. Once the definition file has been
accurately completed, including the list of genes after filtering and the list of data
files, the definition file is then loaded into R and produces output files that rank the
genes that were found to be significant (p-value < 0.05). The p-value is then adjusted
in R using the FDR multiple testing correction. (FSPMA lecture) The model used
is:
yijkl = µ+ αi + βij + Aijk + ijkl
where µ models the gene-specific global mean, αi models the main gene effect, βij
models the gene-time interaction, Aijk models the gene-time-sample interaction and
ijkl models the residual error. The effects that correspond to gene and time are fixed.
The effects corresponding to sample and replicate are random.
i = 1, . . . , n; (n = numberofgenes)
j = 1, . . . ,m; (m = numberoftimepoints)
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k = 1, . . . , a; (a = numberofsamples)
l = 1, . . . , b; (b = numberoftechnicalreplicates)
2-way ANOVA with an Interaction Term
The 2-ways ANOVA considers the interaction between two of the effects. This
model was also used for the Leptin Reversal Study (Chapter 4) to investigate the
interaction between the different treatments.
Xijk = µ+ αi + βj + (αβ)ij + ijk
This equation is similar as to that of the Mixed Model ANOVA. Here the term (αβ)ij
represents the interaction between the i -th factor α and the j -th factor β. This model
was implemented using Limma.
Principle Component Analysis
Principle Component Analysis (PCA) is a multivariate analysis method used for
exploratory analysis. It transforms a number of possibly correlated variables into
a smaller number of uncorrelated variables called principle components. This was
implemented using KDE.
2.3.11 Gene Ontology Analysis
Gene ontology analysis was done using DAVID: Database for Analysis, Visual-
ization, Integrated Discovery [77], Ingenuity Pathway Analysis software (Ingenuity,
Stanford USA) and Onto-Express [78].
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2.4 Polymerase Chain Reaction
2.4.1 Genomic PCR
Genomic DNA PCR was carried out in a total volume of 20 µl containing 2 µl
10x buffer, 3.2 µl dNTPs (2.5 mM each), 2 µl DNA (100 ng/ µl), 2.4 µl primer mix
(5mM each forward and reverse), 0.2 µl Hot Star Taq, and water up to 20 µl. PCR
conditions were adjusted based on the melting temperatures of the primers used in a
particular reaction.
2.4.2 Comparative Quantitative Real Time RT-PCR
The comparative expression levels of genes identified as differentially expressed
from our microarray data were verified by qRT-PCR, together with the expression
levels of several candidate genes not present on the array. Cyclophilin was used for the
generation of a standard curve and normalisation of the RNA concentration. Each
qRT-PCR was performed in triplicate. Real-time RT-PCR was performed in 96-well
white plates (Abgene) using the Verso SYBR Green 2-Step qRT-PCR Fluorescein
Kit (Thermo Scientific, UK) according to the manufacturer’s protocols; the resulting
fluorescence was quantified using an iCycler system (Bio-Rad). The Ct was obtained
for each well as the cycle number at which the measured fluorescence crossed the
arbitrary threshold of 150 units (all values are in log phase). The average Ct was
calculated for each gene in each sample. Data were normalised to cyclophilin, with
∆Ct calculated as follows: ∆Ct = Ct(test)-Ct(cyclophilin). ∆∆Ct values were then
calculated as the change in ∆Ct for the UN sample relative to the ∆Ct value for the
AD sample using the equation: ∆∆Ct = 2Ct(test)-2Ct(cyclophilin) . A melting curve was
also performed to verify the specificity and identity of the RT-PCR product.
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2.5 DNA Extraction
2.5.1 From Tissue (Undernutrition Study)
To extract DNA from tissue, 25 mg of frozen tissue was placed in separate white
capped 10 ml tubes each containing 1 ml of homogenising buffer for each sample. The
tissue was homogenised for 30 seconds. The homogeniser head was thoroughly cleaned
between each sample. To pellet the nuclei, the homogenate was slowly centrifuged
for 5 minutes at 500 g (2500 rpm). The pellet was then resuspended in 500 µl
homogenising buffer. If the pellet was not dissolving immediately a pipet-tip was
used to break it up. To yield a final concentration of 10 mM EDTA, 10 µl 0.5 M
EDTA (pH 7.0) was added to the solution. The solution was mixed thoroughly
and 20 mg/ml of proteinase K (5 µl) was added to yield a final concentration of
100 µg/ml. The solution was mixed thoroughly, and 10% SDS (51.5 µl) was added
to give a final concentration of 1% SDS. The solution was again mixed thoroughly
but gently by inversion. The samples were incubated overnight at 55 ◦C. The next
day 1 volume of 5 M ammonium acetate was added and the solution was mixed by
inversion. The solution was chilled on ice for 30 minutes and then centrifuged at
12,000 x g for 3 minutes. The supernatant was transferred to a clean tube and 0.6a
volume of isopropanol was added to precipitate the DNA. The solution was mixed
by inversion. The samples were then placed in the freezer to aid in precipitation
of DNA, if necessary. The precipitated DNA was carefully removed and washed by
soaking in 70% EtOH for 10 minutes. The DNA was allowed to air dry briefly, but not
completely, sometimes this took a long time. The DNA was dissolved in TE buffer
(approximately 100–300 µl). Finally, DNA samples were purified using the DNeasy
Column purification kit (Qiagen, UK) following the manufacturer’s instructions.
2.5.2 Following RNA extraction
For some samples, DNA was extracted from the frozen remnants (phenol and
interphase mix) of the TRIzol RNA extraction protocol. This frozen phenol and
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interphase mix was centrifuged for 15 minutes at 4 ◦C. It was important to make
sure the aqueous phase had been thoroughly removed before adding 300 ml of 100%
ethanol per 1 mL TRIzol Reagent originally used. This was mixed by inversion and
stored at room temperature for 2–3 minutes. The solution was then centrifuged at
no more than 2000 x g for 5 minutes at 4 ◦C. The phenol-ethanol supernatant was
removed and saved for protein isolation (approx 800 mL per 1 mL TRIzol). The DNA
pellet was washed twice in 0.1 M sodium citrate in 10% ethanol. For large pellets an
additional wash was required. For each 1 mL of TRIzol Reagent originally used, 1 mL
of the sodium citrate solution was used. At each wash, the DNA pellet was stored
in the washing solution for 30 minutes at room temperature with periodic mixing.
The solution was centrifuged at 2000 x g for 5 minutes at 4 ◦C. After two washes,
the DNA was suspended in 75% ethanol (1.5–2 mL per 1 mL TRIzol Reagent). The
solution was then left for 10–20 minutes at room temperature with periodic mixing
before centrifuging at 2000 x g for 5 minutes at 4 ◦C. The DNA was then air-dried
for 5 minutes in an open tube and then was dissolved in 8 mM NaOH such that the
concentration of DNA was 0.2–0.3 µg/µl. For DNA isolated from 50–70 mg of tissue,
300–600 µl of 8 mM NsOH was added. The insoluble (gel-like) material (fragments of
membranes, etc.) was separated by centrifugation at >12,000 x g for 10 minutes. The
supernatant containing the DNA was transferred to a new tube. The A260 value of
an aliquot of the DNA prep was measured in NaOH mixed with water. The expected
yield of DNA per mg of liver tissue was 3–4 µg.
2.6 Methylation PCR
The HpaII-McrBC PCR [79] was used to discriminate patterns of methylation. In
this method, HpaII is used to cut unmethylated alleles
(cutting at sites: 5′ . . . C∧CGG . . . 3′/3′ . . . GGC∧G . . . 5′),
while McrBC is used to cut methylated alleles
(cutting at sites: 5′ . . . PumC(N40−3000)PumC . . . 3′.
MspI was used as a negative control as it cuts independent of methylation at HpaII
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sites. PCR was performed using the HotStarTaq PCR kit and optimised using ‘touch-
down’ techniques for individual primers. Products were separated by gel electrophore-
sis using 1–1.5 agarose with 0.5 mgml EtBr. The methylation changes were inferred
from the intensity of the bands from different digests. The subsequent digestions of
HpaII and McrBC gave four possible results. These results indicate full, null, incom-
plete, or composite methylation. This provides a general idea of where methylation
sites are located. The exact location of the methylation sites can then be examined
in more detail.
2.7 Bisulphite Sequencing
DNA samples were subjected to sodium bisulphite modification using EpiTect
Bisulphite conversion kit (Qiagen, UK) and used as template in PCR.
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Chapter 3
Expression Study of rats
undernourished in utero
3.1 Introduction
The data presented in this chapter has resulted in a manuscript that was published
in PLoSONE ([80]). The results have all been discussed in this chapter and certain
points have been examined in more detail for the purpose of this thesis.
In this chapter, an established rat model of balanced maternal undernutrition
has been used for investigation of gene expression differences in target tissues (liver,
retroperitoneal white adipose fat, and biceps femoris skeletal muscle) between off-
spring of control and undernourished mothers. Male rats are able to breed as early
as 35 days and can live to nearly 550 days. We studied young male adult rats at day
55 when they have not yet developed the abnormal phenotype in order to identify
any gene expression changes that may play a role in predisposing these animals to
the development of the metabolic syndrome. The genes that showed significant gene
expression differences in the liver suggest that the rats have suffered a substantial
impairment of their ability to utilise carbohydrate. They may have lost the flexibility
to switch between carbohydrate and fat as an energy source. The results suggest that
maternal undernutrition leads to offspring that favour fat as an energy source thus,
resulting in mitochondrial dysfunction. This chapter begins with a review of fuel
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metabolism as a background for the discussion of the results. This is followed by a
description of experimental design and data quality. Finally, the analysis is explained
and discussed.
3.1.1 Energy Balance and Starvation
In this study, pregnant rats are subjected to severe undernutrition (30% of their
normal diet). This is approaching a level of starvation. To understand the effects this
might have on their offspring, it is important to understand the basic biochemistry
of fuel metabolism (specifically lipid and carbohydrate metabolism) and the changes
that occur during starvation.
Metabolic Homeostasis
Cells require a constant supply of fuel in order to create adenosine triphosphate
(ATP) that is required for normal cell function and growth. A balance must be main-
tained between carbohydrate, fat, and protein intake; their storage when present in
excess, and their mobilisation; and synthesis when in demand. This is metabolic
homeostasis: the two major hormonal regulators are insulin and glucagon. Insulin
is a major anabolic hormone that promotes the storage of fuels and the utilisation
of fuels for growth. Glucagon is the major fuel mobilisation hormone. Other hor-
mones, such as adrenaline respond to stress and can increase the availability of fuels.
These hormones contribute to homeostasis by responding to changes in the levels of
circulating fuels that are determined by diet. Figure 3.1 shows the major sites of
insulin action on fuel metabolism in liver, adipocytes, and skeletal muscle and figure
3.2 shows the major sites of glucagon action in the same tissues.
Insulin and glucagon are very important in regulating blood glucose levels. After
a high-carbohydrate meal, blood glucose rises quickly. After the meal is digested and
absorbed, blood glucose levels decline because cells continue to metabolise glucose.
If blood glucose continued to rise after a meal, the high level of blood glucose would
cause the release of water from tissues including the brain. However, if blood glucose
48
Figure 3.1: This figure shows the major sites of insulin action in fuel metabolism.
The plus sign represents pathways that are stimulated by insulin; the minus sign
represents pathways that are inhibited by insulin. This figure was adapted from
Lieberman et al. [81]
.
Figure 3.2: This figure shows the major sites of glucagon action in fuel metabolism.
The plus sign represents pathways that are stimulated by glucagon; the minus sign
represents pathways that are inhibited by glucagon. This figure was adapted from
Lieberman et al. [81]
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levels drop after a meal, glucose-dependent tissues would suffer from a lack of energy.
Insulin helps to regulate these levels so that even after 5-6 weeks of starvation blood
glucose levels do not decrease dramatically [81].
Metabolic Fasting
In the initial stages of fasting, stored fuels are used for energy. This state is called
the basal state and is illustrated in figure 3.3. During fasting, fatty acids released
from adipose tissue serve as the body’s major fuel. The liver oxidizes most of its fatty
acids only partially, converting them to ketone bodies, which are released into the
blood. Muscle and many other tissues are able to use fatty acids or ketone bodies;
however, red blood cells, the brain, and other neural tissues use mainly glucose. The
liver is the organ that maintains blood glucose levels during fasting, and therefore, its
role in survival is crucial. When blood glucose levels drop, the liver replenishes blood
glucose via gluconeogenesis. Figure 3.4 illustrates the key reactions of gluconeogene-
sis. During this process, lactate, glycerol, and amino acids (particularly alanine) can
be used as carbon sources to synthesize glucose. Most of the amino acid is supplied
by degraded muscle protein. The nitrogen of the amino acids can form ammonia,
because this is toxic, the liver converts it to urea [81].
Metabolic Starvation
The hormonal changes that occur during fasting stimulate the breakdown of adi-
pose triacylglycerols. This results in the release of fatty acids and glycerol into the
blood. Figure 3.5 shows the tissue interrelationships during fasting. Glycerol is the
major source of carbon for gluconeogenesis. Fatty acids become the major fuel for
the body and are oxidized by various tissues, which enable these tissues to reduce
their consumption of glucose. Fatty acids are also oxidized to acetyl CoA in the
liver to provide energy for gluconeogenesis. Acetyl CoA can be converted to ketone
bodies. If this pattern of fuel utilisation was prolonged, the body’s protein would be
rapidly consumed. Metabolic changes occur during prolonged fasting (starvation) to
conserve muscle protein. The starvation state is illustrated in figure 3.6. After 3-5
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Figure 3.3: This figure represents the basal state. This state occurs after an
overnight (12-hour) fast. The circled numbers serve as a guide indicating the
approximate order in which the processes begin to occur. KB=ketone bodies;
TG=triacylglycerols;FA=fatty acid; AA=amino acid; RBC=red blood cell. This
figure was adapted from Lieberman et al. [81]
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Figure 3.4: This figure depicts the key reactions that occur during gluconeogenesis.
The precursors are amino acids (particularly alanine), lactate, and glycerol. Heavy
arrows indicate steps that differ from those of glycolysis. The conversion of phos-
phoenolpyruvate to glyceraldehyde 3-phosphate requires the reversible enzymes of
glycolysis. This figure was adapted from Lieberman et al. [81]
.
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days of fasting the muscle decreases its use of ketone bodies and depends mainly on
fatty acids for fuel, while the liver continues to convert fatty acids to ketone bod-
ies. The result is that the concentration of ketone bodies in the blood rises. The
brain begins to take the ketone bodies from the blood and oxidise them for energy.
Gluconeogenesis in the liver is now the only process by which the liver can supply
glucose to the blood if fasting continues. However, due to the ketone body utilisation
the rate of gluconeogenesis can decrease, in turn decreasing the amount of protein
degraded to supply amino acids to gluconeogenesis. As the use of ketone bodies in-
creases, the body needs roughly one-third as much glucose. As a result of reduced
glucose utilisation, the rate of gluconeogenesis in the liver decreases, and the produc-
tion of urea go down. For this reason, urea can be used as a measure of the extent
of protein degradation. Proteins function as enzymes, as structural proteins, and in
muscle contraction. If tissue protein is severely degraded then body function can be
compromised. If starvation continues and no other problems occur the individual
can die of severe protein loss that causes organs to malfunction. For this reason, the
increase in ketone body levels that result in the conservation of body proteins allows
individuals to survive starvation for extended periods.
As fatty acids are released from the adipose tissue during fasting, they travel
in the blood complexed with albumin. These fatty acids are oxidized by various
tissues particularly muscle. In the liver, fatty acids are transported into mitochondria
because acetyl CoA carboxylase is inactive, malonyl CoA levels are low, and carnitine
pamlitoyltransferase I is active. Acetyl CoA, produced by β-oxidation, is converted
to ketone bodies.
Our energy expenditure is equivalent to our oxygen consumption. The majority
of our oxygen consumption (90-95%) is used for the synthesis of ATPases in the elec-
tron transport chain by oxidative phosphorylation. Most of the enzymes for the Citric
Acid (TCA) cycle, electron transport, and other pathways for oxidation are located in
the mitochodrial matrix. Fatty acid oxidation is the process in which very long chain
fatty acids are oxidized by peroxisomal β and α-oxidation pathways, which are essen-
tially chain-shortening pathways. Ketone bodies are synthesised in the mitochondrial
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Figure 3.5: This figure illustrates the tissue interrelationships during fasting.
(1)Blood glucose levels decrease, decreasing insulin, and raising blood sugar lev-
els. (2)Glycogenolysis is induced in the liver to raise blood glucose levels. (3,4)The
brain and red blood cells use the glucose released by the liver. (5)Adipose tissues
are signalled to release free fatty acids and glycerol from stored triglycerides. (6)The
muscle and liver use fatty acids for energy. (7,8)The liver converts fatty acid derived
acetyl CoA to ketone bodies for export, which the muscles and brain can use for
energy. (9)Protein turnover is induced in muscle, and amino acids leave the muscle
and travel to the liver for use as gluconeogenic precursors. (10) The high rate of
amino acid metabolism in the liver generates urea, which travels to the kidney for
excretion. (11) Red blood cells produce lactate, which returns to the liver as a sub-
strate for gluconeogenesis. (12)The glycerol released from adipose tissue is used by
the liver set gluconeogenesis. KB=ketone bodies; FA=fatty acid; AA=amino acid;
TG=triacylglycerols. This figure was adapted from Lieberman et al. [81]
.
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Figure 3.6: This figure represents the starved state. Broken lines indicate processes
that have decreased, and the heavy solid line indicates a process that has increased
relative to the fasting state. KB=ketone bodies; FA=fatty acid; AA=amino acid;
TG=triacylglycerols; RBC=red blood cell. This figure was adapted from Liebermanet
al. [81]
.
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Figure 3.7: This figure from Symonds et al. [64] illustrates the importance of the
maternal-fetal nutritional environment in contributing to the developmental program-
ming of cellular energy metabolism in favour of lipid storage.
matrix from acetyl CoA generated from fatty acid oxidation. These examples just
briefly highlight the role of mitochondria in metabolism. Mitochondrial dysfunction
could significantly impact many different aspects of metabolism and energy balance
[81].
In the study presented in this chapter liver, muscle, and fat were used for molecular
analysis based on their importance in metabolism as highlighted in the preceding
biochemical background.
3.1.2 Genes/Pathways Highlighted in Other Studies
Several candidate genes have been highlighted as showing altered expression lev-
els in animal studies using restricted diets. Lillycrop 2005 showed that maternal
protein restriction during pregnancy in rats increased glucocorticoid receptor (GR)
expression and decreased 11β-hsd2 expression and altered the expression of Pparα
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and acetyl-CoA oxidase (Aox ) [82]. These genes are of particular interest because
changes in their expression levels have been linked with disturbances in cardiovas-
cular and metabolic control in humans and animals. GR activity is important for
the regulation of blood pressure, Pparα is central to lipid and carbohydrate home-
ostasis. Aox is the rate-limiting factor in the peroxisomal β-oxidation pathway and
is directly regulated by Pparα. Pepck is the rate-limiting factor in gluconeogenesis,
whereby glucose is synthesised. Studies with mice have shown that over expression
of Pepck can lead to diabetes mellitus type 2.
3.1.3 Initial Study
This study exploited a well defined model of developmental programming via ma-
ternal undernutrition [45, 83]. Virgin Wistar rats (age, 100 ±5 days) were time mated
using a rat oestrous cycle monitor to assess the stage of oestrous of the animals before
introducing the male. After confirmation of mating, rats were housed individually in
standard rat cages with free access to water. All rats were kept in the same room
with constant temperature maintained at 25 ◦C and a 12 h light/12 h darkness cycle.
Animals were assigned to one of two nutritional groups: a) undernutrition (30% of
ad libitum) of a standard chow diet throughout gestation (UN group), b) standard
chow diet ad libitum throughout gestation (AD group). The study design is illus-
trated in Figure 3.8. Food intake and maternal weights were recorded daily until
the end of pregnancy. After birth, pups were weighed, and litter size was adjusted
to 8 pups per litter to assure adequate and standardised nutrition until weaning. A
minimum of four litters per group were used. Pups from undernourished mothers
were cross-fostered onto dams that had received AD feeding throughout pregnancy.
The animals were culled at day 55 following an overnight fast to represent an age
known to precede the development of increased adiposity and altered insulin sensitiv-
ity in UN offspring. Tissues (liver, retroperitoneal white adipose, and biceps femoris
skeletal muscle) were collected as described in Chapter 2. A subcohort of animals
(n=8 per group) were maintained until postnatal day 110 to represent an age where
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Mother Rat
Normal Chow =
=30% Chow
AD
UN
FED
During 
Pregnancy
Figure 3.8: Study Design of Rats Undernourished in Utero. This figure summarises
the study design. During pregnancy rats were fed either ad libitum a standard chow
diet (AD) or 30% of a standard chow diet (UN). Pups from UN mothers were cross-
fostered onto dams that had received AD feeding throughout pregnancy.
phenotypic changes in growth and metabolism between AD and UN offspring have
previously been reported [45, 58].
3.2 Results
3.2.1 Previous Findings: Phenotypic Assessment
Physiological measurements were taken by the collaborators at the Liggins Insti-
tute as part of the initial unpublished study. These findings are summarised here.
Serial dual-energy x-ray absorptiometry (DEXA) analysis was performed on the an-
imals at day 55 to establish body composition and assessment of bone parameters.
In addition to DEXA, body composition was analysed via standard techniques (fat
depot dissection and weighing) following post-mortem. Body weight and food and
water intake were monitored. Plasma analysis incorporated these potential indicators
of metabolic syndrome: IGF-1, insulin, C-peptide (a measure of insulin secretion),
and lipid profiles. For comparison to an animal that had developed the phenotype,
we have included the phenotypic assessment of male rats (AD and UN) at day 110.
These animals were from a different cohort, and were given a saline injection (2.5
µ g/g· d) from day 3-13, but received the same nutritional treatment. Statistical
analyses were performed using KDE software. Differences between groups were de-
termined by a T-test for difference in variance with an FDR correction, and data are
shown as an adjusted p-value ± standard error (tables 3.1 and 3.2).
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Measurement AD Mean UN mean Adjusted p-value
Body weight (grams) 282.4 ± 5.6 234.5 ± 5.5 0.001
Body length (mm) 203.6 ± 1.7 192.63 ± 1.9 0.005
Liver weight (% body weight) 3.7 ± 0.1 3.0 ± 0.1 0.014
Spleen weight (% body weight) 0.32 ± 0.01 0.33 ± 0.02 NS
Heart weight (% body weight) 0.36 ± 0.01 0.38 ± 0.01 NS
Fat pad weight (% body weight) 0.80 ± 0.06 0.59 ± 0.04 0.039
Plasma glucose (mmol/l) 6.24 ± 0.28 6.67 ± 0.48 NS
Urea (mmol/l) 4.76 ± 0.24 6.18 ± 0.29 0.010
Free Fatty Acids (mmol/l) 0.79 ± 0.08 0.68 ± 0.06 NS
Glycerol (mmol/l) 0.21 ± 0.03 0.19 ± 0.01 NS
Total Protein (g/DL) 5.45 ± 0.12 5.39 ± 0.07 NS
Lipase (U/l) 9.10 ± 0.97 9.06 ± 1.19 NS
C-Peptide (pg/ml) 132.18 ± 15.63 162.85 ± 24.72 NS
Triglycerides (mmol/l) 0.78 ± 0.1 0.77 ± 0.06 NS
IGF-1 (ng/ml) 1221.50 ± 55.06 1277.63 ± 63.72 NS
Creatinine (mmol/l) 20.15 ± 0.49 23.64 ± 1.36 0.014
Insulin (ng/ml) 0.33 ± 0.06 0.53 ± 0.07 0.017
Total Fat (%) 24.09 ± 0.95 23.66 ± 0.47 NS
LDL (mmol/l) 0.27 ± 0.03 0.46 ± 0.04 0.006
HDL (mmol/l) 1.27 ± 0.06 1.34 ± 0.07 NS
LDL:HDL ratio 0.21 ± 0.02 0.35 ± 0.02 0.003
Table 3.1: Phenotypic measurements relevant to metabolic syndrome measured for
each of the eight animals in each treatment group at day 55 and shown as mean ±
SEM. The p-value was calculated with a t-test and an FDR correction. NS = not
significant.
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Measurement AD Mean UN mean Adjusted p-value
Body weight (grams) 511 ± 23.30 489 ± 24.45 NS
Body length (mm) 238 ± 2.52 218 ± 2.61 0.05
Total Fat (%) 27.81 ± 1.64 35.89 ± 2.51 0.05
Fat pad weight (% body weight) 1.45 ± 0.14 2.14 ± 0.20 0.05
Leptin (ng/ml) 9.63 ± 1.56 22.53 ± 5.49 0.005
Insulin (ng/ml) 0.26 ± 0.08 0.50 ± 0.08 0.001
C-Peptide (pg/ml) 466 ± 108.6 729 ± 96.8 0.05
Plasma glucose (mmol/l) 7.0 ± 0.44 7.2 ± 0.24 NS
Free Fatty Acids (mmol/l) 0.86 ± ± 0.10 0.99 ± 0.08 NS
Liver weight (% body weight) 2.92 ± 0.07 2.78 ± 0.07 NS
IGF-1 (ng/ml) 1236 ± 70.87 1145 ± 72.69 NS
Table 3.2: Phenotypic measurements relevant to metabolic syndrome measured for
each of the eight animals in each treatment group at day 110 and shown as the mean
± SEM. The p-value was calculated with a t-test and an FDR correction. NS = not
significant.
3.2.2 Microarray
Tissue samples were shipped to the University of Cambridge on dry ice for RNA
extraction. Eight biological replicates were used for each of the two treatment groups
(AD and UN) and for each of three tissues (liver, skeletal muscle, and white adipose
tissue).
MEEBO
The liver samples were hybridised to the MEEBO chip as described in Chapter
2. The experimental design used a reference design with a dye swap as shown in
Figure 3.9. Each MEEBO slide contained one UN individual hybridised against the
reference. The reference was a control pool of all eight AD samples. Only four of
the UN samples were hybridised. A technical replicate was done for each of the four
biological replicates, in addition to two dye swaps. So a total of 16 MEEBO slides were
hybridised, four for each of the four UN samples. RNA extraction, amplifications, and
microarray hybridisations were done as described in Chapter 2 and were randomised
to avoid sample bias.
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UN Sample
AD Sample
Array A Array B
Figure 3.9: Design of the Dye Swap Experiment for the Samples Hybridised on the
MEEBO Array. Control (AD) and treatment (UN) samples were labelled with cy3 or
cy5 dye and hybridised to MEEBO arrays. Samples were then labelled with alternate
dyes and again hybridised to arrays. These technical replicates allowed experimental
control over dye bias.
Data Quality Control
It is important to first check the quality of the hybridisations (described in Chapter
1). This can be done using a variety of visualisation tools. Figure 3.10 is a density
plot of the signal intensity against the density for each sample in each channel. This
is useful for visualising huge differences in intensity between samples or even between
dyes. Figures 3.11 and 3.12 show box plots of the amplitudes of intensities for each
dye separately across all samples. Both of these methods have revealed that although
there is variation in intensity across the samples, there does not seem to be a dye
bias.
Further quality control assessments can be made by comparing replicates within
treatment groups. This was determined using M-A plots which are shown for all
the samples in Figure 3.13. For most of the samples, the plot shows a funnel shape
indicating that there is higher variance at the lower intensities.
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Figure 3.10: This is a density plot of all MEEBO samples in each channel before
normalisation. This figure shows the density of intensities for the red and green
channels on each array. There is clearly variation in intensity, which can be corrected
with normalisation; however, there is no dye bias.
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Figure 3.11: This is a boxplot showing the amplitude of the intensities for each sample
in the red channel.
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Figure 3.12: This is a boxplot showing the amplitude of intensities for each sample
in the green channel.
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Normalisation/Differential Expression
Two different analyses of the data were performed. The initial analysis was done
using the R library FSPMA [75] for normalisation and to calculate p-values; FSPMA
is based on the mixed model ANOVA library YASMA [76] and is described in more
detail in Chapter 2. FSPMA averaged technical and biological replicates and nor-
malised the data using a loess normalisation. The analysis revealed 75 upregulated
genes (p-value < 0.001) and 100 significantly downregulated genes (p-value < 0.001)
(see Appendix C, Table 1).
The second analysis utilised the R library Limma. The data was normalised using
a loess within-array background correction and a quantile between-array normalisa-
tion. The differentially expressed genes were determined by pairwise comparison
with a FDR multiple testing correction to calculate p-values. This analysis revealed
956/38976 significant genes (see Appendix C, Table 2).
For both of these analyses the significant genes largely had A-flags with a few
B-flags which confirm that the data is reliable. This chip included several candidate
genes that are of interest in the literature including (Ppargc1b, Ppard, Pparc1a, Pparg,
Pparbp, Ppara, Acox1, Nr3c1, and Hsd11b2 ). Although all of these genes had A-
flags indicating successful hybridisation, none of them had significant p-values for
differential expression.
Illumina
After the initial hybridisation on the MEEBO chip, the Illumina platform was
acquired so the study was repeated and expanded using this technology. Subsequent
and more detailed analysis have focused on this dataset. Each Rat-Ref12 Illumina
chip has twelve arrays. As it is a single colour system there is no need for a dye swap.
In addition, as samples are hybridised independently AD samples were individually
hybridised rather than combined into a pool. In total, 4 Illumina slides (48 arrays)
were hybridised for the three tissue samples and two treatment groups. Figure 3.14
illustrates the experimental design. RNA was extracted from liver, muscle, and fat
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Figure 3.14: Microarray Design. This study included two treatment groups and three
different tissues. There were eight biological replicates for each treatment group.
RNA was extracted from the liver, muscle, and fat of each animal. The samples were
hybridised independently on Illumina RatRef12 chips. Each chip has 12 arrays; the
48 samples filled 4 Illumina slides.
tissue and hybridised to Illumina microarrays as described in Chapter 2.
Data Quality Control
The Illumina system includes several internal controls for estimating hybridisation
quality. Figure 3.15A-F shows six graphs of the quality control data for the liver,
muscle, and fat samples. Figure 3.15A compares the low, medium, and high intensities
across arrays. Ideally, arrays should have signal intensities in the same range. It is
expected that there be a linear increase of signal between the three intensities. In
figure 3.15A, there is a slight dip at medium intensity. To investigate this, it is
necessary to look at the individual data points for the medium intensity signals.
Figure 3.15B shows the detailed data for each array for the medium intensity signals.
This shows that all samples are not completely consistent. The medium intensity
signals, for the liver tissue samples, all fall in the tight range of 14,000-16,000 while the
muscle (12,000-22,000) and WAT (6,000-18,000) are much more spread out. Figure
3.15C shows the high stringency of the data. For high quality data, it is expected that
the biotin signal would be 3–4 fold lower than the high stringency signal, as shown
for this data. Figure 3.15D shows the low stringency of the data, by comparing the
signal intensity of two mismatches to the signal intensity of a perfect match. The
perfect matches should have a 3–4 fold higher signal, as shown for this data. No
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signal intensity indicates the hybridisation failed. Figure 3.15E shows the data for
the negative control. The background signal should be approximately 70. This value
is accounted for in the normalisation algorithms. The noise signal should be very low
for high quality data. Figure 3.15F compares the signal from the housekeeping genes
to the signal from all genes. As housekeeping genes are always expressed they should
have a much higher signal compared with all genes. This shows that this data was
generally high quality although a few of the muscle and WAT arrays had intensities
slightly higher or lower than most of the arrays.
To compare the samples in more detail the data was exported from BeadStudio
and imported into R Bioconductor. Here the raw data was plotted in several graphs
(pairwise, MA, density plot, boxplot), then normalised and re-plotted to compare
pre and post normalisation. In addition, the arrays were clustered using hierarchical
clustering. The hierarchical clustering in figure 3.16 shows that with few exceptions
the data clusters based on tissue type. This indicates there are more differences
between tissues than between treatment groups. In addition, it is a good quality
control check to confirm that samples do not cluster based on day of experiment or
other factors. Figures 3.17 to 3.22 show pairwise comparisons for each of the two
treatment groups for each of the three tissues. A tight diagonal line is expected
for replicates, as this indicates low variability between samples. Figure 3.20 and 3.22
reveal some data that do not look good. The UN-muscle samples 101.1 and 105.0 and
the UN-fat sample 105.0 show much more scatter than the others. Taking another
look at figure 3.16 reveals that two of these samples are the ones that did not cluster
in the same way as the other samples.
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A                                                                  C
B                                                                  D
                                                                     E                                                          
                                                                     F
Figure 3.15: Illumina Internal Controls. This figure shows the details of the internal
quality control tools for the Illumina platform. (A)Low, medium and high intensities
across arrays. Ideally, arrays should have signal intensities in the same range. It is
expected that there be a linear increase of signal between the three intensities. In
this data, there is a slight dip at medium intensity. (B)Detailed data for each array,
for the medium intensity signals. Individual array data is available for all internal
control measures, this one is being shown as an example. It shows that all samples are
not completely consistent. The medium intensity signals for the liver tissue samples
all fall in the tight range of 14,000-16,000 while the muscle (12,000-22,000) and WAT
(6,000-18,000) are much more spread out. (C)High stringency of the data. For high
quality data, it is expected that the biotin signal would be 3–4 fold lower than the
high stringency signal as shown for this data. (D)Low stringency of the data by
comparing the signal intensity of two mismatches to the signal intensity of a perfect
match. The perfect matches should have a 3–4 fold higher signal as shown for this
data. No signal intensity indicates the hybridisation failed. (E)Data for the negative
control. The background signal should be approximately 70. This value is accounted
for in the normalisation algorithms. The noise signal should be very low for high
quality data. (F)Comparison of the signal from the housekeeping genes to the signal
from all genes. As housekeeping genes are always expressed, they should have a much
higher signal compared with all genes. This shows that this data was generally high
quality although a few of the muscle and WAT arrays had intensities slightly higher
or lower than most of the arrays.
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Figure 3.16: Hierarchical Clustering of All Tissues Before Normalisation. We would
expect the biological replicates to cluster together. Here samples have clustered based
on tissue type. The samples that have clustered out of place (UN-muscle sample
101.1 and the UN-WAT sample 105.0) are also two of the samples that show a larger
variability in the pairwise plots in figure 3.20 and 3.22
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Figures 3.23 and 3.24 are plots of the arrays before normalisation. Figure 3.23
is a boxplot of the amplitude across and arrays and figure 3.24 is a density plot of
the intensity for each array. These plots show that there is variation between arrays,
therefore, normalisation is necessary.
Normalisation/Differential Expression
The three samples that had been shown as being poor data in the quality control
assessment were removed from subsequent analysis. In total, there were 22,226 genes
represented on the Illumina RatRef Chip. The data was filtered for genes expressed on
at least one array. This left 12,951 genes. Data was then transformed with a variance
stabilising transformation and normalised with a quantile normalisation (described
in more detail in Chapter 2). Figure 3.25 and 3.26 show a boxplot and density plot
of all samples after normalisation.
A pairwise comparison produced p-values and a list of differentially expressed
genes. This analysis revealed no significantly, differentially expressed genes amongst
the muscle and fat samples. This suggested that the larger variation among these
samples might be affecting the normalisation. Filtering and normalisation was re-
peated separately for samples from each tissue. Muscle was filtered to 10,644, fat
was filtered to 9,941, and liver was filtered to 10,887 genes. When the same transfor-
mation and normalisation was done to each data set, still no genes were revealed as
being differentially expressed in muscle and fat. For the liver samples, genes with a
p-value < 0.05 were considered to show significant differential expression between the
two groups. The comparison for liver revealed a list of 249 differentially expressed
genes, which is shown in table 3.3 with associated p-values and fold changes between
the two treatment groups. Appendix C Tables 1, 2, and 3 summarise the expression
values for all genes represented on the array for liver, muscle, and WAT.
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Boxplot of All Tissues Before Normalisation
Figure 3.23: Boxplot Before Normalisation. The box itself contains the middle 50%
of the data points. The line in the box indicates the median value of the data. If
the median line within the box is not equidistant from the hinges, then the data
is skewed. The ends of the vertical lines or ‘whiskers’ indicate the minimum and
maximum data values of the data from each array. The plot compares the amplitude
of all expression values on each array. This shows that the majority of the signal is
at lower expression levels. It also shows that there is some variability between each
array. This analysis was done in Lumi.
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Density Plot of All Tissues Before Normalisation
Figure 3.24: Histogram of Density of Log2 Intensities For All Arrays. This is a
histogram of each array showing the density of intensities (log2). This plot shows
that the majority of intensity values are low and that there is significant variation
between samples. This analysis was done in Lumi.
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Bloxplot of All Tissues After Filtering, VST, and Quantile Normalisation (n=12951)
Figure 3.25: Boxplot After Quantile Normalisation. This plot compares the ampli-
tude of all expression values on each array. This shows that the majority of the signal
is at lower expression levels and that there is no variability between the arrays. The
normalisation has effectively adjusted the expression values to remove the variability.
This analysis was done in Lumi.
8 10 12 14 16
0.
0
0.
2
0.
4
0.
6
0.
8
Log2 Intensity
D
e
n
si
ty
UN-liver_101.0
UN-liver_101.1
UN-liver_102.0
UN-liver_102.1
UN-liver_105.0
UN-liver_105.1
UN-liver_106.0
UN-liver_106.1
AD-liver_1.0
AD-liver_1.1
AD-liver_2.0
AD-liver_2.1
AD-liver_4.0
AD-liver_4.1
AD-liver_8.0
AD-liver_8.1
UN-muscle_101.0
UN-muscle_101.1
UN-muscle_102.0
UN-muscle_102.1
UN-muscle_105.0
UN-muscle_105.1
UN-muscle_106.0
UN-muscle_106.1
AD-muscle_1.0
AD-muscle_1.1
AD-muscle_2.0
AD-muscle_2.1
AD-muscle_4.0
AD-muscle_4.1
AD-muscle_8.0
AD-muscle_8.1
UN-wat_101.0
UN-wat_101.1
UN-wat_102.0
UN-wat_102.1
UN-wat_105.0
UN-wat_105.1
UN-wat_106.0
UN-wat_106.1
AD-wat_1.0
AD-wat_1.1
AD-wat_2.0
AD-wat_2.1
AD-wat_4.0
AD-wat_4.1
AD-wat_8.0
AD-wat_8.1
Density Plot of All Tissues After Filtering, VST, and Quantile Normalisation (n=12951)
Figure 3.26: Histogram of Density of Log2 Intensities For All Arrays After Quantile
Normalisation. This is a histogram of each array showing the density of intensi-
ties (log2). This plot shows that the majority of intensity values are low and that
there is no variation between samples. The normalisation has effectively adjusted the
expression values to remove the variability. This analysis was done in Lumi.
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Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
1.1003 0.0315 NM 013122.1 Igfbp2
0.7059 0.0114 NM 012733.3 Rbp1
0.6239 0.0483 NM 013089.1 Gys2
0.577 0.038 NM 001008363.1 RGD1310991 - Zfand2a
0.4877 0.0278 NM 053907.1 Dnase1l3
0.4662 0.024 NM 030832.1 Fabp7
0.4596 0.0331 NM 001007732.1 MGC94010 - Serpinb9
0.4265 0.0252 NM 175756.1 Fcgr2b
0.3684 0.0319 NM 024400.1 Adamts1
0.3412 0.038 NM 017334.1 Crem
0.3406 0.038 XM 573570.1 Crlz1 predicted
0.3322 0.0492 NM 001001507.1 Oit3
0.3299 0.0259 XM 235156.3 Ptprb predicted
0.3254 0.0278 XM 579533.1 Ugcg
0.3248 0.0319 NM 199085.1 Serpinb6
0.3181 0.0252 XM 576256.1 LOC500859 - similar to 60S ribosomal pro-
tein L7a
0.3151 0.0278 NM 001007657.1 RGD1359127 - similar to RIKEN
0.3125 0.0252 NM 022396.1 Gng11
0.3065 0.0278 XM 579502.1 LOC497936- Tmem88
0.3027 0.0319 XM 221702.3 LOC304138 - Cyyr1
0.2884 0.0286 XM 235041.3 LOC314733 - similar to ribosomal protein
S19
0.2863 0.0395 XM 575053.1 Sh3glb1 predicted
0.2854 0.038 XM 223786.3 Zfp503 predicted
0.2798 0.0407 XM 235308.3 Col14a1 predicted
0.2789 0.0309 NM 138974.1 Gstp2
0.2774 0.0315 NM 022510.1 Rpl4
0.2716 0.0328 NM 057137.1 Ebp
0.2702 0.0112 XM 216482.3 LOC298370 - Txndc12
0.2696 0.0326 XM 578896.1 LOC367566 - similar to Y-linked testis-
specific protein
0.2684 0.0317 NM 199372.1 Eif4a1
0.2602 0.0326 NM 001004279.1 Ppid
0.2535 0.0418 XM 213058.2 LOC298785 - similar to ribosomal protein
S26
79
Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
0.2529 0.0319 NM 198765.1 BicD2
0.2526 0.0252 XM 217279.3 Scap predicted
0.2521 0.0395 XM 577114.1 LOC501709 - similar to 60S ribosomal pro-
tein L23a
0.2515 0.0252 NM 031552.1 Add3
0.2494 0.0492 XM 235687.3 LOC315324 - Kb40
0.2494 0.0252 NM 001009674.1 Itm2c
0.2483 0.033 NM 053525.1 Ddx52
0.2481 0.0326 XM 579342.1 Tacr1
0.2479 0.0423 XM 233462.3 Tie1
0.2433 0.0252 XM 343771.2 LOC363450 - Ftsj1
0.2425 0.0492 NM 031646.1 Ramp2
0.2417 0.0492 NM 173116.1 Sgpl1
0.2406 0.0417 NM 001004085.2 Crat
0.2382 0.0326 NM 001009620.1 MGC105601 - Tmem204
0.2355 0.0278 XM 215041.3 Rpl27a predicted
0.2348 0.0417 NM 031093.2 Rala
0.2325 0.0006 XM 212922.3 LOC294700 - similar to ribosomal protein
L21
0.2313 0.0405 XM 343002.2 Cebpz predicted
0.2313 0.033 XM 235689.3 LOC315329 - similar to expressed sequence
AW556797
0.2288 0.0259 XM 341612.2 Sema6a predicted
0.2277 0.0395 XM 224350.3 Fndc3 predicted
0.2257 0.0423 XM 217105.3 Ei24 predicted
0.2252 0.0282 NM 001009702.1 RGD1306106 - Rrp15
0.2251 0.0259 XM 213960.3 LOC289324 - Cnih4
0.2248 0.0328 NM 017178.1 Bmp2
0.2219 0.0315 XM 578657.1 LOC366887 - similar to ribosomal protein
L31
0.2214 0.0497 NM 017233.1 Hpd
0.2205 0.0259 XM 345933.2 LOC367077 - similar to 40S ribosomal pro-
tein S26
0.2205 0.0278 XM 232937.3 LOC313196 - similar to KIAA0368
0.2205 0.0457 XM 214553.3 Atp8b1 predicted
0.2155 0.038 XM 342911.2 LOC362593 - Gnl2
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Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
0.2138 0.0233 NM 022605.1 Hpse
0.2124 0.0211 NM 001004245.1 Esam
0.2121 0.0457 XM 227556.3 LOC310760 - Cttnbp2nl
0.208 0.0315 NM 031745.2 Rsn
0.2067 0.0211 NM 017199.1 Ssr4
0.2062 0.0417 NM 013135.1 Rasa1
0.2057 0.0252 XM 221473.3 LOC498078 - similar to 60S ribosomal pro-
tein L7a
0.204 0.0469 XM 343850.1 LOC363531 - similar to 40S ribosomal pro-
tein S19
0.202 0.0424 XM 579528.1 B4galt6
0.2015 0.0315 XM 214191.3 Xpo4 predicted
0.2013 0.0319 NM 054004.1 Cand1
0.1992 0.0407 XM 580138.1 LOC500939
0.1982 0.0259 NM 012875.1 Rpl39
0.1952 0.0252 XM 216499.3 LOC298425 - RIKEN
0.1945 0.0211 XM 576096.1 LOC500714 - similar to ribosomal protein L6
0.1915 0.0282 XM 213403.3 LOC287541 - Ift20
0.1907 0.0226 XM 215053.3 LOC293454 - Ubfd1
0.1893 0.0395 XM 343490.2 LOC363151 - Ccdc12
0.1891 0.0252 XM 577309.1 LOC364108 - similar to ribosomal protein
S17
0.1887 0.0492 XM 573428.1 LOC498211-MAT-II
0.1883 0.0315 NM 053302.1 Admr
0.1882 0.0423 XM 575861.1 LOC366411 - similar to ribosomal protein
S24
0.1866 0.0259 NM 031085.2 Prkch
0.1859 0.0492 NM 133528.1 Prei3
0.1815 0.0278 NM 198787.1 Rutbc3
0.181 0.0312 NM 053720.1 Aatf
0.181 0.0315 XM 573168.1 LOC497974 - similar to novel protein
0.1802 0.0081 NM 001009696.1 RGD1307008 - Dcun1d5
0.18 0.029 NM 022005.1 Fxyd6
0.1739 0.0487 XM 228760.3 LOC317376 - Tcfe3
0.1734 0.0315 XM 574016.1 Serpinb6b predicted
0.1711 0.0314 NM 053345.1 Gtf2a2
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Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
0.1706 0.0407 XM 576398.1 Tmem24 predicted
0.1683 0.0252 NM 021681.1 Epb4.1l1
0.1674 0.0416 NM 133297.1 Sep-15
0.1637 0.0417 XM 576285.1 LOC500885 - similar to 40S ribosomal pro-
tein S19
0.1586 0.0492 XM 213394.2 LOC287477 - Tmem93
0.1585 0.028 XM 233982.3 LOC313974 - Trib2
0.1581 0.034 NM 053927.1 Epb4.1l3
0.158 0.0417 XM 219373.3 LOC309009 - similar to cDNA sequence
BC025641
0.1577 0.0407 XM 341863.2 Gtf2h1 predicted
0.1552 0.0395 XM 343037.2 Ddx1
0.1539 0.0315 XM 227527.3 Wdr3 predicted
0.1524 0.0417 NM 012500.1 Apeh
0.1514 0.009 XM 215404.2 Bxdc1 predicted
0.1501 0.0315 XM 232531.3 Surb7 predicted
0.1501 0.0278 NM 012745.2 Klrd1
0.1501 0.0395 NM 138532.1 Nme7
0.1488 0.0435 NM 001008290.1 RGD1310861 - similar to RIKEN cDNA
1500011H22
0.1484 0.0492 XM 573294.1 LOC498088 - similar to hypothetical protein
A
0.1452 0.0492 NM 031735.1 Stk3
0.1451 0.0418 NM 021682.1 Negr1
0.1446 0.0278 NM 001005536.1 p49/STRAP
0.1429 0.0335 XM 579788.1 LOC498118 - RGD1564468
0.1426 0.0435 XM 232995.3 Rnf20 predicted
0.1419 0.0278 XM 573749.1 LOC498489 - RGD1559923
0.1416 0.0315 NM 022700.1 Arl3
0.1338 0.0287 XM 214983.3 RGD1310022 predicted
0.1294 0.0309 XM 216759.3 Med6 predicted
0.1279 0.0444 XM 225053.2 LOC290916 - similar to 60S ribosomal pro-
tein L23a
0.1251 0.0252 NM 001009689.1 Cdc42ep2
0.1228 0.0492 NM 001008357.1 Hcfc2
0.1223 0.0418 XM 341918.2 LOC361639 - RGD1307507
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Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
0.1217 0.0259 XM 578086.1 LOC502599 - similar to 40S ribosomal pro-
tein S26
0.1215 0.0331 XM 218415.2 Gpr4 predicted
0.1209 0.0411 XM 573303.1 LOC498097 - Wdr53
0.1205 0.0328 XM 236438.3 LOC315843 - similar to WD repeat domain
11 protein
0.1202 0.0278 NM 145680.2 Gimap5
0.1195 0.0326 XM 215017.3 LOC293181 - Galntl4
0.1159 0.0252 XM 214874.3 LOC292724 - Ccdc97
0.1154 0.038 XM 222868.3 Olfml2b predicted
0.1146 0.0278 XM 574766.1 LOC499443 - Lims1
0.1126 0.0252 XM 342168.2 Cetn3
0.1034 0.0497 XM 219309.2 LOC293472 - similar to 60S ribosomal pro-
tein L13
0.1024 0.0278 XM 579982.1 LOC499580 - RGD1561695
0.097 0.0395 XM 574926.1 LOC499600 - RGD1560944
0.0923 0.0492 XM 236644.3 Smarcc1 predicted
0.0923 0.0492 XM 215902.3 RGD1311678 predicted
0.0921 0.0407 XM 573169.1 LOC497975 - Znhit3
0.083 0.0481 XM 218452.2 Lgtn predicted
-0.087 0.0331 XM 579952.1 LOC499365 - RGD1561823
-0.092 0.0315 XM 237146.2 LOC301388 - RGD1562317
-0.101 0.0417 XM 218346.1 LOC308444 - Axl
-0.102 0.0305 NM 145789.1 Il13ra1
-0.105 0.0416 XM 573373.1 LOC498160 - Zkscan1
-0.112 0.038 NM 138976.1 Mfn1
-0.116 0.0417 XM 230291.3 Fnbp4 predicted
-0.116 0.038 XM 221043.3 Tex2 predicted
-0.119 0.0319 NM 198757.2 Srr
-0.13 0.033 XM 341579.2 Npc1 predicted
-0.134 0.038 XM 212982.3 LOC296724 - RGD1565758
-0.137 0.0328 XM 580139.1 LOC500955 - RGD1561356
-0.137 0.0328 XM 226417.2 Thap11 predicted
-0.137 0.0494 XM 237326.2 LOC316550 - similar to Rab18
-0.138 0.0402 XM 215626.3 LOC295245 - Rag1ap1
-0.138 0.0379 XM 232647.3 LOC312946 - Tmem68
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Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
-0.139 0.0278 XM 342238.2 RGD1310132 predicted
-0.141 0.0278 NM 139332.1 Tpcn1
-0.147 0.0379 NM 031030.1 Gak
-0.148 0.0278 NM 013177.1 Got2
-0.148 0.0492 XM 216255.3 Crbn predicted
-0.15 0.0278 XM 574939.1 LOC499612 - similar to NADH dehydroge-
nase (ubiquinone) 1, subcomplex unknown,
1
-0.153 0.0259 XM 342838.2 Mapk9
-0.155 0.038 XM 342838.2 Fcmd predicted
-0.156 0.0407 XM 575280.1 LOC499935 - RGD1562582
-0.158 0.0315 XM 576379.1 Atpi
-0.159 0.0395 XM 233196.3 Hook1 predicted
-0.161 0.0326 XM 218848.3 Stard5 predicted
-0.161 0.038 NM 133387.1 Tmlhe
-0.163 0.0252 NM 013173.1 Slc11a2
-0.166 0.0335 XM 220076.3 Atad1 predicted
-0.166 0.0226 NM 080787.1 Dgka
-0.167 0.0315 NM 001009290.1 Ndufc2
-0.171 0.0429 XM 220047.3 Tnks2 predicted
-0.174 0.0497 XM 343513.2 Aplp2
-0.174 0.0382 NM 020076.1 Haao
-0.179 0.0252 NM 031353.1 Vdac1
-0.18 0.0497 XM 222022.3 Trfr2 predicted
-0.181 0.0287 XM 575959.1 Tardbp predicted
-0.181 0.0481 NM 053357.2 Ctnnb1
-0.184 0.0423 NM 138883.1 Atp5o
-0.184 0.0417 XM 579951.1 LOC499357 - RGD1562275
-0.187 0.0492 XM 214276.2 LOC290555 - Spcs1
-0.188 0.0305 XM 216928.3 LOC299949 - Wdr67
-0.188 0.0417 XM 342268.2 Trim2 predicted
-0.189 0.0315 NM 001008304.1 Ptov1
-0.191 0.038 XM 573163.1 LOC497971 - withdrawn
-0.194 0.0392 NM 017033.1 Pgm1
-0.194 0.0326 XM 579608.1 LOC497802 - Manea
-0.196 0.0407 XM 578010.1 LOC502525 - similar to homolog of yeast
TIM14 isoform c
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Log Fold Adjusted Gene Accession Gene Symbol
Change p-value
-0.197 0.0483 NM 139081.1 Oaz1
-0.198 0.0497 XM 573972.1 LOC498687 - RGD1564910
-0.198 0.033 NM 017022.1 Itgb1
-0.2 0.0487 XM 224617.3 Capn7 predicted
-0.205 0.0372 XM 223745.3 LOC305633 - similar to Antxr2 protein
-0.205 0.0328 XM 235768.3 Tmprss6 predicted
-0.207 0.0252 NM 001009646.1 Qprt
-0.211 0.0319 XM 233808.3 Prkcn predicted
-0.212 0.0287 NM 172091.1 Gcgr
-0.214 0.0492 NM 172008.1 Canx
-0.214 0.038 XM 575138.1 Axot predicted
-0.215 0.0417 XM 216378.3 Ndufb6 predicted
-0.216 0.0417 XM 341854.2 LOC361571 - Aldh16a1
-0.216 0.0309 XM 344301.1 LOC364258
-0.217 0.0252 XM 342695.2 LOC362370
-0.22 0.0492 XM 579362.1 Nfia
-0.221 0.0319 XM 579711.1 LOC497803
-0.222 0.0326 XM 219895.3 RGD1305246 predicted; Fam108b1
-0.228 0.038 XM 214409.3 LOC290964
-0.23 0.0278 XM 228158.3 LOC309788
-0.235 0.0405 NM 199404.1 Man2b1
-0.24 0.033 XM 576497.1 LOC501085 - rSULT1C2
-0.249 0.0476 NM 173123.1 Cyp4f4
-0.253 0.0252 NM 053600.1 Fez2
-0.255 0.0407 XM 216044.3 Ndufa8 predicted
-0.257 0.0315 XM 213943.3 Mgst3 predicted
-0.263 0.0435 NM 178105.2 Gpm6a
-0.266 0.0114 XM 343935.2 RGD1307010 predicted; Glod4
-0.272 0.0497 XM 341824.2 Capns1
-0.278 0.0278 NM 031013.1 Abcc6
-0.29 0.0407 XM 345167.2 LOC365699 - similar to hypothetical protein
FLJ30596
-0.298 0.0114 XM 576040.1 LOC500662 - GST 8-8
-0.302 0.0278 XM 346854.2 Besh3
-0.32 0.0372 NM 013146.2 Cald1
-0.335 0.0315 XM 579586.1 LOC497846 - Magt1
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Change p-value
-0.337 0.0319 XM 575256.1 LOC499912
-0.35 0.0315 XM 343776.2 Pls3
-0.358 0.038 XM 576370.1 LOC500959 - triosephosphate isomerase
-0.359 0.0226 NM 001009636.1 RGD1308082 - Prelid1
-0.36 0.0328 XM 214551.3 Cidea predicted
-0.363 0.0435 NM 153318.1 Cyp4f6
-0.367 0.0417 NM 031144.2 Actb
-0.371 0.0031 BC088177 BC088177 - Qprt
-0.371 0.0392 NM 022272.1 Fbxl20
-0.377 0.0326 XM 341557.2 Dhtkd1 predicted
-0.38 0.0226 NM 130403.1 Ppp1r14a
-0.389 0.0278 XM 574498.1 Dgat2
-0.394 0.0326 XM 219925.3 Ankrd15 predicted
-0.413 0.0326 XM 231739.3 RGD1306512 predicted
-0.427 0.029 NM 012992.2 Npm1
-0.444 0.0252 NM 016991.2 Adra1b
-0.446 0.022 XM 230613.3 Hao1
-0.471 0.0417 XM 221747.3 Gbe1 predicted
-0.553 0.0418 XM 342965.2 Arhgef19 predicted
-0.662 0.038 XM 221358.3 LOC303861 - Cpn2
-0.875 0.0252 XM 575821.1 LOC500457
Table 3.3: Differentially Expressed Genes from Illumina Microarray. This table shows
the 249 genes that were differentially expressed on the Illumina Rat-Ref12 chip in
the livers of the 55 day old male offspring of mothers that had been undernourished
during pregnancy. The table shows the log fold change, the adjusted p-value, the
genbank accession ID, and the gene symbol.
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3.2.3 QRT-PCR for Microarray Verification
Quantitative RT-PCR analysis of selected genes was performed in order to confirm
the expression data derived from array analysis. Seven genes (Igfbp2, Fabp7, Zfand2a,
Dgat2, Gys2, Adra1b, and Rbp1 ) found to be differentially expressed were selected for
qRT-PCR on the pooled RNA samples for the biological replicates in each treatment
group. qRT-PCR was performed as described in Chapter 2. Cyclophilin was used as
an invariant control for normalisation.
Figure 3.28 summarises the data and illustrates that the differences in ∆∆Ct
values between the AD and UN RNA populations for each gene are consistent with
the expression changes determined by array analysis.
Previous analysis has provided evidence that the expression of the Pparα, GR,
and Aox genes is altered in the liver of offspring from normally nourished mothers
compared to mothers who had either a low protein diet or balanced undernutrition
during pregnancy [82, 84]. It has also been suggested, that Pepck (phosphoenolpyru-
vate carboxykinase) and 11β-hsd2 (11β-hydroxysteroid dehydrogenase type 2) may
also be genes influenced by diet [85, 86]. As these genes were not represented by any
of the oligonucleotides on the RatRef12 array, they were assessed by qRT-PCR in the
AD and UN RNA populations using cyclophilin as the normalisation control. The
qRT-PCR expression results of the five candidate genes are shown in figure 3.27 for
the 8 biological replicates in each treatment group. For Pparα and Pepck, there is no
evidence for any differences in expression levels between the two treatment groups.
However, GR, Aox, and 11β-hsd2 show 1.5 to 2–fold increases in expression in the
UN treatment group. As previously mentioned, some of these genes were represented
on the MEEBO chip, but without significant p-values. It is interesting to note that
the study done by Sedova et al. [87] used a diet high in sucrose and therefore also
low in protein, making it similar to the diet used by Lillycrop et al.. Sedova found
early indicators of the metabolic syndrome consistent with the findings of Lillycrop
et al., which suggests that sucrose may be involved in dietary programming.
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Gene Expression Validation by q  RT-PCR
Figure 3.27: Five previously published candidate genes from Lillycrop et al. [82] were
analysed by qRT-PCR. Each of the eight individual samples was run in triplicate (24
data points for each treatment group). The ∆∆CT values are shown for each gene
along with error bars for standard error. Due to the large number of data points the
error bars are very small and difficult to see.
Gene Expression Validation by q  RT-PCR
Figure 3.28: Seven genes were chosen from the 249 significantly differentially ex-
pressed genes on the Illumina microarray. The RNA from the 8 biological replicates
was pooled for each of the two treatment groups. qRT-PCR for the two samples was
run in triplicate with cyclophilin as a control. The ∆∆CT values are shown for each
gene along with error bars for standard error. The values have been converted into a
fold change for comparison to the array results shown in table 3.4.
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Gene Name Illumina Microarray QRT-PCR Meebo Microarray
Expression Expression Expression
(Fold Change) (Fold Change) (Fold Change)
ADRA1B 0.7 1.9 NS
DGAT2 0.8 0.5 NS
FABP7 1.4 1.7 0.887
GYS2 1.5 1.6 NS
IGFBP2 2.1 2.7 NS
Zfand2a 1.5 2.5 NS
RBP1 1.6 1.2 NS
Table 3.4: Microarray and QRT-PCR Data. Fold change for the QRT-PCR data and
the Illumina and MEEBO expression data is compared for each of the seven genes
from the Illumina array that were analysed by QRT-PCR. NS = not significant
3.3 Discussion
Animals at postnatal day 55 were chosen for the study because they had com-
pleted puberty, but had not begun to exhibit the features of the metabolic syndrome
phenotype observed later in adulthood and, as shown in the present study, as early
as day 110 postnatally [45, 57]. Our results presented show that while there are dif-
ferences in gene expression in hepatic tissue in day 55 males, there are no observed
differences in retroperitoneal white adipose or biceps femoris. This is an intriguing
finding, as both fat and skeletal muscle is adversely affected in the adult. This sug-
gests that there is a cascade of biological processes that amplifies over time to lead to
the phenotypic abnormalities. Previously Ozanne et al. [88] has shown, in a different
but related experimental model of maternal low protein intake, that the expression
of a limited number of genes in skeletal muscle is minimal early in life and accumu-
lates later in life. It would appear that major changes in gene expression in the liver
precede those in other metabolically relevant tissues.
The data for all three tissues is derived from 8 biological replicates in each treat-
ment group with technical replication on each array varying from 20–30 fold. This
means that for each gene represented on the array, there are between 160 and 240
measurements of expression level. This permits an accurate estimate of the variance
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that is used to derive the final p-value and provides confidence in the detection of
small gene expression changes. Thus the changes found in liver are based on many
measurements and are highly significant. This is further underscored by the absence
of any significant changes in gene expression between the two groups in muscle or
adipose tissue subjected to the same analysis. The qRT-PCR analysis of candidate
genes (Pparα and GR) showed very little difference in expression levels between the
two groups in the day 55 male offspring. This contrasts with the 10–fold, 3–fold, and
3–fold increase for Pparα, GR, and Aox, respectively, in the day 34 offspring born to
nutritionally restricted mothers as reported by Lillycrop et al. [82]. Four factors may
explain this difference. First, the restricted diet is different (50% protein restriction
only) whereas the diet in the study reported here is 30% of normal chow for all nu-
trients and may impact differently on gene expression. Second, in the Lillycrop et al.
study the animals were weaned on day 28 and spent only 6 days in the postweaning
period compared to 33 days in this present study. Third, the composition of the
postweaning diet in the present study is grain-based as opposed to a purified diet
containing 50% sucrose in the Lillycrop et al. study. Finally, the male and female
tissues were pooled in the Lillycrop et al. study and there may be gender differences
we have not explored. Similar to previous reports, 11β-hsd2 and Aox show increases
of between 1.5 to 2–fold in the offspring of undernourished mothers used in this study
[82].
Analysis of the gene categories and associated pathways associated with differen-
tially expressed genes (see Appendix C, Table 4) has revealed some relevant changes
that potentially impact on the metabolic phenotype. Table 3.5 summarises the rel-
evant categories to emerge from analysis of gene functions (some of which emerged
from DAVID and Ingenuity analyses) associated with the list of differentially ex-
pressed genes. Figures 3.29A and B summarise the interrelationships between path-
ways involved in glucose, fat, and energy metabolism and highlights differentially
regulated genes that influence these pathways.
90
AB
Figure 3.29: (A)Summarises the interrelationships between pathways involved in glu-
cose, fat, and energy metabolism and highlights differentially regulated genes that
influence these pathways. (B) A summary of the genes that are altered in signalling
through the IFG-1 and PI3K signalling pathways and their relevance to glucose and
fat metabolism. Normal arrows indicate no change in gene expression; dashed arrows
indicate down regulation; bold arrows indicate up-regulation.
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3.3.1 Glucose Metabolism
In utero, the foetus relies mainly on maternal glucose for its energy supply and
only in late gestation develops the capacity for glucose storage, mobilization, and
gluconeogenesis in preparation for postnatal life. Glucose and glycogen metabolism
appears to have developed inappropriately in the livers of UN animals [4, 89]. Many
of the changes in hepatic gene expression we detected are relatively modest and this
may reflect alterations in hepatic development. Burns et al. reported changes in the
balance of periportal to periarterial hepatocytes that have different metabolic profiles
in the offspring of low protein fed dams [90].
The livers of UN animals show changes in the anomalous expression of RNA for
several enzymes involved in glycogenesis, glycogenolysis, and glycolysis. There is a
54% increase in the expression of the glycogen synthase gene (Gys2 ); however, this
is counterbalanced by a marked decrease in expression of glucan branching enzyme
(Gbe1 ) that is essential for the formation and storage of glycogen. Furthermore,
there is a modest decrease in phosphoglucomutase (Pgm1 ) that converts the glucose-
1-phosphate resulting from glycogenolysis to glucose-6-phosphate destined for glycol-
ysis. There is also a deficit of triose phosphate isomerase, which could result in an
inefficient conversion of fructose 1-6 bisphosphate to glyceraldehyde-3 phosphate in
the glycolytic process. The reduced expression of triose phosphate isomerase would
therefore, affect the efficiency of glucose conversion to pyruvate and might indicate an
increased accumulation of dihydroxyacetone phosphate. This can readily be reduced
to glycerol-3-P that is the backbone for phosphatidates and signalling phospholipids.
Overproduction of these could disrupt intracellular function. The efficiency of the
TCA would be compromised by the reduction in dehydrogenase E1 (DHTKD1). This
enzyme catalyses the conversion of α-ketoglutarate to succinyl CoA- a key step in the
TCA. Its subsequent conversion to succinate is the only step in glucose catabolism
that produces high-energy phosphate (GTP) directly, without the need for oxidative
phosphorylation. The GTP can be used for nucleotide-specific metabolic reactions or
it can convert ADP to ATP. Production of oxaloacetate further on in the cycle would
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also be affected. This would slow the rate of formation of citric acid and the entry
into the TCA of acetyl-CoA from oxidative decarboxylation of pyruvate. Supplemen-
tation of oxaloacetate from metabolism of branched-chain amino acids would also be
reduced. This means that most of the oxaloacetate is required as an intermediate for
TCA function and less is available for gluconeogenesis. It is interesting to note, that
there is a reduction in the transcripts of other enzymes involved in the catabolism of
amino acids that supply intermediates to the TCA cycle. In the foetus, this impasse
may be circumvented to an extent by the presence of the glyoxalate cycle in which
acetate can be converted to either glucose or succinate. However, this pathway dis-
appears after birth and hence the inability for gluconeogenesis would be exacerbated
postnatally.
3.3.2 Insulin and IGF-1 Signalling
The insulin and IGF-1 receptors are closely related structurally and share many
post-receptor signalling mechanisms. The livers of UN animals show changes in ex-
pression of genes whose products are known to attenuate the PI3 kinase signalling
pathway that is common to both receptors. Both Igfbp2 and Rbp1 are known to
interact with components of the PI3Kinase/Akt signal
A primary function of IGF-1 is to drive postnatal cell proliferation and growth,
principally through the MAP kinase signal
3.3.3 Mitochondrial Activity
The array analysis indicates a number of changes in the expression of genes that
could affect the efficiency of electron transport and ATP generation in the mito-
chondrion in liver from UN animals. Transcripts of NADH dehydrogenase subunits
(Ndufc2, Ndufb6, and Ndufa8 ) of complex I of the electron transport chain are all
reduced as is quinolate phosphoribosyltransferase (Qprt) required for the synthesis
of NAD, the electron carrier. In addition, the ATP synthase (Atp5o) that generates
ATP from the electron gradient is reduced by a similar amount. Changes are also
93
observed in peptidylprolyl isomerase D (Ppid) that controls the mitochondrial perme-
ability transition pore and Tim14, a component of the mitochondrial protein import
motor. Taken together these findings suggest a degree of mitochondrial dysfunction
in the livers of UN animals that could significantly affect the energy balance of the
tissue and may be the precursor of later adiposity. Since the liver acts as the initial
nutrient sensor, this defect could affect not only its own metabolism but also that of
other organs that respond to its systemic signals.
3.3.4 Fat
In this well-characterised model, it has been shown that undernourishment of
dams during pregnancy predisposes offspring to later adiposity and hyperinsulinaemia
when fed a normal diet [91] but only at an age later than we have undertaken gene
expression analysis. In the present study, even as early as day 110, male offspring
of UN dams are showing features of metabolic syndrome related to increased adi-
posity, hyperinsulinemia, and hyperleptinemia. The absence of any differences in fat
expression profiles between control and UN animals at day 55 may suggest that the
development of adiposity is secondary to early metabolic perturbations in postnatal
life. It is interesting to note that at day 35 UN rats show the onset of a sedentary phe-
notype (and hence reduced energy expenditure) before the presence of obesity [92].
This may reflect early changes in neurological gene expression modifying behaviour.
The elevated expression of RNA for fatty acid binding protein (FABP7) suggests
that in livers from UN animals there is an increase in the intracellular trafficking
of fatty acids. This is paralleled by increases in expression of Aox (from qRT-PCR
analysis), which catalyses the first step in the peroxisomal degradation of fatty acids,
and carnitine acyltransferase (CRAT) that shuttles fatty acids into the mitochondrial
matrix. It is interesting to note that the expression of the first enzyme in the biosyn-
thetic pathway of carnitine, trimethyllysine hydroxylase (Tmlhe) is down regulated
and this may reflect a homeostatic response to excess fatty acid trafficking. These
findings suggest that more energy is derived from β-oxidation of fatty acids in these
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animals. However, this can only be achieved if the NADH from β-oxidation regener-
ates NAD and forms ATP. The observed defects (especially in complex I) indicate a
disruption in this process. The provenance of these fatty acids is not clear, since there
were no significant differences between treatment groups in the circulating levels of
either triglycerides or frees fatty acids, although LDL levels are elevated by mater-
nal undernutrition. Other possible sources of fatty acids could be from increased
endogenous synthesis or from turnover of cellular components. There is no evidence
from the microarray analysis for an increase in enzymes for the latter; indeed the
modest decrease in levels of diacylglycerol acyltransferase (DFAT2) in UN animals
would indicate a blunting of triglyceride synthesis in liver.
The increased expression of SREBP cleavage activating protein (SCAP) suggests
that there may be higher levels of sterol synthesis taking place in livers of undernour-
ished animals. The formation of a transcriptionally active sterol response element
binding protein (SREPB) involves the proteolytic action of SCAP [32]. In support
of these observations, the level of circulating LDL cholesterol in the UN group is
significantly elevated. Interestingly a 60% increase in 11β-hsd2 transcripts was seen
in the livers of UN animals accompanied by a similar increase in the expression levels
of GR. 11β-hsd2 appears in late gestation/postnatal tissues in human fetal tissues
[93]. Elevated levels of this enzyme in the livers of UN animals would be a mechanism
to moderate the effects of high levels of circulating corticosterone that may arise in
response to nutritional deprivation/stress.
3.3.5 Ribosomal Proteins and Protein Turnover
An intriguing finding of the analysis is an increase (in the range 7-24%) in tran-
scripts in UN animals of 13 of 80 recognised ribosomal proteins (79 of which are
represented on the array by multiple oligonucleotides) that occur in the large and
small ribosomal subunits. Eight of the proteins are components of the mitochondrial
ribosome. Similar increases in expression are also seen in: brix (Bxdc1 ), which is
involved in ribosome biogenesis; NPG1, a nucleolar GTPase required for the mat-
95
uration and nuclear export of pre-ribosomes; and Cebpz, a gene important in the
processing of rDNA involved in the 60s subunit [94]. These findings suggest a greater
degree of metabolic flux in ribosomes from UN animals; however it is difficult to
understand the significance of these observations given the fact that on the basis of
the current annotation only about 16% of the ribosomal proteins show changes in
expression levels. It is possible that the increased turnover of ribosomal proteins is
contributing to the higher levels of urea observed in the day 55 UN animals.
3.3.6 Effects on Gene Transcription
It is notable that a group of genes that influence transcription show upregulation
to varying extents. Some (such as the Gtf and Med factors) have a general effect on
the transcriptional apparatus. The most notable increase is in the Rpb1 gene known
to be expressed highly in the liver, particularly in hepatic stellate cells [95, 96].
In liver, Rpb1 has an important role in the production of retinoid derivatives that
activate the RAR and RXR retinoic acid receptors [97]. RXR can heterodimerise
with the PPAR proteins to form active nuclear receptors that target genes involved
in fat metabolism and energy homeostasis; for example Crat and Aox are shown to
be upregulated in the UN offspring. Thus elevated or abnormal Rbp1 expression may
have a major role in establishing the metabolic syndrome phenotype.
Two other genes show significant changes in gene expression that may impact
hepatic function. The first is Col14a1 (a member of the collagen gene family) that
was originally called undulin [98, 99]. This gene is expressed in hepatic stellate
cells that have a role in the formation of the hepatic extra cellular matrix [100] and
shows a 20% increase in gene expression. This may be a marker of some underlying
pathology as Col14a1 has been associated with the rearrangement of connective tissue
occurring in hepatic fibrosis [98]. It is of note that Rbp1 expression changes have
also been associated with hepatic fibrosis [96] and thus the gene may be involved in
the regulation of Col14a1. The second gene is Adra1b (adrenergic receptor alpha 1b
showing a 79% upregulation) that has been associated with carbohydrate metabolism
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in the liver [101] and disruption of glucose homeostasis when the gene is inactivated
[102, 103]. Given that the role of the receptor is to stimulate glycogenolysis and
the process of glycogen formation is impaired in UN animals, the significance of
increased expression is not clear. This may reflect an irreversible change in response
to the intrauterine nutritional state or a postnatal compensatory mechanism to the
altered metabolic profile set in utero.
3.4 Conclusions
Studies to date have primarily focused on a candidate gene approach in animals,
where the classical features of the metabolic syndrome in the programmed phenotype
are already evident. There is a relative paucity of data on gene expression, either by
candidate or an array-based approach, on key tissues related to the metabolic syn-
drome in animals at an age preceding development of the metabolic phenotype. The
gene expression changes in appropriate pathways in the livers of the male offspring
of maternally undernourished dams at day 55 would suggest that these animals may
be predisposed to a persistent and perturbed ability to coordinate fat and carbohy-
drate metabolism with a shift to a use of fatty acids as an energy source. We have
also shown that these animals proceed to develop a phenotype similar to that of the
metabolic syndrome, as early as postnatal day 110. Array analysis of tissues at the
day 110 time point was beyond the scope of the present trial. However, although
the present study cannot directly correlate the observed gene expression changes at
day 55 with the phenotype at day 110, it provides a clear evidence of disturbed hep-
atic function in a number of key genes related to lipid oxidation and mitochondrial
function at a pre-phenotypic age. There are parallels with the observations of Koves
et al. [89] and Sparks et al. [104], where diet induced obesity in adult life induces
oxidative stress associated with increased β-oxidation of fat metabolism, impaired
switching of carbohydrate substrates, depletion of TCA cycle intermediates and de-
creased expression of components of the electron transport chain. They propose that
mitochondrial dysfunction may be driving the pre-diabetic insulin resistant state.
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The observations in our rat model indicate that the liver is irreversibly programmed
to respond to a nutritionally restricted environment and that this persists into early
adulthood (day 55). At this age, similar changes are not observed in adipose tissue
or skeletal muscle, suggesting that the liver can meet the immediate energy require-
ments of these peripheral tissues and that it manifests metabolic abnormalities in
advance of the full metabolic syndrome phenotype. These data have uncovered po-
tential candidate genes and pathways that when perturbed lead to the development
of the metabolic syndrome in older animals and therefore, provide a focus for more
detailed gene-specific studies.
It is clear that developmental changes are occurring in these animals due to the
difference in maternal diet during pregnancy that is in turn affecting metabolic path-
ways later in life. However, it is yet to be established exactly what is the mechanism
of this developmental programming. Gluckman et al. suggests epigenetic means.
Epigenetic changes have been found in humans affected by the Dutch Hunger Winter
and have also been associated with specific aspects of metabolic disease [65]. The
details of the window in which these changes occur and whether they are primary
changes or simply a result of a cascade of events remain unclear. In Chapter 5, this
thesis will explore how methylation may be involved in the metabolic syndrome as a
result of developmental insults and will investigate the phenomenon with a prelimi-
nary study. Additional work is being done by collaborators at the Liggins Institute
and it is hoped that in the near future more answers will be available.
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Chapter 4
Leptin Reversal Study
4.1 Introduction
As previously described, adult offspring of rats subjected to undernutrition during
pregnancy develop symptoms of the metabolic syndrome. In Chapter 3, we inves-
tigated gene expression changes in the muscle, fat, and liver tissue of such male
offspring at 55 days old. At this age, the rats have not yet begun to exhibit the
metabolic syndrome phenotype.
Vickers et al. published two papers [57, 58] in which the same model of maternal
undernutrition was used to investigate the effects of neonatal leptin treatment on
the metabolic phenotype of adult offspring. Results for female offspring and male
offspring differed significantly and were published separately. This chapter will focus
on the results for the female study and all experiments in this chapter utilise those
samples. The postnatal (day 3-13) leptin treatment in the female offspring of un-
dernourished mothers resulted in a slowing of neonatal weight gain and normalised
caloric intake, locomotor activity, body weight, fat mass, fasting plasma glucose, in-
sulin, and leptin concentrations in programmed offspring. These data were taken
in adult life (day 170) and contrast data from saline-treated offspring of undernour-
ished mothers who only developed these features on a postweaning high fat diet.
Neonatal leptin had no demonstrable effects on the adult offspring of normally fed
mothers. These results suggest that developmental metabolic programming is poten-
tially reversible by an intervention late in the phase of developmental plasticity. The
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complete normalisation of the programmed phenotype by neonatal leptin treatment
implies that leptin has effects that reverse the prenatal adaptations resulting from
relative fetal undernutrition.
This chapter investigates the molecular mechanism of leptin reversal in adult fe-
male rats. Female rats can breed as early as 30 days of age and are considered middle
age at approximately 270 days of age. In this study we used liver samples from female
rats that were 170 days old from the study described above. The samples were anal-
ysed using microarray gene expression assays. The results do not reveal molecular
evidence for a leptin reversal. However, they show that the interaction between a
combination of the three treatments (prenatal diet, leptin treatment and postnatal
diet) do have significant metabolic consequences. These changes in gene expression
affect pathways involved in the immune response, circadian rhythm, transport, and
metabolism. This chapter begins with a review of leptin, the leptin receptor, and
their role in energy balance, causes of obesity, and the genetics of obesity, reproduc-
tion, and puberty. In addition, the biochemical effects that leptin has on appetite,
behaviour, circadian rhythm, and immune response are considered. This background
information will be followed by a description of experimental design, data quality,
and a presentation and discussion of the results. The discussion aims to unravel the
complexity of the experiment, interpret the results, and suggest future avenues of
investigation.
4.1.1 Leptin
Leptin is an adipocyte specific protein that functions to sense and regulate body
energy stores in humans and in animals. It is largely synthesised and secreted in white
adipose tissue; however, low concentrations are also synthesised and secreted by the
hypothalamus, pituitary, skeletal muscle and bone, arterial endothelium, intestines,
foetus, testes, and placenta. The leptin in these tissues may play a role in the immune
system and reproduction [122]. Leptin is remarkably similar across species.
The initial view was that leptin was an anti-obesity hormone, preventing the
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storage of excess adipose tissue by feeding back to the hypothalamus to reduce food
intake and increase energy expenditure. However, obesity in humans is often ac-
companied by increased levels of leptin in a state of leptin resistance [57]. Ahima
et al. suggested that the physiological response to decreasing leptin concentration
with starvation may be the dominant role of leptin. His study showed that falling
leptin concentration is a critical signal that initiates the neuroendocrine response to
starvation, potentially increasing survival by limiting procreation, increasing stress
steroids, and decreasing thyroid thermogenesis [123]. Studies investigating leptin ex-
pression levels in the foetus and the placenta suggest that leptin may also have a
broader range of actions, particularly during growth and development [124].
Early studies investigating the role of leptin were done using the ob/ob and db/db
mouse models. Each of these models has a single distinct gene mutation. The ob
mutation is on mouse chromosome 6 and the db is on mouse chromosome 4. The
classic experiments involving parabiosis [125] of ob/ob mice with lean wild-type (WT)
mice resulted in suppression of feeding and weight loss in the ob/ob mice. In contrast,
the parabiosis of WT or ob/ob mice with db/db mice caused dramatic weight loss in
the WT and ob/ob mice, but the db/db mice continued to gain weight. This study
suggested that the ob locus encoded a circulating ‘satiety’ factor (discovered later to
be leptin [126]). The mutation in the ob/ob model, leads to a non-functional leptin
protein and mice with the ob/ob mutation became obese on a normal ad-libitum diet.
These mice have low levels of circulating leptin and reduced metabolic rates and body
temperature. Injection of exogenous leptin to ob/ob mice reduces hyperphagia and
weight gain while increasing circulating leptin concentrations, physical activity, and
energy expenditure. Humans that have a leptin deficiency due to a genetic mutation
exhibit a similar phenotype including congenital obesity and endocrine abnormalities
[127]. Leptin treatment in these people decreases energy intake and results in a
dramatic fat loss. However, very few human obesity cases are due to this genetic
mutation that reduces leptin production.
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4.1.2 Leptin Receptor
Leptin interacts directly with the leptin receptor (Ob-R or LEPR). Ob-R is en-
coded by the db gene and binds leptin. The Ob-R gene has been shown to have six
splice variants. The long form, OB-RB, has a long cytoplasmic region containing sev-
eral motifs required for signal transduction and it is essential for the weight-reducing
effects of leptin [122]. It is abundant in the hypothalamus, but it is also found
throughout the body. The parabiosis experiments suggested that the db/db mice
were defective in their ability to respond to the satiety factor, leptin, and subse-
quently obesity in the db/db mice has been linked to a defect of Ob-R [123]. Cle´ment
et al. [128] reported an example of human obesity due to a homozygous mutation
in Ob-R that resulted in a truncated leptin receptor lacking the transmembrane and
intracellular domains. This mutation resulted in morbid obesity and infertility, sim-
ilar to that of the db-db mouse. This mutation is rare, and the affected offspring
were children of first cousins. Very few obesity cases are due to defects in Ob-R.
Considine et al. suggests obesity may more commonly be caused by defects in one
of the isoforms of Ob-R or in one of the specific pathways activated by the isoforms
[129].
4.1.3 Genetics of Obesity
Although genetic mutations in the leptin gene and leptin receptor gene are rare
causes of obesity, genome-wide association studies have led to the discovery of novel
genes in which differential expression levels have been linked to obesity. There are
a number of additional rare cases occurring in families with rare genetic mutations.
Particular polymorphisms seem to affect certain populations more than others. The
Trp64Arg variant in the Beta-3 adrenergic receptor gene has been the subject of 60
independent studies with varying results. There seems to be a significant effect in
Asian populations which does not seem to hold true for other populations [130].
Further investigation has shown that obesity is often related to expression changes
that affect pathways involved in leptin signalling and brain feedback mechanisms for
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controlling diet and weight gain. These pathways that are essential for energy balance
may hold the explanation for the more common obesity cases. An example of this is
the Jak-Stat pathway. The leptin receptor is important for the activation of the Jak
(janus kinase) -Stat (signal tranducers and activators of transcription) pathway (see
figure 4.1). Mice that have a mutation in the Stat3 binding site of Ob-R have much the
same phenotype as db/db mice including hyperphagia and severe early onset obesity,
but retained fertility. This suggests that Stat3 is important for the regulation of
feeding behaviour, but is not required to regulate other functions of leptin including
reproduction and growth [131]. Two genes involved in negative-regulation of leptin-
Jak-Stat signalling are Socs3 (suppressor of cytokine signalling 3) and Ptn1 (protein
phosphatase nonreceptor type 1). Mice with reduced expression of either one of these
genes are lean and exhibit leptin sensitivity, but how their function might be related
to human obesity is still unknown [131].
4.1.4 Energy Balance: Interactions of Leptin and the Brain
The cause of obesity is often blamed on human decisions to engage in behaviours
including lack of exercise and increased food intake. It is interesting to investigate
the biochemistry of energy balance, appetite and satiety. The role of leptin in these
affects feedback to the brain and affects behaviour decisions toward food and even
exercise. Changes in pathways affecting energy balance and behaviour may underpin
the difficulty that obese individuals have in losing weight and keeping it off [132].
The control of energy balance is orchestrated by the hypothalamus via signalling
pathways, several of which are affected by changing leptin levels.
The arcuate nucleus (ARC) is an important site in the hypothalamus for regu-
lating leptin’s effect on energy balance [133]. Abundant expression of the long form
of the leptin receptor (LEPR-B) has been found in the ARC and other areas of
the hypothalamus including the ventromedial hypothalamus (VMH), the dorsome-
dial (DMH), and the paraventricular nucleus (PVN). Figure 4.2 shows a three-armed
interaction between the brain and peripheral tissues that are involved in the home-
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ostatic pathway. The three arms divide the afferent (blue), central (brown) and
efferent (white) pathways. The VMH (and the ARC) receives peripheral peptide
signals related to adiposity (leptin), metabolism (insulin), hunger (ghrelin) and sati-
ety (peptide Y Y3−36). The second arm consists of neurons that translate this signal
to the PVN and lateral hypothalamic area. These areas then integrate the signals
to alter caloric intake and energy expenditure. The third arm consists of signals
from the CNS (efferent signals) via the autonomic nervous system. The sympathetic
nervous system (SNS) promotes energy expenditure and the vagus nerve promotes
energy storage. Leptin is part of the afferent pathway (signalling the CNS) and the
SNS and vagus nerve are part of the efferent pathway, which receive these signals and
then send signals to the rest of the body. Insulin is part of both afferent and efferent
pathways [134]. Leptin conveys a signal of peripheral energy sufficiency to neurons
(afferent signal) expressing the leptin receptor. Leptin triggers a permissive signal to
the CNS for the initiation of high-energy processes, such as puberty and pregnancy
[134]. A drop in leptin is interpreted by the hypothalamus as a diminished energy
reserve and invokes the starvation response that is shown in figure 4.1. Inadequate
transport of leptin into the CNS could be a contributing factor to obesity. The effects
of insulin and leptin on the central nervous system parallel each other (i.e. mice with
a knocked out insulin receptor become hyperphagic, obese and infertile) [134].
Leptin has also been shown to have an important role in hypothalamus devel-
opment. Bouret et al. [135] found that leptin is important for the development of
hypothalamic circuits. The outgrowth of fibres projecting from the ARC is slower
in the absence of leptin and some of the projections never catch up. The connec-
tion between the arcuate nucleus and the parvocellular part of the PVN is one such
connection. Figure 4.3 shows a focused figure of the brain that includes all of the
areas where the leptin receptor expressing neurons are located and those areas that
are part of the associated signalling network. In particular, this figure shows the
arcuate nucleus, where leptin resistance is predominantly detected [136]. Leptin
stimulates POMC (pro-opiomelanocortin) and CARTPT (cocaine and amphetamine
related transcript prepropeptide) gene expression in neurons located in the ARC. A
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cascade of events leads to neurons that express MC4R (melanocortin receptor 4).
The signal transduction pathways involved in this process interact with various brain
centres to coordinate eating behaviour. The identification of human mutations oc-
curring in ligands and receptors of this pathway have revealed how this pathway is
involved in the regulation of food intake, energy expenditure, lipid and carbohydrate
metabolism, and reproductive, thyroid, and immune function [131]. In particular, it
has been shown that PI3k signalling is required for leptin’s effects on feeding. PI3k
signalling enables leptin to depolarise POMC neurons and in effect, suppress food
intake [137].
It is hypothesised each human has a different leptin ‘set-point’. The set-point is a
concentration of leptin, which conveys a message of energy sufficiency to the hypotha-
lamus. Leptin levels drop quickly during short-term fasting (12hours/overnight) and
can decline faster than body fat stores are depleted, but still activate the starvation
response. In the case of obesity, where this hypothetical set-point is dysfunctional,
leptin levels are increased, but do not trigger reduced food intake or lipolysis. If
energy intake declines again (as in the case of dieting), the starvation response will
be triggered again, resulting in a cycle of overeating [134].
This cycle can be exacerbated by the effects of leptin on the ‘hedonic pathway’.
The hedonic pathway regulates pleasurable and motivating responses to stimuli. In
figure 4.3, several components and regulators of the mesolimbic dopamine system
are shown in brown. This is the neural mechanism by which leptin can affect food
reward. The relationship between insulin, leptin, reward and obesity is summarised
in figure 4.4. Food intake is responsive to the hedonic pathway. Susceptibility to
addictive behaviour and pleasurable response increases after food deprivation and
can be measured by dopamine release. Obesity results in decreased density of D2
dopamine receptors [134]. Other neural pathways that input into the regulation of
food reward may also undermine leptin’s influence preventing it from deterring an
affected individual from consuming something palatable [136].
This section highlights the complexity involved in the regulation of energy balance
and the effects that errors in brain feedback mechanisms could potentially have on
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Figure 4.1: This figure was adapted from Lustig et al. [134] and depicts the over-
lap between insulin and leptin signalling pathways (shown in black) in the ven-
tromedial hypthalamic neuron. Insulin stimulates the insulin receptor substrate 2-
phosphatidylinositol 3 kinas pathway, whereas leptin stimulates the Janus kinase 2-
signal transduction and transcription 3 pathway; however, both the insulin receptor
and the leptin receptor recruit the low-abundance-message second messenger insulin
receptor substrate 2. Lack of available insulin receptor substrate 2 for the leptin re-
ceptor following hyperinsulinemia could result in defective leptin signal transduction.
Alternatively, insulin induction of suppressor of cytodine signalling 3 could inactivate
the leptin receptor, through dephosphorylation of tyrosine 1138.
eating behaviour. A vast number of biochemical pathways are involved in maintaining
energy homeostasis.
4.1.5 Leptin and the Circadian Rhythm
Leptin has been shown to have an effect on the circadian rhythm. A nocturnal rise
in leptin occurs in ad-libitum fed rodents and can be prevented by fasting. Fasting
can shift the peak plasma leptin level from nocturnal to diurnal. Leptin levels also
peak at night in humans, and this pattern is thought to be mediated by insulin levels.
This leptin rhythm seems to be blunted with aging, and associated with an increase in
visceral adiposity and insulin resistance [138]. A study by Kaneko et al. [139] found
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Figure 4.2: This figure shows the homeostatic pathway of energy balance adapted
from Lustig et al.[134]. It shows the afferent(blue), central(brown) and efferent(white)
pathways. The hormones insulin, leptin, ghrelin, and peptide Y Y3−36 send afferent
signals relating to short-term energy metabolism and energy sufficiency to the ventro-
medial hypothalamus (VMH). The VMH sends anorexigenic and orexigenic signals
to the melanocortin 4 receptor in the paraventricular nucleus (PVN) and lateral hy-
pothalamic area (LHA). These signals lead to efferent signals via the locus coeruleus
and the nucleus tractus solitarius, which activates the sympathetic nervous system
and causes adipocytes to undergo lipolysis, or via the dorsal motor nucleus of the
vagus, which activates the vagus nerve and causes energy storage, both by increasing
pancreatic insulin secretion, and (in rodents) by increasing adipose-tissue sensitivity
to insulin.
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Figure 4.3: This figure was adapted from Myers et al. and shows the network of leptin
receptor (LRb) expressing neurons. Blue, yellow and brown bubbles indicate regions
containing LRb expressing neurons. Yellow bubbles are areas where little is known
about the projections of these LRb expressing neurons. The arrows show projection
patterns. Light green bubbles indicate areas where the LRb neurons project but do
not contain any. Components and regulators of the mesolimbic dopamine system are
shown in brown bubbles. ARC, arcuate nucleus; PVH, paraventricular hypothalamic
nucleus; VMH, ventromedial hypothalamic nucleus; DMH, dorsomedial hypothalamic
nucleus; LHA, lateral hypothalamic area; PMv, ventral premammilary nucleus; POA,
preoptic area; VTA, ventral tegmental area; PAG, periaqueductal gray; DR, dorsal
raphe; PB, parabrachial nucleus; NTS, nucleus of the solitary tract.[136]
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Figure 4.4: This figure was adapted from Lustig et al. [134] depicts the role of
hyperinsulinemia in the dysfunction of the energy balance pathway. Various factors
can lead to hyperinsulinemia, including vagus nerve mediated insulin hypersecretion
or hepatic and/or skeletal muscle insulin resistance. Hyperinsulinemia can interfere
with leptin signal transduction in the hypothalamus, promoting leptin resistance.
This interference can cause resting energy expenditure to decrease and appetite to
increase, promoting further weight gain. Hyperinsulinemia can also cause reduced
dopamine uptake, which can lead to increased reward associated with eating food,
again promoting further weight gain. Hyperinsulinemia can convert homeostatic and
hedonic pathways from negative-feedback to feed-forward mechanisms.
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that gene expression of core clock genes were down regulated in the caudal brainstem
nucleus of the solitary tract (NTS) in obese mice. This perturbation of clock genes
may have an effect on energy homeostasis as well as glucose and lipid metabolism.
From an evolutionary standpoint it is sensible that the circadian rhythm would be
involved in the regulation of hunger as historically finding food was easier and safer
during the day. If metabolic processes have adjusted to this cyclical hunger cycle,
one can imagine that a disturbance in a clock gene could have a cascade affect on
other processes involved in energy balance.
4.1.6 Leptin During Pregnancy, Lactation and Puberty
Hyperinsulinemia and insulin resistance are both symptoms of pregnancy and
puberty. Leptin levels are elevated during pregnancy and seem to be regulated by
factors other than body fat content, including sex hormones such as progesterone.
Leptin levels are regulated to insure the weight accrual necessary for pregnancy oc-
curs. Variable concentrations of immunoreactive leptin are also present in human milk
and the concentration is correlated with maternal adiposity [140]. It has not been
determined what effect this exposure to leptin in milk in human infants might have
on long-term infant growth, development and adiposity. Similarly, growth hormones
during puberty increase leptin levels to insure necessary weight gain [134].
4.1.7 Leptin Differences in the Sexes
In several species, a sexual dimorphism for leptin has been shown. In humans,
females have higher leptin levels than males. The absolute peak leptin concentrations
are 2 times higher in women than in men [138]. This may be attributed to the fact that
females have greater amounts of subcutaneous fat. Additionally, males tend to have
a higher percentage of fat-free mass and this will further lower leptin concentrations
relative to females. Differences can also be attributed to the stimulation of leptin by
oestrogen in females and suppression of leptin by testosterone in males. The gender
difference may be influenced by the amount of leptin released or removed per unit
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time, which may suggest that women are more resistant to leptin feedback than men.
This may explain the female’s greater susceptibility to eating disorders and body
weight regulation [123].
This sexual dimorphism was mentioned by Vickers et al. 2000 [45], ‘the pro-
grammed phenotype is expressed only in the presence of the high-fat postweaning
diet, whereas in males it was previously shown that programming could manifest
independently of nutrition’. It was also seen by Vickers in the study discussed in
this chapter, [57], and in a similar study of male rats at day 110 [58]. Neonatal
leptin treatment promoted obesity in AD male offspring, particularly when given a
postweaning HF diet. Whereas in UN males, leptin prevented diet-induced obesity
if males were fed a chow postweaning diet. This contrasted with the data in females
in which neonatal leptin treatment had no significant effect on body composition or
metabolism, regardless of the postweaning diet. Neonatal leptin treatment protected
UN females from becoming obese on both a HF and a standards chow diet [58].
Clegg et al. suggests male rats are more sensitive to the anorectic effects of insulin,
whereas females are more sensitive to changes in serum leptin levels [141]. This may
be indicative of altered leptin set-points rather than leptin resistance.
4.1.8 Overview
This background highlights many of the major pathways that may be affected
by a leptin treatment. It has provided some insight into the relationship between
the feedback mechanism to brain in relationship to food and energy balance. It
has highlighted the involvement of leptin in energy homeostasis, feeding behaviour,
fat storage, hunger and behaviour toward food. It has mentioned the difference
between leptin in males and females. This introduction gives a platform in which
to consider the complexity of the results. Many pathways may have been affected
by the treatments in this study and therefore additional studies would need to be
conducted to tease out the details. However, this study provides a vast amount of
food for thought and definitely reveals the importance of the hypothalamus.
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4.1.9 Initial Study
The aim of the leptin reversal study conducted by Vickers et al. [57] was to
establish whether neonatal leptin treatment can alleviate postnatal obesity and the
associated metabolic syndrome that occurs in the offspring of undernourished moth-
ers. Methods are described in that paper, but will also be summarised here. The
study design is illustrated in figure 4.5.
The study utilised the same model of undernourishment as the study in Chapter
3. Virgin Wistar rats (age 100 ±5 days) were time mated using a rat oestrous cycle
monitor to assess the stage of oestrous of the animals prior to introducing the male.
After confirmation of mating, rats were housed individually in standard rat cages with
free access to water. All rats were kept in the same room with constant temperature
maintained at 25 ◦C and a 12-h light: 12-h darkness cycle.
Animals were randomly assigned to one of two nutritional groups: a) undernu-
trition (30% of ad-libitum) of a standard diet throughout gestation (UN group), b)
standard diet ad-libitum throughout gestation (AD group). Food intake and mater-
nal weights were recorded daily until the end of pregnancy. After birth, pups were
weighed and litter size was adjusted to 8 pups per litter to assure adequate and stan-
dardised nutrition until weaning. A minimum of six litters per group were used. At
postnatal day 3 female AD and UN pups were randomised to receive either saline or
recombinant rat leptin (2.5 µ g/g· d) for 10 days by subcutaneous injection. Pups
from undernourished mothers were cross-fostered onto dams that had received AD
feeding throughout pregnancy. All animals were fed ad-libitum until weaning (day
22) and then animals were weight matched and put on either a standard rat chow diet
(CHOW group) or high-fat diet (45% kcal as fat; HF group). Weight matching was
done to ensure that the mean starting weight was similar for the two post natal diets.
In each litter of 8 pups, there were four males and four females. Pairs of females
were randomly placed on either the chow or HF diet. Mean weight of the cages were
checked to ensure that the offspring placed into the HF group were not statistically
different from those allocated to the chow diet. The animals were culled and tissue
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=30% Chow
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Leptin
Saline
=
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CHOW
HF
=
=
Normal Chow
High Fat Chow
FED
FED
During 
Pregnancy
Day 3-10
Weaning-
Day 170
Figure 4.5: Design of Leptin Reversal Study. This figure summarises the study design.
During pregnancy rats were fed either ad libitum a standard chow diet (AD) or 30%
of a standard chow diet (UN). The female offspring were given either leptin (LEP)
or saline (SAL) injections from day 3-10, and then from weaning offspring were fed
either ad libitum a standard chow diet (CHOW) or a high fat chow diet (HF).
samples were collected at postnatal day 170. The results of the study are described
in detail by Vickers et al. [57], but are summarised here.
Phenotypic Assessment
Physiological measurements were taken as described in [57]. These values are
summarised in table 4.1. The values for insulin, leptin and c-peptide are shown in
figure 4.6 taken from Vickers et al..
The study demonstrates that all the measured metabolic consequences of mater-
nal undernutrition were reversed by a period of neonatal leptin treatment in female
rats. Neonatal leptin treatment resulted in reduced pup weight gain for both AD
and UN offspring. The high fat diet after weaning significantly increased weight gain
with a marked amplification of the weight gain in the UN pups. The leptin treatment
normalised the diet-induced weight gain in the UN animals to match the AD animals.
These results indicate that leptin induced a phenotype reversal and possibly a rever-
sal of epigenotype. The female infant rats that had not been prenatally nutritionally
programmed had no phenotypic effects, but those who had been nutritionally pro-
grammed did not develop the metabolic phenotype even when placed on a high fat
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diet after weaning. The findings indicate that, at least in the rat, there is an early
postnatal window during which the process can be reversed. This animal model re-
sembles the increased weight gain and metabolic abnormalities seen in humans born
small for gestational age (SGA), thus the mechanisms responsible for the effects in
rats may be similar in humans.
The results of this study indicate that developmental adaptations during fetal life
can be reversed by interventions in the neonatal period. The goal of this chapter is
to use the samples from Vickers et al. [57] to investigate the molecular mechanisms
that were affected by the prenatal diet, the leptin treatment and the postweaning
diet. We hypothesised that gene expression and methylation studies would provide
information on mechanisms and may enable us to pinpoint the postnatal age after
which leptin intervention may be ineffective.
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Figure 4.6: (A)Fasting plasma insulin concentrations at day 170 in AD and UN ani-
mals on either a chow (C) or high-fat (HF) diet after neonatal saline or leptin treat-
ment. Neonatal leptin treatment normalised fasting plasma insulin concentrations
in UN leptin-treated HF (UNLHF) animals compared with saline-treated animals
(P<0.05 for effect of programming and diet; programming x treatment, program-
ming x diet, and treatment x diet interactions, P<0.05) (B)Fasting plasma leptin
concentrations at day 170. Neonatal leptin treatment normalised fasting plasma lep-
tin concentrations in UNLHF animals compared with saline-treated animals (P<0.05
for effect of diet and treatment; programming x diet, programming x treatment,
treatment x diet, and programming x treatment x diet interactions, all P<0.05).
(C)Fasting plasma C-peptide concentrations at day 170. Neonatal leptin treatment
normalised fasting plasma C-peptide concentrations in UNLHF animals compared
with saline-treated animals (P<0.05 for effect of programming; P<0.0001 for effect
of diet; programming x treatment, programming x diet, and treatment x diet inter-
actions, P<0.05). Data were analysed by three-way factorial ANOVA, mean ± SEM;
n=8 per group. Result from Vickers et al. [57]
.
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AD_Saline_Chow
X8 each (Liver)
{
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(64 Total Samples)
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Figure 4.7: Microarray Design. This study included eight separate treatment groups.
For each of these groups there were eight biological replicates. RNA extracted from
the liver of each of these replicates was hybridised on an Illumina Rat-Ref12 chip.
Each chip has 12 separate arrays; 6 chips were used in total.
4.2 Results
4.2.1 Illumina Microarray
On two separate visits to the Liggins Institute, RNA was extracted from eight bi-
ological replicates in each of eight treatment groups for both liver and skeletal muscle
tissue. Extracted RNA samples were shipped to the University of Cambridge on dry
ice along with the remnant phenol-interphase mix for subsequent DNA extraction.
Only the liver samples were hybridised to the Illumina chip.
Hybridisations
RNA extracted from liver was hybridised to Illumina microarrays as described in
Chapter 2. Extractions, amplifications, and hybridisations were randomised. The
microarray study design is shown in figure 4.7.
Data Quality Control
The Illumina system incorporates a number of internal controls for estimating
hybridisation quality. These controls are described in more detail in Chapter 2.
Figure 4.9 shows the details of the five graphs for the internal controls across all
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64 arrays. In figure 4.9A the low, medium and high intensities are shown across
all arrays. Ideally, arrays should have signal intensities in the same range. It is
expected that there be a linear increase of signal between the three intensities. In
figure 4.9B low stringency of the data is analysed by comparing the signal intensity
of two mismatches to the signal intensity of a perfect match. The perfect matches
should have a 3–4 fold higher signal as seen in this data. No signal intensity indicates
the hybridisation failed. Figure 4.9C shows the high stringency control of the data.
For high quality data it is expected that the biotin signal would be 3–4 fold lower
than the high stringency signal as seen here. Figure 4.9D shows the data for the
negative control. The background signal should be approximately 70. This value is
accounted for in the normalisation algorithms. The noise signal should be very low
for high quality data as seen in this data. Figure 4.9E compares the signal from the
housekeeping genes to the signal from all genes. As housekeeping genes are always
expressed they should have a much higher signal compared with all genes. The overall
quality of this data set was generally high.
To compare the samples in more detail the data was exported from BeadStudio
and imported into R Bioconductor. Here the raw data was plotted in several graphs
(pairwise, MA, density plot and box plot), then normalised and replotted to compare
pre- and post-normalisation. In addition, the arrays were clustered using hierarchical
clustering. The hierarchical clustering is shown in figure 4.8. The samples appear
to be distributed evenly, not clustering on biological replicate or similar treatments.
The sample for UNSALCHOW 28.0.0 appears to be an outlier.
Figures 4.10 to 4.17 show pairwise comparisons for each of the eight treatment
groups. A tight diagonal line is expected for replicates, as this indicates low variability
between samples. Figures 4.18 and 4.19 show plots of all samples before normalisa-
tion. These reveal that there is variation in intensity between arrays and therefore a
normalisation is necessary.
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Figure 4.8: This figure shows the hierarchical clustering for all 64 arrays before
normalisation. Arrays do not seem to cluster on any extraneous factor, nor does one of
the treatments cause enough difference for them to cluster together. UNSALCHOW
28.0.0 appears to be an outlier.
Normalisation/Differential Expression
Following the quality control assessment, all samples were confirmed to be of
good quality and the data was filtered for genes present on at least one array. The
original 22,517 genes were filtered down to 10,774, by this low stringency filtering
method. Data was then transformed with a variance stabilising transformation and
normalised with a quantile normalisation (as done in Chapter 3 and described in
Chapter 2). Figures 4.20 and 4.21 show a boxplot and density plot of all samples
after normalisation.
Due to the complexity of the study design, several methods of analysis were im-
plemented to find the most biologically relevant method appropriate for interpreting
the data. Initially, the FSPMA method was used (as described in Chapter 2). This
method utilises a mixed model ANOVA in R and can be rerun to look at the effects
of different treatments. FSPMA was run three times, once for each of the treatments
(maternal diet, leptin treatment, and postweaning diet). The lists of differentially
expressed genes were subjected to a FDR adjustment and genes with a p–value <
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Figure 4.9: Illumina Internal Controls. This figure shows the details of the internal
quality control tools for the Illumina platform. (A)Low, medium, and high intensi-
ties across arrays. Ideally, arrays should have signal intensities in the same range.
It is expected that there be a linear increase of signal between the three intensities.
(B)High stringency of the data. For high quality data it is expected that the biotin
signal would be 3–4 fold lower than the high stringency signal as shown for this data.
(C)Low stringency of the data by comparing the signal intensity of two mismatches
to the signal intensity of a perfect match. The perfect matches should have a 3–4
fold higher signal as shown for this data. No signal intensity indicates the hybridi-
sation failed. (D)Data for the negative control. The background signal should be
approximately 70. This value is accounted for in the normalisation algorithms. The
noise signal should be very low for high quality data. (E)Comparison of the signal
from the housekeeping genes to the signal from all genes. As housekeeping genes are
always expressed they should have a much higher signal compared with all genes.
This shows that this data was generally high quality.
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Pairwise plot with sample correlationPairwise Plot for Sample Correlation for ADSALCHOW Samples
Figure 4.10: Pairwise Comparison of ADSALCHOW Samples Before Normalisation.
This plot compares all eight ADSALCHOW biological replicates against each other.
These replicates should be very similar and should be tightly distributed on the x=y
axis, as these samples are. The correlations for these comparisons are ≥ 0.93.
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Pairwise plot with sample correlationPairwise Plot for Sample Correlation for UNSALCHOW Samples
Figure 4.11: Pairwise Comparison of UNSALCHOW Samples Before Normalisation.
This plot compares all eight UNSALCHOW biological replicates against each other.
These replicates should be very similar and should be tightly distributed on the x=y
axis, as these samples are. The comparisons show higher variability of sample 28.0.0.
All other comparisons have a correlation ≥0.94.
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Pairwise plot with sample correlationPairwise Plot with Sample C rrelation for ADLEPCHOW Samples
Figure 4.12: Pairwise Comparison of ADLEPCHOW Samples Before Normalisation.
This plot compares all eight ADLEPCHOW biological replicates against each other.
These replicates should be very similar and should be tightly distributed on the x=y
axis, as these samples are. The correlations for these comparisons are ≥ 0.94.
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Pairwise plot with sample correlationPairwise Plot for Sample Correlation for UNLEPCHOW Samples
Figure 4.13: Pairwise Comparison of UNLEPCHOW Samples Before Normalisation.
This plot compares all eight UNLEPCHOW biological replicates against each other.
These replicates should be very similar and should be tightly distributed on the x=y
axis, as these samples are. The correlations for these comparisons are ≥ 0.94.
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Pairwise plot with sample correlationPairwise Plot for Sample Correlation for ADSALHF Samples
Figure 4.14: Pairwise Comparison of ADSALHF Samples Before Normalisation. This
plot compares all eight ADSALHF biological replicates against each other. These
replicates should be very similar and should be tightly distributed on the x=y axis,
as these samples are. The correlations for these comparisons are ≥ 0.94.
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Pairwise plot with sample correlationPairwise Plot for Sample Correlation for UNSALHF Samples
Figure 4.15: Pairwise Comparison of UNSALHF Samples Before Normalisation. This
plot compares all eight UNSALHF biological replicates against each other. These
replicates should be very similar and should be tightly distributed on the x=y axis,
as these samples are. The correlations for these comparisons ≥ 0.93.
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Pairwise plot with sample correlationPairwise Plot for Sample Correl tion for ADLEPHF Samples
Figure 4.16: Pairwise Comparison of ADLEPHF Samples Before Normalisation. This
plot compares all eight ADLEPHF biological replicates against each other. These
replicates should be very similar and should be tightly distributed on the x=y axis,
as these samples are. The correlations for these comparisons ≥ 0.94.
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Pairwise plot with sample correlationPairwise Plot for Sample Correlation for UNLEPHF Samples
Figure 4.17: Pairwise Comparison of UNLEPHF Samples Before Normalisation. This
plot compares all eight UNLEPHF biological replicates against each other. These
replicates should be very similar and should be tightly distributed on the x=y axis,
as these samples are. The correlations for these comparisons ≥ 0.96.
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Boxplot Before Normalisation
Figure 4.18: Boxplot Before Normalisation. The box itself contains the middle 50%
of the data points. The line in the box indicates the median value of the data. If
the median line within the box is not equidistant from the hinges, then the data
is skewed. The ends of the vertical lines or ‘whiskers’ indicate the minimum and
maximum data values. The plot compares the amplitude of all expression values on
each array. This shows that the majority of the signal is at lower expression levels. It
also shows that there is some variability between each array. This analysis was done
in Lumi.
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Denisty Plot Before Normalisation
Figure 4.19: Histogram of Density of Log2 Intensities For All Arrays. This is a
histogram of each array showing the density of intensities (log2). This plot shows
that the majority of intensity values are low and that there is significant variation
between samples. This analysis was done in Lumi.
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Boxplot After Filtering, VST, and Quantile Normalisation (n=10774)
Figure 4.20: Boxplot After Quantile Normalisation. This is a boxplot of the data
from each array. The plot compares the amplitude of all expression values on each
array. This shows that the majority of the signal is at lower expression levels. This
plot shows that there is no variability between the arrays. The normalisation has
effectively adjusted the expression values to remove the variability. This analysis was
done in Lumi.
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Density Plot After Filtering, VST, and Quantile Normalisation (n=10774)
Figure 4.21: Histogram of Density of Log2 Intensities For All Arrays After Quantile
Normalisation. This is a histogram of each array showing the density of intensi-
ties (log2). This plot shows that the majority of intensity values are low and that
there is no variation between samples. The normalisation has effectively adjusted the
expression values to remove the variability. This analysis was done in Lumi.
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Figure 4.22: This figure shows the results of three FSPMA analyses. FSPMA uses a
mixed model ANOVA to compute p–values based on a particular effect. The analysis
was run three times, once for each of the treatments (maternal diet, leptin treatment,
and postweaning diet). This Venn diagram shows the number of significant (p–
value<0.05) genes in each list and the overlap between each list.
0.05 were selected as statistically significant for further investigation. The lists of
genes affected by maternal diet, leptin treatment and postweaning diet had 1,089
genes, 555 genes and 1,414 genes respectively. There was some overlap between these
lists as shown on the venn diagram in figure 4.22, including 17 genes that appeared
on all three lists.
The second analysis involved pair-wise comparisons performed in Limma as utilised
in Chapter 3. To compare the 8 different treatment groups against each other resulted
in 28 separate comparisons. The number of genes for each of these comparisons is
shown in figure 4.23. Of these comparisons, 13 revealed one or more significantly
expressed genes. The combined list revealed a total of 160 significantly (p–value <
0.05) differentially expressed genes. Of the 160 genes, 55 had also been revealed by
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Figure 4.23: This figure shows the results of the pairwise comparisons between each
combination of treatment groups. The groups are shown at the top and the number
shown below the arrow connecting two treatment groups indicates the number of
genes that were significantly, differentially expressed for that comparison.
the FSPMA analysis
A final analysis was done in KDE. It was a simple one-way ANOVA with an FDR
multiple testing correction. This revealed 99 significant genes. Many of the genes
found in the other two analyses (especially FSPMA) revealed genes that had very
small expression differences, thus we added a filtering regime to the one-way ANOVA
in an effort to remove outliers and focus on genes with larger fold-changes. The
filtering removed individual outliers which were > 1.96 standard deviations from the
mean of the 8 biological replicates. Genes were excluded from ANOVA if they were
detected in fewer than 16 of the 64 samples. In this list, we found 79 of the 99 genes
from the first one-way ANOVA and 139/160 genes found in the pair-wise comparisons.
Using this method, 334 genes were found with a fold-change between the maximum
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and minimum values that was less than 25% after averaging the biological replicates
and 127 genes were found when the fold-change difference was less than 50% after
averaging the biological replicates. By eliminating outliers in this way, the error bars
were tightened and a less stringent FDR correction could be used. It also allowed us
to focus on genes with the largest fold-change differences. Gene lists for all analyses
can be found in Appendix C (FSPMA results, Tables 7-9; Pairwise results, Tables
10-22; one-way ANOVA results, Table 23).
Hierarchical Clustering
Hierarchical clustering was performed on the 127 genes with an ANOVA p-value
less than 5% and at least a 50% change in gene expression between the highest and
lowest values. The data was normalised to a median value of 0 to allow clustering. The
hierarchical clustering dendrogram is shown in figure 4.24. The hierarchical clustering
analysis separated genes into 10 clusters based on the expression patterns between
treatment groups. By plotting the expression values in a dendrogram (see figure
4.24), generalisations can be made about the expression patterns in each cluster. In
this figure, each row represents a gene and each column a treatment group. Cluster
0 (the one closest to the top) consists of three genes. These appear to have gene
expression induced by a HF diet in the offspring of AD mothers and repressed by a
HF diet in the offspring of UN mothers. There also may be some interaction with
leptin. Cluster 1 has 10 genes and is induced by a HF diet in the offspring of AD
mothers and is repressed by a HF diet in the offspring of UN mothers. Cluster 2 has
6 genes and is induced by the combination of leptin treatment and a postnatal chow
diet in the offspring of both AD and UN mothers. Clusters 3 and 4 have only 3 genes
and 2 genes respectively; therefore, they are difficult to interpret. Cluster 5 has 28
genes and the gene expression is induced by leptin. Leptin induction in this cluster
is reduced in the UNLEPHF group. Cluster 6 has 10 genes and gene expression is
induced by UN and repressed by AD with a possible leptin effect. Clusters 7 and 8
have only one gene each; they are also difficult to interpret. Cluster 9 has 13 genes
and gene expression is repressed by a HF diet in the offspring of AD mothers and
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the expression is induced by a HF diet in offspring of UN mothers. Cluster 10 has
49 genes and gene expression is repressed by leptin in general, however, the leptin
repression is less effective in the UNLEPHF treatment group and more effective in
the UNLEPCHOW treatment group. This can also be described as the interaction
of two effects: repression by leptin, and induction by a HF diet, specifically in the
offspring of UN mothers.
Pathway Analysis
Initially Pathway Analysis was performed on the FSPMA gene lists, as these are
larger and could potentially reveal trends based on the effect of an individual treat-
ment. Onto-Express [78] was used to find biological processes, molecular functions
and cellular components associated with each gene list. The results of this analysis
are shown in figures 4.25-4.27. These pie charts represent all the genes involved in
biological processes, molecular functions or cellular components. The gray area shows
the proportion of biological processes, molecular functions or cellular components not
represented in the gene list, while the coloured wedges represent the categories that
are most enriched in the gene list. A similar analysis was also done in DAVID, which
revealed the most enriched categories for the list of genes affected by maternal diet to
be related to protein binding, localisation and transport; those for the leptin treat-
ment to be immune response, nucleobase metabolism and transport; and those for
the postweaning diet to be related to cytoplasm, catalytic activity and metabolism
(cellular lipid, lipid, alcohol, sterol, and steroid metabolism specifically).
Once the other analyses had been done and the dendrogram for the one-way
ANOVA had been produced, a pathway analysis was performed on each of the clus-
ters to determine if they represented genes involved in related biological processes,
molecular functions or cellular components. Table 4.2 shows the key biological pro-
cesses and kegg pathways that were significantly enriched for each cluster based on
DAVID pathway analysis. During this process, it also became interesting to compare
the overlap between the lists produced in the three separate analyses. Table 4.3 shows
the 83 genes that overlapped between the FSPMA analysis and the filtered one-way
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Figure 4.24: This is a heatmap showing the results of hierarchical clustering of the
data normalised to a median value of 0. Each treatment group is represented in a
separate column as shown on the top. The ten clusters are shown with coloured
brackets on the left side.
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Maternal Diet
Leptin Treatment
Post-Weaning Diet
Figure 4.25: This pie chart shows the biological processes most enriched in each of
the gene lists produced with the FSPMA analysis. The circle represents all the genes
involved in biological processes. The gray area represents the biological processes
not represented in the gene list. The coloured wedges show the proportion of genes
involved in a particular biological process. This figure was made using Onto-Express
[78].
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Leptin Treatment
Post-Weaning Diet
Maternal Diet
Figure 4.26: This pie chart shows the molecular functions most enriched in each of
the gene lists produced with the FSPMA analysis. The circle represents all the genes
involved in molecular functions. The gray area represents the molecular functions
not represented in the gene list. The coloured wedges show the proportion of genes
involved in a particular molecular function. This figure was made using Onto-Express
[78].
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Maternal Diet
Leptin Treatment
Post-Weaning Diet
Figure 4.27: This pie chart shows the cellular components most enriched in each of
the gene lists produced with the FSPMA analysis. The circle represents all the genes
involved in cellular components. The gray area represents the cellular components
not represented in the gene list. The coloured wedges show the proportion of genes
involved in a particular cellular component. This figure was made using Onto-Express
[78].
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ANOVA analysis listed by cluster. This table has a column to indicate which of the
three FSPMA lists the gene was present in (M for maternal diet, L for leptin treat-
ment and/or D for postweaning diet). Another column shows which, if any, pair-wise
comparisons the gene was present in.
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Cluster Number of genes Biological Process/Kegg Pathway
Cluster0 4 Not found in pathway software
Cluster1 10 Antigen processing and presentation
immune response
Cluster2 6 Regulation of biological processes
Cluster3 3 Transport of lipid (1gene)
Cluster4 2 Not found in pathway software
Cluster5 28 Metabolic processes (carboxylic acid, organic acid, amino
acid etc), cholesterol biosynthetic process
kegg pathways: carbon fixation, biosynthesis of steroids
alanine and aspartate metabolism, arginine and proline
metabolism,
Cluster6 10 Lipid transport, transport, digestion, establishment of
localisation,response to drug
kegg pathway: PPAR signalling pathway
Cluster7 1 Proteolysis
kegg pathway: Metabolism of xenobiotics by
cytochrome P450
Cluster8 1 Not found in pathway software
Cluster9 13 Response to external stimulus, humoral immune response,
defence response, immunoglobulinn mediated immune
response
kegg pathway: complement and coagulation cascades
Cluster10 49 Metabolic processes (glucan,glycogen,polysaccharide,
and more)
kegg pathway: circadian rhythm
Table 4.2: This table lists the number of genes found in each of the hierarchical
clustering clusters and the main biological processes and kegg pathways that are
affected by the genes in the particular cluster found using DAVID [77].
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4.2.2 qRT-PCR for Microarray Validation
Quantitative RT-PCR analysis of selected genes was performed in order to confirm
the expression data derived from array analysis. Eight genes (Igfbp2, Rt1-149, Rt1-
ba, Rt1-m6-2, Orm1, Ca3, Gck, and Per2 ) found to be significantly, differentially
expressed on the Illumina microarray were selected for qRT-PCR validation. qRT-
PCR was performed as described in Chapter 2 on the pooled RNA samples of the
biological replicates in each treatment group. Cyclophilin was used as an invariant
control for normalisation. The individual CT values are shown for the cyclophilin
technical replicates in figure 4.28. All except one of the replicates vary less that
4% from the mean of all replicates. The microarray and qRT-PCR data for each
treatment group for each gene are shown in figures 4.29-4.32.
4.2.3 Comparison of Treatment Groups
The genes selected for qRT-PCR are also shown in figures 4.33-4.36. These graphs
aim to compare the effects of the leptin treatment across the x-axis and the post-
weaning diet along the y-axis.
Genes/Pathways Highlighted in Other Studies
Gluckman et al. [91] also used the liver tissue from this initial leptin reversal study
for molecular analysis, but utilising a candidate gene approach. They examined the
gene expression of 11β-hsd2, Pparα, Pepck, and GR. They found a significant effect
of leptin in UN animals that had been fed a high-fat postweaning diet for 11β-hsd2,
Pparα, and Pepck (results shown in figure 4.37A). We repeated these experiments
for comparison using the same primers and a similar protocol. We obtained different
results that showed no significant change between treatment groups (results shown
in figure 4.37B).
Figure 4.38 shows the array signals for the five genes from Gluckman et al. [91]
plotted with leptin treatment on the x-axis and the postweaning diet on the y-axis
to determine the effect of the treatment on the gene expression.
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Figure 4.28: This figure shows the 12 technical replicates run with primers for cy-
clophilin. This data served as the invariant control for the other qRT-PCR data
presented in this chapter. The lines represent 4% of the mean.
Comparison of Day 170 Female Saline Data to Day 55 Male Undernour-
ished Data
Although the samples used in this chapter and in Chapter 3 are very different
and were not chosen for comparison, a brief analysis was done out of interest. The
comparison was between the ASC and USC samples from this chapter and all the
AD and UN samples from Chapter 3. For review, the two studies are from different
cohorts that went through experimental protocols with slight variations. The two
groups are different sexes and the samples are from different time points.
Two separate analyses were done; a simple pairwise comparison between each
of the combinations of the 4 groups (AD-Day170, UN-Day170, AD-Day55 and UN-
Day55) and a three way ANOVA with interaction term. Figure 4.39 shows the num-
ber of genes significantly, differentially expressed in each of the pairwise comparisons.
The number in brackets shows the genes unique to that comparison. Although it is
impossible to say whether the genes are being up or downregulated due to sex differ-
ences or age differences, it does highlight the need to do a more detailed study looking
at different developmental windows (see Appendix C Tables 24-27 for genelists).
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Microarray Expression Data
Figure 4.29: This figure shows four of the genes (Igfbp2, Rt1-149, Rt1-ba, and Rt1-
M6-2 ) that were chosen from the list of significantly, differentially expressed genes
on the Illumina microarray. For each gene 8 biological replicates for each of the 8
treatment groups were hybridised and analysed. The data here is shown as a % of
ASC expression.
160
00.2
0.4
0.6
0.8
1
1.2
IGFBP2 RT1-149 RT1-Ba RT1-M6-2
ASC
ALC
ASHF
ALHF
USC
ULC
USHF
ULHF
Microarray Validation by qRT-PCR
Figure 4.30: This figure shows four of the genes (Igfbp2, Rt1-149, Rt1-ba, and Rt1-
M6-2 ) that were chosen from the list of significantly, differentially expressed genes
on the Illumina microarray. The RNA from the eight biological replicates was pooled
for each of the eight treatment groups. qRT-PCR for the eight samples was run in
triplicate with cyclophilin as an invariant control. The data have been normalised to
the ASC treatment group at 1.
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Figure 4.31: This figure shows four of the genes (Orm1, Ca3, Gck, and Per2 )that
were chosen from the list of significantly, differentially expressed genes on the Illumina
microarray. For each gene 8 biological replicates for each of the 8 treatment groups
were hybridised and analysed. The data here is shown as a % of ASC expression.
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Microarray Validation by qRT-PCR
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Figure 4.32: that were chosen from the list of significantly, differentially expressed
genes on the Illumina microarray. The RNA from the eight biological replicates
was pooled for each of the eight treatment groups. qRT-PCR for the eight samples
was run in triplicate with cyclophilin as an invariant control. The data have been
normalised to the ASC treatment group at 1.
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Figure 4.33: The figure on the left shows the array signals for Gck and the figure on
the right for Per2. The x-axis represents the effect of the leptin treatment and the y-
axis represents the postweaning diet. The blue and red lines show the undernourished
maternal diet (UN) and the green and purple lines show the ad-libitum fed maternal
diet (AD).
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Figure 4.34: The figure on the left shows the array signals for Igfbp2 and the figure on
the right for Igfbp4. The x-axis represents the effect of the leptin treatment and the y-
axis represents the postweaning diet. The blue and red lines show the undernourished
maternal diet (UN) and the green and purple lines show the ad-libitum fed maternal
diet (AD).
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Figure 4.35: The figure on the left shows the array signals for Rt1-ba and the figure
on the right for Rt1-149. The x-axis represents the effect of the leptin treatment
and the y-axis represents the postweaning diet. The blue and red lines show the
undernourished maternal diet (UN) and the green and purple lines show the ad-
libitum fed maternal diet (AD).
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Figure 4.36: The figure on the left shows the array signals for Rt1-m6-2 and the figure
on the right for Ca3. The x-axis represents the effect of the leptin treatment and the y-
axis represents the postweaning diet. The blue and red lines show the undernourished
maternal diet (UN) and the green and purple lines show the ad-libitum fed maternal
diet (AD).
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Figure 4.37: (A)This figure was taken from Gluckman et al. [91] and shows RT-PCR
results for the mRNA expression of 11β-hsd2, Pparα, and Pepck for the same adult
day 170 female rats as used in this chapter. Data are means±SEM for n=8 per group;
values for gene expression are expressed relative to those of normally nourished (AD
maternal diet and CHOW postnatal diet) saline-treated offspring set as 100%. All
three genes were found to have a significant p< 0.05 effect of leptin treatment in
UN high-fat animals (+). (*) indicates data is significantly p<0.05 different from
ADSALCHOW. (B) We performed similar qRT-PCR experiments and found no sig-
nificant differences among treatment groups. In this case, data are means±SEM for
n=3 per group except PPARα, which is n=8.
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Figure 4.38: This figure shows the array signals for the five genes from Gluckman
et al. [91] plotted with leptin treatment on the x-axis and the postweaning diet on
the y-axis to determine the effect of the treatment on the gene expression. GR and
11β-HSD2 are the only plots to show interactions between the treatments.
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Figure 4.39: This figure shows the results of pairwise comparisons between the AD-
SALCHOW and UNSALCHOW data from this chapter with the AD and UN data
from Chapter 3. The number of genes that came up as differentially expressed for the
comparison (p<0.05) is shown in the colour of the arrow for that comparison. The
number shown in brackets is the number of genes unique to that comparison. The
effects of sex and time point cannot be separated.
Cluster Symbol Biofunction
Cluster 0 Clic2 regulation of cellular processes
Cluster 0 Hrasls3 role in adipogenesis [142]
Cluster 1 Igfbp2 impaired IGD binding to receptor
Cluster 1 RT1-149 histocompatability complex
Cluster 1 RT1-A3 histocompatability complex
Cluster 1 RT1-Ba histocompatability complex
Cluster 1 RT1-CE15 histocompatability complex
Cluster 1 RT1-M6-2 histocompatability complex
Cluster 1 Sds regulation of cell cycle
Cluster 1 Sparcl1 glycoprotein that binds calcium
Cluster 1 Tnfsf13 important for B cell development
Cluster 2 Cgref1 cell growth; response to stress
Cluster 2 Colq collagen-like tail subunit
Cluster 2 Hspb1 Heat shock 27kD protein induced by environmental
stress
Cluster 4 Csad involved in taurine biosynthesis
Cluster 5 Asl involved in urea cycle
Cluster 5 Cd63 cell growth; associated with tumour progression
Cluster 5 Csrp2 regulation of development and cell differentiation
Cluster 5 Cyp3a13 drug metabolism
Cluster 5 Dhcr7 cholesterol metabolism
Cluster 5 Ftl1 regulation of iron storage
Cluster 5 Got1 amino acid metabolism; involved in urea cycle
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Cluster 5 Hnrpab mRNA metabolism and transport
Cluster 5 LOC316130 M6prbp1 -receptor binding protein
Cluster 5 Me1 activity links glycolytic and TCA cycles
Cluster 5 Nnmt predicted methyltransferase activity; implicated in cancers
Cluster 5 Orm1 regulation of immune system; inflammatory re-
sponse
Cluster 5 Prkcdbp negative regulation of cell cycle; tumour suppres-
sor
Cluster 5 Rnf125 predicted T-cell activation
Cluster 5 Slc16a13 transport
Cluster 5 Slc22a5 transport; linked to metabolic decompensation
Cluster 5 Tmod1 actin binding; organisation of actin filaments
Cluster 5 Tor3a nucleotide binding
Cluster 5 Trpm6 predicted calcium ion and nucleotide binding
Cluster 6 Abcg5 nucleotide binding; transport of dietary cholesterol
Cluster 6 Afp metal ion binding
Cluster 6 Ctsh degradation of proteins in lysosome
Cluster 6 Fabp2 binds long-chain fatty acids; maintains energy
homeostasis by acting as lipid sensor
Cluster 6 Fabp7 expressed during development; involved in brain
development
Cluster 6 Hdc modulates numerous physiologic processes
Cluster 6 Serpina7 thyroid hormone transport protein
Cluster 6 Synj2 signal transduction
Cluster 9 C2 proteolysis
Cluster 9 Mlc1 predicted may be involved in transport; associated with neu-
rological disorders
Cluster 9 Sod2 protein binding; mitochondrial
Cluster 9 Ugt2b10 predicted metabolic processes
Cluster 10 Aadac lipid mobilisation (regulated diurnally)
Cluster 10 Acox2 involved in degradation of long chain Fas
Cluster 10 Ak3l1 mitochondrial nucleotide mobilisation
Cluster 10 Avpr1a receptor mediates cell contraction and prolifera-
tion, platelet aggregation, release of coagulation
factor and glycogenolysis
Cluster 10 Bche drug metabolism
Cluster 10 Bhlhb2 basic helix-loop-helix domain
Cluster 10 Btg1 regulates cell growth and differentiation
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Cluster 10 Ca3 involved in cellular response to stress
Cluster 10 Car14 predicted carbonic anhydrase
Cluster 10 Cyp2b3 cyt P450 complex
Cluster 10 Dclre1a predicted involved in blocking transcription, replication, and seg-
regation of DNA
Cluster 10 Enpp2 modulator of cell motility; may induce parturition; stim-
ulates tumour cell motility
Cluster 10 Gck important in glucose utilisation
Cluster 10 Gclc rate limiting step in glutathione synthesis
Cluster 10 Klf15 glucose and fat metabolism [143]
Cluster 10 Kmo required for synthesis of quinolinic acid
Cluster 10 LOC497901 Leap2-may have antimicrobial activity
Cluster 10 LOC500015 Samd9l
Cluster 10 LOC500080 similar to Slc13 member4 - may be involved in lifespan
determination [144]
Cluster 10 Olr59 sensory perception of smell
Cluster 10 Otc involved in the urea cycle
Cluster 10 Per2 regulation of circadian rhythm [145],[139] and [146]
Cluster 10 Polg2 predicted mitochondrial DNA polymerase gamma subunit
Cluster 10 Ppp1r3b regulates enzymes (PYGL) involved in glycogen
metabolism
Cluster 10 Ptprf regulates cell growth and differentiation
Cluster 10 Pygl important in carbohydrate metabolism [147]
Cluster 10 Rarb regulates gene expression and affects development
Cluster 10 Serpina3m protein metabolism
Cluster 10 Sez6 cell-cell recognition and neuronal membrane signalling
Cluster 10 Slc40a1 regulation of iron levels
Cluster 10 Stac3 predicted intracellular signalling
Cluster 10 Tdo2 tryptophan metabolism
Cluster 10 Thrsp may have a controlling role tumour lipid metabolism
Cluster 10 Xpnpep2 role in inflammatory process and response to injury
Table 4.4: This list includes most of the genes that were found in the filtered one-
way ANOVA and the FSPMA analysis. The list includes the cluster as in table 4.3
for cross reference. These are the functions as found in literature search or online
database information (genecards, NCBI or wikipedia).
170
4.3 Discussion
By comparing the transcriptional profiles of liver RNA from 170 day old rats that
have been subjected to undernourishment during pregnancy, a leptin treatment and a
postnatal high fat diet; this study has highlighted many genes that have been altered
due to a combination of these treatments. Pathway analysis has revealed that many
of the genes are involved in biological functions that are relevant to metabolism and
may reveal primary or secondary effects of the treatments. An understanding of the
role of leptin, its signalling to the brain, and the evolution of diet in humans (as
discussed in Chapter 1) enables us to hypothesise the reasons for the phenotypes
that develop. This study has now provided molecular evidence to back up some of
these theories.
In this study, significant gene expression differences were dependent on the inter-
action between three treatments: maternal diet during pregnancy, leptin treatment
and postweaning diet. Initial analysis aimed to separate the three treatments and
consider, independently, the genes being influenced by each treatment. This analysis
resulted in very large gene lists that included a majority of genes with very small
expression changes. The large gene lists, however, were useful for pathway analy-
sis. Figures 4.25 (biological processes), 4.26 (molecular functions), and 4.27 (cellular
components) show the breakdown of the results of these analyses. These figures were
made using Onto-Express and analysis done in David (see Chapter 2) supported the
results. These analyses indicated that genes affected by maternal diet were involved
in pathways related to protein binding, localisation, transport, organ development
and apoptosis. The presence of organ development seems particularly logical given
the hypothesis that a restricted diet during pregnancy causes the foetus to focus
resources on brain development rather that organ development. The genes affected
by the leptin treatment were related to immune response, nucleobase metabolism
and transport. As mentioned in the introduction to this chapter, leptin has been
implicated as affecting immune response. Finally, the genes affected by the post-
weaning diet were related to cytoplasm, catalytic activity, signal transduction and
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metabolism (cellular lipid, lipid, alcohol, sterol and steroid metabolism specifically).
Pair-wise analysis of treatment groups against each other produced interesting results
that have proven challenging to interpret (see figure 4.23). Three of these comparisons
stood out as having greater than 50 significantly expressed genes and intriguingly all
three of these comparisons involved the UNLEPCHOW treatment group. This is the
group that was undernourished during pregnancy, received the leptin treatment and
was then put on a standard chow postnatal diet. Vickers et al. [57] has claimed that
female rats that are undernourished during pregnancy only show the programmed
phenotype if they are then subjected to the mismatch of the postnatal HF diet. This
treatment group did not show significant phenotypic differences from the control AD-
SALCHOW treatment group. It is also worth mentioning the three treatment groups
that showed the most significant differences to the UNLEPCHOW group. The most
differences (88 genes) were found in comparison to the UNSALHF treatment group,
which is the programmed phenotype of maternal undernourishment followed by the
mis-match of the postnatal HF diet. Interestingly, the fourth largest gene list (28
genes) occurred in the comparison of this programmed phenotype (UNLEPHF) and
the normal control treatment (ADSALCHOW). Phenotypically it seems to be the
same comparison, but there must be metabolic changes induced by the maternal
undernourishment given the larger number of differentially expressed genes in that
comparison. Without the HF diet insult, these metabolic changes did not affect
the phenotype. The second and third largest gene lists occurred in the comparison
against the ADLEPHF (65) and ADSALHF (55) treatment groups. These treatments
result in similar phenotypes although the leptin treated rats had slightly higher body
fat, locomotor activity, insulin, leptin, and C-peptide levels and slightly lower food
intake as would be expected with raised leptin levels, but these measurements were
not statistically significant. A large number (51) of the genes occur in at least 2 of
the three largest lists.
As described in the results, the gene lists from the different analyses were com-
pared and a table of overlapping genes was created. A close look at table 4.3 shows
the agreement of the ‘Treatments’ (this column indicates which gene list that the
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gene was significant for in the FSPMA analysis) and the ‘Pair-wise Comparisons’.
The lists were sorted by the clusters obtained from the hierarchical clustering of the
one-way ANOVA across all eight treatment groups. Table 4.2 lists each cluster and
the most enriched biological process/molecular function for each cluster. Table 4.4
then goes into more detail and provides the specific biological function or proposed
biological function for most of the 83 genes that overlapped in the different analyses.
The largest cluster and the one that seems to include the most intriguing genes is
cluster 10. This cluster has 49 genes and gene expression appears to be repressed
by leptin in general, however the leptin repression is less effective in the UNLEPHF
treatment group and more effective in the UNLEPCHOW treatment group. This can
also be described as the interaction of two effects: repression by leptin, and induction
by a HF diet specifically in the offspring of UN mothers. The rest of this discus-
sion will focus on the function of these genes and hypotheses on how they might be
affecting the observed phenotypes in this study.
4.3.1 Cluster 10
Cluster 10 is the cluster that drew the most interest and includes genes involved
in metabolic processes: sensory perception, stress response, regulation of circadian
rhythm, transport and signalling. All of these genes were shown to be significantly
affected by the postnatal high fat diet in the FSPMA analysis. Although, several were
also shown to be affected by the maternal diet and six were shown to be significantly
affected by all three treatments. The genes affected by all three treatments were Gck,
Per2, Klf15, Enpp2, Xpnpep2, and Slc40a1 ; four of which are well characterised and
are summarised here.
Gck (glucokinase) is a rate-limiting enzyme in glycolysis that regulates the con-
version of ATP and D-glucose to ADP and D-glucose 6-phosphate. The gene is found
to have reduced expression in patients with type-2 diabetes and in diabetic animals
[148]. Insulin stimulates Gck, which in turn activates glucose disposal in the liver.
Down regulation of Gck could, therefore, play a role in reduced insulin sensitivity.
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Bogdarina et al. [149] found that fasting causes reduced Gck expression, but that
re-feeding will result in an immediate insulin-induced increase in Gck. However, in
this study, animals that were exposed to maternal undernutrition during gestation
have reduced GCK expression in adulthood compared to control animals. This gene
has come up as being differentially expressed in all three treatment groups and fig-
ure 4.33 clearly reveals an effect of leptin in conjunction with the maternal UN diet,
which is in line with the reduced insulin sensitivity in the UN animals.
Per2 (period homolog 2) is one the core clock genes involved in regulation of the
circadian rhythm. The circadian rhythm is the 24-hour cycle by which biological
processes in the body are regulated. There are several core clock genes including
(Npas2, Bmal1, Per1, Rev-erbα, and Per2 ) [139]. Per1 was significantly, differentially
expressed due to the maternal diet and the leptin treatment in the FSPMA analysis,
however, it was not present as significant in the other two analyses. Changes in
the expression of the core clock genes have been tied to obesity. As mentioned at
the beginning of this chapter, leptin has been shown to affect the circadian rhythm.
Figure 4.33 shows an effect of leptin in both AD and UN fed animals.
Klf15 (Krupple-like Factor 15) is a gene that was significant in the FSPMA anal-
ysis as being affected by the postnatal diet and in the pair-wise analysis it came
up in the comparison of ASHFvsULC; which indicates it has been affected by all
treatments. Figure 4.40 shows the expression signals and emphasises the effect of
leptin and the postnatal diet. Gray et al. has shown that Klf15 plays a role in the
regulation of gluconeogenesis [143]. Klf15−/− mice are capable of gluconeogenesis
but are less efficient at using alanine as a source for the process.
Enpp2 is found in adipose tissue and Ferry et al. [150] conducted a detailed
study into its role in this tissue. They found it is strongly up-regulated during
adipocyte differentiation and it seems to be a consequence of the differentiation as
it is associated with the accumulation of triglycerides. The expression levels are
significantly increased in obese diabetic db/db mice and, therefore, Enpp2 may be
associated with diabetes or obesity. Although this study was done in adipocyte tissue
and our study involved liver tissue, it can be assumed that Enpp2 may also be related
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Figure 4.40: The figure on the left shows the array signals for KLF15 and the figure on
the right for Enpp2. The x-axis represents the effect of the leptin treatment and the y-
axis represents the postweaning diet. The blue and red lines show the undernourished
maternal diet (UN) and the green and purple lines show the ad-libitum fed maternal
diet (AD).
to obesity in liver tissue [150]. Figure 4.40 shows an effect of leptin and the postnatal
diet.
4.3.2 Genes Involved in the Immune Response
Several genes involved in the histocompatibility complex were found to be sig-
nificantly, differentially expressed. These genes (RT1-Ba, RT1-149, RT1-A3, RT1-
CE15, RT1-A1, RT1-M62, RT1-CE16, RT1-CE12, RT1-CE7, RT1-N2, RT1-CE13,
and Ca3 ) were down regulated in animals that had been treated with leptin. This
was the case for offspring of both AD and UN mothers. There was more down regu-
lation in those that had subsequently received a high fat postnatal diet. The animals
were 170 days of age so increased expression may be due to aging or to repair of liver
damage. However, it is intriguing that the data show the down regulation in the
treated animals indicating less inflammation and a lower immune response. Vila et
al. conducted a study of hepatic gene expression on a mouse model of senescence in
which the mice experience accelerated aging. They found that at 5 months (approxi-
mately 150 days) inflammation is taking place in the liver and HSP1 is upregulated.
This rat model also shows an increase in expression of HSPb1 in ULC and less so
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in ALC rats. Previous studies have shown that HSP1 decreases in expression with
aging; the increase in this mouse model would indicate a counter-anti-inflammatory
response [151]. It is possible, the decreased gene expression in the leptin treated
rats could be due to errors in signalling pathways that have suppressed the immune
system.
4.3.3 Relevant Genes in Other Clusters
IGFBP2 is another relevant gene that was significantly, differentially expressed
in all three analyses. The FSPMA analysis revealed it as being affected by the
postnatal diet, it was in cluster 1, and was significant in the pairwise comparison
of ALHFvsULC. A relative, Igfbp4, also showed up in the FSPMA analysis, but not
in the pairwise comparison. Both of these genes are expressed in mammary tissue.
Igfbps are involved in fetal and neonatal development and Igfbp2 is predominantly
expressed in the liver while Igfbp4 is only expressed in small amounts in the liver.
The expression of both Igfbp2 and Igfbp4 is known to increase in aging. IGFs are
involved in inhibition of insulin-like activity [152]. Figure 4.34 shows an obvious effect
of leptin and the maternal diet for Igfbp2, but no effects are seen in Igfbp4.
4.3.4 Candidate Genes
The qRT-PCR analysis of candidate genes 11β-hsd2, Pepck, Pparα, GR, and Aox
showed no significant expression difference between the treatment groups (see figure
4.37). This was in contrast with the results obtained by Gluckman et. al [65] for
expression changes in 11β-hsd2, Pparα, and Pepck. Gluckman used the same tissues
from the same animals so the difference in results cannot be explained. Figure 4.38
shows the qRT-PCR expression signals for comparison of the effect of each of the
treatments. This figure shows some small effect from the leptin treatment on the
expression of GR and 11β-hsd2.
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4.3.5 Adipose Tissue
In an unpublished study, (KA Lillycrop, GC Burdge, MH Vickers, MA Hanson,
and PD Gluckman) used the adipose tissue samples from the same animals used here
and conducted a candidate gene expression study using RT-PCR to determine mRNA
concentrations in Pparα, Pparγ2, Aox, Cpt-1 (carnitine:palmitoyl transferase), Lpl
(lipoprotein lipase), GR, 11β-hsd2, and leptin. These samples were normalised to
ribosomal 18S RNA using the ∆CT method. The results showed that maternal diet
and leptin treatment had independent effects on the gene expression and there was
no leptin reversal. Similar to their results we found an effect of the maternal diet and
postnatal diet on GR mRNA expression, but there was no effect on Pparα, Aox, or
11βhsd-2 (or Pepck). This was not statistically significant but the comparisons are
shown in figures 4.37 and 4.38.
The RNA had been extracted from muscle tissue for the same animals; however,
due to time constraints these samples were not used. It would be interesting to see
how the expression changes in muscle differ from fat and liver. In addition in future
studies it would be of interest to collect brain tissue as this is would give insight into
the origin of signalling errors.
4.4 Conclusions
The initial goal of this study was to uncover the molecular mechanism of the leptin
reversal; however, we did not uncover any evidence of the leptin reversal. This finding
was supported by the unpublished work done by Lillycrop et al.. Instead we found,
the interaction between the maternal diet, leptin treatment, and the postweaning
diet could have significant effects on gene expression in a number of metabolically
relevant genes. Many of the changes were supported by functional data found in
the literature. A comparative analysis of the results of this study and those of the
study in Chapter 3 revealed a large number of differentially expressed genes, however,
these were confounded due to the difference in sex of animals and time-point of
tissue collection. This has highlighted the need to perform a more detailed study
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incorporating different tissues taken at different time points to really understand the
changes that have occurred. In this study the effect of leptin was associated more
with the postweaning chow diet rather than the postweaning high-fat diet. This is
an unexpected result and difficult to explain. A simplified study design that looks at
the immediate effects of leptin may help unravel the details of the cascade of events
that lead to the metabolic syndrome.
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Chapter 5
Methylation Study
5.1 Introduction
The work presented in this chapter aimed to investigate whether epigenetic effects
through methylation at CpG dinucleotides in promoter sequences, are responsible for
gene expression and resulting phenotypic changes in the rat model. We wanted to
gain a general impression of the presence, scale, and significance of such methylation
change, by exploring a diverse range of genes that were highlighted in the previously
described genome-wide expression studies. This chapter includes experiments done
by a research student under the author’s guidance. Neil Graham was a part II student
in 2007-2008, that used DNA previously extracted from the AD/UN liver samples
described in Chapter 3, to look for methylation differences in differentially expressed
genes with the McrBC assay (see Chapter 2). Neil was able to follow up on 87 genes
highlighted in the microarray analysis.
A second research student, Chathika Weerasuriya, was a summer student in 2008,
that extracted DNA from the leptin liver samples described in Chapter 4 and pre-
ceded to treat them with bisulphite conversion and then, use PCR and sequencing to
determine if there were methylation changes. Due to the inability to get high quality
DNA from the leptin samples, the bisulphite conversion that summer was largely
unsuccessful and no results were produced.
This chapter begins with background information on epigenetics, specifically methy-
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lation and how it has been tied to the metabolic syndrome. This is followed by a
description and discussion of the results.
5.1.1 Epigenetics
The term epigenetics was first coined by Conrad Waddington [153], to unite the
fields of developmental biology and genetics. His definition was general and said
simply, ‘All those events which lead to the unfolding of the genetic program for
development’. Over the years, this term has taken on the more specific definition to
describe the changes in gene function that occur without a change in gene sequence.
It refers to modifications that regulate gene activity; the modifications can affect
the DNA itself or the proteins that package it (histones), but the DNA sequence
does not change [154]. Figure 5.1 illustrates the epigenetic mechanisms that can
cause changes in gene activity. One component of epigenetic regulation, imprinting,
allows the control of whether the maternal or paternal allele for a particular gene is
expressed. For instance, the epigenetic imprinting of IGF2 regulates fetal growth and
fetal size depending which of the parents’ alleles is silenced [155]. Methylation occurs
depending on the availability of methyl groups and can be affected by nutrition. As
discussed in this thesis, changes in gene expression can increase the risk of disease.
Changes in components of epigenetic regulation affect gene expression and in turn,
can lead to disease. Knowing the epigenotype related to a disease state could help to
target treatments for disease.
In mammals, there are two main developmental windows when epigenetic modi-
fications occur. During gametogenesis, complete demethylation occurs, followed by
remethylation before fertilisation. A second demethylation event occurs in early
embryogenesis, and then in early embryonic life, just after implantation, the methy-
lation is re-established. The imprinted genes are able to escape this second wave of
demethylation [157]. Other genes may also be able to escape this second wave of
demethylation. This may explain transgenerational effects of undernutrition, as ob-
served in offspring of those that were pregnant during the Dutch Hunger Winter, for
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Figure 5.1: Epigenetic Mechanisms. Epigenetic changes are referring to modifications
that regulate gene activity without changes in the DNA sequence. Two common
mechanisms for epigenetic changes are shown in this figure adapted from Qiu [156].
The modifications can affect the DNA itself (through methylation) or the proteins
that package it (histone modification).
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example. These events may represent critical windows of time when reprogramming
could occur.
Methylation
Methylation is essential for the development of mammals and it has been shown
that embryos that cannot maintain normal methylation die after gastrulation [158].
DNA methylation is the addition of a methyl group CH3 to the fifth carbon position
of the cytosine pyrimidine ring via a methyltransferase enzyme. There are three
major enzymes involved in the establishment and maintenance of DNA methylation
pattern: DNMT 3A and 3B are de novo methyltransferases, and DNMT1 is the
maintenance DNMT that ensures that methylation patterns are copied throughout
each cell division [159]. The majority of DNA methylation in mammals occurs in
5’-CpG-3’ dinucleotides, but other methylation patterns do exists. In fact, about
80% of all 5’-CpG -3’ dinucleotides in mammalian genomes is methylated, whereas
the majority of the 20% that remain unmethylated is within promoters or in the first
exons of genes. CpG dinucleotides, the site of almost all methylation in mammals,
are underrepresented in DNA. Clusters of CpGs called CpG islands, are often found
in association with genes, most often in the promoters and first exons, but also in
regions more toward the 3’ end [160].
CpG islands often function as strong promoters and have been proposed to func-
tion as replication origins. Even though they are generally not methylated, most
investigations into the role of DNA methylation in mammals have focused on CpG
islands, rather than on the regions in which the majority of methylation is found [161].
There is a growing understanding as to how the methylation signal is interpreted by
mammalian cells. The post-synthetic addition of methyl groups to the 5-position
of cytosines alters the appearance of the major groove of DNA to which the DNA
proteins bind. These epigenetic ‘markers’ on DNA can be copied after DNA synthe-
sis, resulting in heritable changes in chromatin structure. Methylation of CpG-rich
promoters is used by mammals to prevent transcriptional initiation and to ensure
the silencing of genes on the inactive X chromosome, imprinted genes, and parasitic
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DNAs [161]. Methylation has been shown to block gene transcription by two general
mechanisms. The first involves the modification of the cytosine bases. The methyla-
tion at a single site within the binding region for a transcription factor can strongly
inhibit the binding of the factor to the DNA recognition sequence [162]. The sec-
ond involves methyl-CpG-binding proteins (MBPs) that recognise methyl CpGs and
use transcriptional co-repressor molecules to silence transcription and to modify sur-
rounding chromatin. MBPs provide a link between DNA methylation and chromatin
remodelling and modification [163, 164]
Histone Modification
Histone modifications (particularly posttranslational modifications of amino-terminal
tail domains) are another important epigenetic mechanism for controlling gene ex-
pression [165]. Histone acetylation is associated with active gene transcription while
other histone modifications such as the methylation of histone H3 lysine 9 (H3K9)
are indicative of condensed and inactive chromatin [166]. Histone modification and
DNA methylation work together in a reciprocal relationship to control gene expres-
sion. Methylation of histone H3 lysine 9 can be triggered by DNA methylation [167].
DNA methylatransferases have been shown to interact with histone deacetylases, his-
tone methyltransferases, and methyl-cytosine-binding proteins in a complex network
[168, 169, 170].
5.1.2 Epigenetic Change, Developmental Programming, and
the Metabolic Syndrome
Epigenetic modifications offer the mechanism for the fixed genome to have a flex-
ible means to alter gene regulation that can be transferred through mitosis without
changing the DNA sequence. Epigenetics enables an organism to respond to the en-
vironment and change its gene expression, offering phenotypic plasticity with a fixed
genotype [171, 33]. Waterland and Michels proposed the term ‘Epigenetic Epidemi-
ology’ as the study of the associations between epigenetic variation and the risk of
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disease based on the increasing evidence that epigenetic mechanisms play a role in
DOHaD [172]. This is similar to genetic epidemiology, but rather than focusing on the
role of inherited genes in disease etiology, epigenetic epidemiology also considers epi-
genetic inheritance, developmental stochasticity, environment influences, and aging.
Recent epigenomic advances are accelerating the rate of discovery of human loci where
epigenetic regulation can be correlated with early environmental exposures. Linking
this to a growing understanding of the mechanisms by which epigenetic change leads
to metabolic syndrome is key to the future research in DOHaD.
Wolff et al. conducted the first study that demonstrated that the maternal diet
during pregnancy could trigger epigenetic changes in the offspring [173]. The study
was done on mice with the agouti gene (Avy). The agouti gene is an example of a gene
with metastable epialleles. Metastable epialleles are gene loci that can be modified by
an epigenetic component in a variable or reversible way. This will result in a range
of phenotypes from one genotype. The agouti gene encodes a signalling molecule
that promotes the production of yellow phaeomelanin rather than black eumelanin
pigment. If the degree of methylation varies, then it can produce a wide distribution in
coat colour (from yellow for unmethylated alleles to brown for methylated). Changing
the maternal dietary supplementation to include methyl-donor nutrients (i.e. folic
acid, vitamin B12, choline, and betaine) shifts the coat colour of the offspring toward
the brown phenotype. In addition to the change in coat colour, the hypomethylation
of the agouti gene promoter leads to obesity and in a particular strain of mouse it
leads to cancer [174]. Figure 5.2 shows mice that have differing levels of methylation
of the agouti gene based on the maternal diet they were exposed to during gestation.
Other studies revealed that, epigenetic changeability based on early nutrition is a
characteristic of metastable epialleles. In humans, population studies have shown
folate status is highly correlated with coronary artery disease [175]; however, this has
not yet been linked to a change in methylation of affected genes.
Additional studies in rodent models of intrauterine growth restriction have shown
that maternal diet during pregnancy leads to epigenetic changes in the offspring. A
study on protein-restricted rats found that the promoters of GR and PPARα were
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Figure 5.2: Diet and Methylation. This image, adapted from Waterland et al. [174],
shows mice that have been exposed to different maternal diets during gestation, which
has resulted in differing levels of methylation of the Agouti gene. This has caused
changes in the phenotype and has also made the mice prone to obesity and cancer.
hypomethylated in the offspring and were associated with increase gene expression
[176]. A study on hypertension used the offspring of protein restricted dams and found
decreased methylation in the promoter of the Agr1b gene and increased expression
[177]. These changes affected the regulation of blood pressure and were associated
with the development of hypertension in later life. These findings give evidence to
the hypothesis that maternal nutrition may affect the methylation in the offspring
and in turn, lead to disease later in life. Methylation changes in offspring of indi-
viduals exposed to the Dutch hunger winter has shown that maternal diet can have
long-term effects on the epigenome [178]. These individuals had decreased levels of
methylation of the IGF2 gene in adulthood. In addition to nutrition, other environ-
mental factors including maternal behaviour during pregnancy and early life of the
offspring can affect the establishment and/or maturation of epigenetic mechanisms,
causing persistent changes in gene expression [172].
5.1.3 Available Techniques for Methylation Analysis
Recent advances in genomics have led to the development of multiple new tech-
niques for DNA methylation profiling and the profiling of histone modifications.
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These techniques cover a range of resolution and throughput. A very recent re-
view, by Laird et al. [179], compares and contrasts these techniques. Measurement
of methylation can be made by determining the pattern of methylated target se-
quences along individual DNA molecules or by finding an average methylation level
at a single genomic locus across many DNA molecules. The uneven distribution of
methylation in CpG islands creates an extra complication. Simple PCR to look for
methylation changes is not possible, as methylation is erased during amplification.
This makes it necessary to perform some type of methylation dependent treatment
before the amplification process. The three approaches to the methylation treatment
are: endonuclease digestion, affinity enrichment, and bisulphite conversion. After
one of these approaches has been used to treat the DNA, a variety of techniques
are available (i.e. probe hybridisation and sequencing) to reveal the location of the
methylated cytosine residues.
Endonuclease Digestion
Restriction enzyme digestion utilises methylation sensitive restriction enzymes for
DNA methylation studies. These enzymes are inhibited by a 5-methyl-C in a CpG
region of a sequence. This reveals DNA methylation by the pattern of cutting that
is determined from the digestion. The most common are HpaII and SmaI. This is
largely because for each of these enzymes there is another enzyme (MspI and XmaI
respectively that is not inhibited by CpG methylation [179]. This is the method of
methylation detection that has been utilised for the data presented in this chapter.
Affinity Enrichment
Chromatin immunoprecipitation is a technique used to identify the location of
DNA-binding proteins and epigenetic marks in the genome. Genomic sequences that
are methylated or contain another mark of interest are enriched by binding solu-
ble DNA chromatin extracts to an antibody that recognises the mark. ChIP-chip
technology uses this technique followed in conjunction with microarray hybridisation
and is very useful for identifying histone modifications. Affinity purification is use-
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ful for identifying methylation patterns when a methyl-binding protein is used (i.e.
MECP2). Techniques that use this approach include MeDIP, mDIP, or mCIP.
Bisulphite Conversion
Sodium bisulphite conversion is a chemical treatment of DNA that turns an epi-
genetic difference into a genetic difference (unmethylated Cs are converted to Ts by
uracil). This enables the detection of DNA methylation using PCR or sequencing.
Bisulphite sequencing is the best method for producing base-pair resolution. The
Golden Gate BeadArray technology has been adapted to interrogate DNA methy-
lation using bisulphite converted DNA. Illumina has also developed the Infinium
platform, which is a more comprehensive approach to DNA methylation analysis.
5.1.4 Summary
The techniques mentioned above can be coupled with array based analysis or
sequencing approaches to obtain a high-throughput method for methylation interro-
gation. An alternative approach to sequencing or hybridisation, involves detection by
matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spec-
trometry. This requires gene-specific amplification and is best suited to a candidate
gene study. Sequenom has developed the EpiTYPER which enables automation for
a large number of samples. A number of factors will play into the choice of technique
used including number of samples, quality and quantity of DNA, desired coverage,
resolution, and cost. Figure 5.3 shows a variety of different techniques and plat-
forms available, the different enzymatic pre-treatment each requires, and the analysis
method used.
5.1.5 Study Design
In this thesis, endonuclease digestion has been utilised to look for methylation
changes highlighted in the gene expression profiling study. Genes were selected based
on the results of the MEEBO expression study and preliminary microarray expression
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Figure 5.3: Methylation Techniques. This figure from Laird et al. shows a majority of
the methylation techniques available. The chart shows which enzymatic pretreatment
and which analytical step is used for each of the available techniques.
results for the Illumina expression study, presented in Chapter 3. There were 87 genes
selected and analysed according to the pipeline shown in figure 5.4.
5.2 Results
Of the 87 genes analysed in the methylation assay, 12 were significantly differ-
entially expressed on the MEEBO microarray platform and 26 were significantly
differentially expressed in the final analysis of the data from the Illumina platform.
The full list of 87 genes is shown in table 5.1. The table reveals which chip the gene
was found on. Those genes found using the MEEBO chip are labelled ‘M’ and those
that were in the final Illumina analysis are labelled ‘I-FL’. The remaining genes, la-
belled ‘I’ that were found in the preliminary Illumina analysis, are not considered
significantly differentially expressed, but are included here, as a significant amount of
work did go into locating their CpG islands and determining the methylation status
of these genes. The sequence for each of the genes was obtained and promoters were
found. The region 5kb upstream of the promoter was analysed in search of CpG
islands using the EBI CpG island prediction software. In the instances where no
island was detected, the UCSC CpG searching tool was also used with a less strin-
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Design Primers
Use Primer3
Gene Analysis:
Define Promoter Region
Search for CpG Island
Found Not found
Look for Methylation 
Changes
 (McrBC Assay)
Transcription Factor Binding Site Analysis
CpG Island is:
Figure 5.4: Methylation Analysis Pipeline. This figure shows steps followed in this
chapter to assess the methylation status of the genes highlighted in the microarray
expression studies.
189
gent search algorithm to provide negative confirmation. One CpG island or more
was identified in 56% of the promoter regions; flanking primers were designed using
Primer3 software. In cases where two islands were found, primers were designed for
both. The primers were then used in the McrBC assay. Separate pools of DNA for the
8 biological replicated from ad-libitum fed (AD) and undernourished (UN) rats were
digested by methylation sensitive restriction enzymes. The high frequency cutting
enzymes make it possible to assay a large proportion of CpG islands. The enzymes
used were: HpaII (cuts unmethylated alleles), McrBC (cuts methylated alleles), and
MspI (used as a negative control as it cuts independent of methylation). Digestions
of HpaII and McrBC give four possible results: full, null, incomplete, or composite
methylation. Before running the assay, the New England Biolabs NEBcutter tool
was used to confirm HpaII and MspI cutting sites. In addition, GC content was
confirmed by searching for the frequency of rare-cutter sites (NarI, NaeI, SacII, NotI,
BssHII, EagI, SmaI, MnlI, and MluI ). Products were separated by gel electrophore-
sis, and then the methylation status of the island was determined by the relative
band intensities. The findings and details of each gene are shown in table 5.1. In
addition, to the gene name and the chip the gene was found on, the table shows the
direction of the expression change, whether or not the gene has CpG islands, whether
or not primers were designed for methylation analysis, and whether a methylation
change was revealed by the McrBC assay. Finally, the promoter sequences of each
of the genes were analysed for possible transcription factor binding sites. The assay
succeeded for 18 genes and there was little or no apparent methylation difference
between the AD and UN samples. CpG islands were generally unmethylated in the
AD samples (61%). Of the 18 genes assayed, 5 were from the preliminary Illumina
expression analysis and their PCR results will not be included here. Figures 5.5 and
5.6 show the PCR images from the McrBC assay for the 13 genes that were shown as
differentially expressed in the MEEBO expression study or the Illumina expression
study (final list). Differential methylation was observed in 4 of the 18 successful as-
says (Mapk4, Tnfsf13, Zfand2a, and Atf4 ), all of which were demethylated. Two of
these genes were found as significantly differentially expressed in one of the microar-
190
ray platforms. Mapk4 was differentially expressed on the MEEBO chip, and Zfand2a
was differentially expressed in the final analysis of the Illumina data. The other two
genes (Tnfsf13 and Atf4 ) came from the preliminary Illumina analysis and are not
considered significant.
Gene Chip Exp. CpG Primers Initial Meth.
Symbol Change islands Designed Meth. Change
Aass M ↓ 0 N/A Unk N/A
Adamts1 I-FL ↑ 2 yes Not No Change
Adn I ↑ 0 N/A Unk Not Examined
Adra1b I-FL ↓ 1 yes Unk PCR fail
Amd1 I ↑ 2 yes Not No Change
Arhgef19 pred I-FL ↓ 3 yes Mixed No Change
Arl6ip2 pred I ↓ 1 no Unk Not Examined
Atf4 I ↑ 1 yes Mixed Demethylation (isl1)
Besh3 I-FL ↓ 1 no Unk N/A
Bhlhb2 I ↓ 1 no Unk Not Examined
C4-2 I ↑ 0 N/A Unk Not Examined
Calm3 I ↓ 1 no Unk Not Examined
Cbx3 M ↑ 0 N/A Unk N/A
Cdo1 I ↑ 1 no Unk Not Examined
Ces3 I ↑ 0 N/A Unk Not Examined
Cidea pred I-FL ↓ 1 yes Not No Change
Cited2 I ↓ 1+ no Unk Not Examined
Cpa1 I ↑ 0 N/A Unk Not Examined
Crlz1 pred I-FL ↑ 2 yes Not No Change
Csng M ↑ 0 N/A Unk N/A
Cyp2c40 I ↓ 0 N/A Unk N/A
Dhtkd1 pred I-FL ↓ 1 yes Not No Change
Dnajb9 I ↓ 1 no Unk Not Examined
Dnase1l3 I-FL ↑ 2 yes Unk PCR fail
Eef2k I ↓ 1+ no Unk Not Examined
Eif4g2 pred I ↓ 1 no Unk Not Examined
Fabp7 I-FL ↑ 0 N/A Unk N/A
Fcgr2b I-FL ↑ 0 N/A Unk N/A
Fxyd6 I-FL ↑ 0 N/A Unk Not Examined
Galnt11 I ↑ 1 yes Not No Change
Gng11 I-FL ↑ 1 N/A Unk N/A
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Gene Chip Exp. CpG Primers Initial Meth.
Symbol Change islands Designed Meth. Change
Gstp2 I-FL ↑ 1 yes Not No Change
Igfbp2 I-FL ↑ 1 yes Mixed No Change
isg12(b) I ↑ 1 no Unk Not Examined
LOC299823 I ↑ 0 N/A Unk Not Examined
LOC301711 I ↓ 0 N/A Unk Not Examined
LOC303576 I ↑ 0 N/A Unk Not Examined
LOC303861 I-FL ↓ 0 N/A Unk N/A
LOC314964 I ↓ 1 no Unk Not Examined
LOC361061 I ↑ 0 N/A Unk Not Examined
LOC363151 I-FL ↑ 1 yes Unk PCR fail
LOC365214 I ↓ 0 N/A Unk Not Examined
LOC366485 I ↑ 1+ no Unk Not Examined
LOC366941 I ↑ 0 N/A Unk Not Examined
LOC498731 I ↑ 0 N/A Unk Not Examined
LOC500322 I ↑ 1+ no Unk Not Examined
Magel2 M ↑ 0 N/A Unk N/A
Mapk4 M ↓ 2 yes Mixed Demethylation (isl2)
MGC105601 I-FL ↑ 0 N/A Unk N/A
MGC94010 I-FL ↑ 0 N/A Unk N/A
Mgst1 I ↑ 0 N/A Unk Not Examined
Mx1 I ↑ 0 N/A Unk Not Examined
Mybph I ↑ 0 N/A Unk Not Examined
Myl2 M ↓ 0 N/A Unk N/A
Npm1 I-FL ↓ 2 yes Not No Change
Olfr802 M ↑ 0 N/A Unk N/A
Paip1 pred I ↓ 1 no Unk Not Examined
Pck1 I ↑ 0 N/A Unk Not Examined
Pde4d I ↓ 1 no Unk Not Examined
Pdia5 M ↓ 0 N/A Unk N/A
Phka1 I ↓ 1 no Unk Not Examined
Plekhb1 I ↑ 0 N/A Unk Not Examined
Plvap I ↑ 1 no Unk Not Examined
Pmp22 I ↑ 0 N/A Unk Not Examined
Ppap2a I ↑ 0 N/A Unk Not Examined
Psip1 M ↓ 1 yes Unk PCR fail
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Gene Chip Exp. CpG Primers Initial Meth.
Symbol Change islands Designed Meth. Change
Ptprb pred I-FL ↑ 0 N/A Unk N/A
Rabepk M ↑ 1 yes Unk PCR fail
Rbp1 I-FL ↑ 1 yes Unk PCR fail
RGD1306512 pred I-FL ↓ 1 yes Unk PCR fail
RGD1308082 I-FL ↓ 1 yes Not No Change
Zfand2a I-FL ↑ 1 yes Mixed Demethylation
RGD1311155 pred I ↑ 0 N/A Unk N/A
Rpl10l pred I ↓ 1 yes Mixed No Change
Rpl23a pred I ↑ 1+ no Unk Not Examined
Sara2 I ↓ 1 no Unk Not Examined
Serpinb6 I-FL ↑ 1 yes Not No Change
Sgpl1 I-FL ↑ 0 N/A Unk N/A
Slfn3 I ↑ 0 N/A Unk Not Examined
Tceal8 I ↓ 0 N/A Unk Not Examined
Tcf15 pred I ↓ 1 no Unk Not Examined
Thbs4 I ↓ 0 N/A Unk Not Examined
Tmpo I ↓ 1 no Unk Not Examined
Tnfsf13 I ↑ 1 yes Mixed Demethylation
Ubl3 pred I ↓ 1 no Unk Not Examined
Usf2 M ↑ 1 yes Unk PCR fail
XM 978865 M ↓ 1 yes Not No Change
Table 5.1: Table of Methylation. This table shows the 87 genes that were chosen from
the microarray study presented in Chapter 3. The promoter regions of the genes were
characterised, CpG islands were identified, primers were designed and the McrBC as-
say was performed. This table shows the results of each process of the pipeline for
each gene including: the chip it was found on (MEEBO ‘M’ or Illumina ‘I’) and
whether it made it to the final Illumina gene list ‘I-FL’, the direction of expression
change found in microarray, the number of CpG islands, whether primers were de-
signed for CpG Islands, whether the McrBC assay was performed and successful and
if this assay showed a methylation change.
Bisulphite Sequencing
Additional work attempting to use bisulphite sequencing for methylation analysis
was attempted using these DNA samples. After multiple attempts, bisulphite conver-
sion was finally successful, but problems with sequencing caused the termination of
this avenue of investigation. Primers designed for these assays are listed in Appendix
A.
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Adamts1 isl1 AD Adamts1 isl1 UN Arhgef19 isl1
Arhgef19 isl2 Cidea
Crlz Isl1 Crlz Isl2
Dhtkd1 Gstp2 AD Gstp2 UN
Igfbp2 Mapk4 Isl2 AD* Mapk4 Isl2 UN*
Figure 5.5: PCR results for 8 of the 13 genes that were significantly differentially
expressed in the microarray study and were successfully assayed using McrBC. Some
genes were assayed twice for different CpG islands. Those that show a methylation
change due to the nutrition treatment in utero are indicated with an *.
5.3 Discussion
This chapter aimed to investigate the methylation status of genes that were found
to be differentially expressed in the livers of day 55 rats exposed to maternal under-
nourishment during gestation (as presented in Chapter 3). This study was conducted
by a part II student during the preliminary stages of the analysis of the Illumina
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Npm1 Isl1 Npm1 Isl2
RGD1308082 Zfand2a*
Serpinb6 XM_978865
Figure 5.6: PCR results for 5 of the 13 genes that were significantly differentially
expressed in the microarray study and were successfully assayed using McrBC. Some
genes were assayed twice for different CpG islands. Those that show a methylation
change due to the nutrition treatment in utero are indicated with an *.
BeadArray data set. For this reason, many of the genes that were assayed for this
chapter did not show up in the final microarray statistical analysis. Of the 87 genes
analysed, only 26 were in the final list of differentially expressed genes presented in
Chapter 3. Of these 26, only one showed a change in methylation. This gene was
Zfand2a. Another 12 included in the methylation analysis were genes found to be
differentially expressed on the MEEBO microarray platform. Of these 12, one showed
a methylation change in the McrBC assay. That gene was Mapk4. The discussion
below will elaborate more on the function of Zfand2a and Mapk4 and their potential
role in the metabolic syndrome. Due to the timing of this study, many genes that did
show up in the final microarray analysis were not assayed. Therefore, this chapter
does not represent a thorough analysis of the methylation status of the genes impli-
cated in Chapter 3, but is a preliminary study and a test of the McrBC assay and
bisulphite sequencing as methods for future use.
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5.3.1 Zfand2a
Zfand2a was found to be upregulated by 40% on the Illumina microarray. This is
an arsenite inducible RNA associated protein that adapts proteosomes to counteract
stress-induced proteotoxicity [117]. This transcript is located on chromosome 12.
The CpG island search revealed one island spanning the transcription start site.
Separation of PCR products on an agarose revealed the presence of bands in the
HpaII AD digests, absent in the corresponding HpaII UN position, see figure 5.6.
Given that HpaII cuts DNA at unmethylated positions, this indicates the presence of
some methylated CpGs in the AD pool, and thus, failed digestion, permitting PCR
amplification of the fragment. Absence of visible bands in the HpaII UN position
thus suggests an increase in the proportion of unmethylated CpGs. It would appear
that a subtle change in the direction of demethylation has taken place.
An analysis to characterise likely sites for transcription factor binding was per-
formed. The CpG island spans the transcription start site and four potential binding
sites were found (CREB, E2F, c-Ets, and TATA). It is proposed, these sites, playing
a role in the binding of the basal transcription machinery, may be responsible for me-
diating the repressive effects on transcription of generalised promoter methylation.
Results of transcription factor binding site analysis are shown in Appendix C Figure
1. Upregulation of Zfand2a may indicate an alteration in oxidative stress due to the
effects of undernutrition. Sequence similarity also suggests Zfand2a may be involved
in nucleic acid interactions.
5.3.2 Mapk4
Mitogen-Activated Protein Kinase 4 (Mapk4 ) is located on chromosome 18 and
gene ontology entries suggest a role in the regulation of cell cycle processes and thus,
this gene product may be important in producing long-term pathogenic phenotypes
implicated in the metabolic syndrome. The CpG island prediction software revealed
two CpG islands. Primers flanking the first island (the long transcript) failed to
amplify efficiently. However, in island 2, following separation of PCR products on an
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agarose gel (see figure 5.5), the McrBC UN band is more intense than the correspond-
ing AD band. As McrBC digests methylated sites, this change indicates decreased
methylation due potentially to undernutrition in utero. This decreased methylation
would suggest increased expression of (Mapk4 ); however, the Illumina gene expres-
sion assay highlighted it as being downregulated. This result is paradoxical and
further investigation is necessary to clarify what is going on. Computational anal-
ysis to show likely transcription factor binding sites within the CpG island showing
potential differential methylation were performed. The nucleotides in the promoter
sequence comprising the CpG island in the short transcript were selected and TF
binding site analysis was performed on the reverse complement. One possible tran-
scription factor binding site (CREB) was found in the CpG island that could be
affecting the expression of downstream genes. Bisulphite sequencing or protein as-
says would enable verification. Results of transcription factor binding site analysis
are shown in Appendix C Figure 1.
5.4 Summary
A number of studies have investigated the methylation status of genes associ-
ated with metabolism that have previously been highlighted as candidate genes for
the metabolic syndrome. Fujiki et al. found the promoter of the Pparγ2 gene is
hypermethylated in pre-adipocytes, then it is progressively demethylated, as the dif-
ferentiation into adipocytes progresses and as mRNA expression increases [180]. In
addition, they found decreased Pparγ mRNA and increased methylation of the Pparγ
promoter in the visceral adipose tissue of a diabetic mouse model compared to the
wild-type mice. This suggests the methylation of the promoter region of PPARγ
influences the expression of the downstream gene.
A study by Plagemann et al., investigated the effects of prenatal and neonatal
overfeeding on methylation patterns in hypothalamic promoter regions of genes in-
volved in the regulation of food intake and body weight [181]. The study found
nutritional intake affects the methylation pattern and as a result, the ‘set-point’ is
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altered in the gene promoter of genes involved in body weight regulation. This ties
in closely with the introduction to Chapter 4.
In this study, that majority of genes showed no change in methylation status. As
the sites tested were all upstream of a CpG island, the results are consistent with
studies that show CpG islands are largely unmethylated and methylation changes
tend to occur in intergenic regions [182]. In addition, work on Pdx1 has shown that
histone modifications precede methylation changes. Progressive histone modifications
accompanied the gradual decrease in Pdx1 expression [183]. The increased histone
modifications occur as glucose homeostasis deteriorates and oxidative stress increases.
This suggests that the expression changes could be the result of a cascade of events
and that testing for methylation changes would not necessarily reveal the mechanism
for decreased expression.
A more detailed epigenetic investigation into the methylation changes and histone
modifications occurring in the tissues from Chapter 4, in addition, to an expression
study of the hypothalamus of rats similarly undernourished during pregnancy, would
be interesting to tie together the interaction of brain and peripheral organs along
with the interaction of methylation, histone modification, and expression changes.
The work in this chapter barely scratched the surface of interesting avenues of
exploration in the understanding of the involvement of methylation in developmental
programming and the later occurrence of the metabolic syndrome. This chapter was
intended to be a preliminary study to see if interesting methylation differences could
be uncovered in the genes highlighted in the gene profiling study from Chapter 3. The
methylation work done revealed that most genes showed no change in methylation
status. There are three possible explanations for this result. First, the McrBC assay
is not as sensitive as a sequencing based approach and therefore by using this assay
subtle changes in methylation status may be overlooked. The assay is not sensitive
enough to detect methylation differences among cell types. Liver cells may show a
heterogeneous pattern of methylation between cell types which would have been lost
when RNA was extracted. Second, this thesis has been investigating gene expression
profiles as a consequence of the change in maternal diet during pregnancy. The
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changes we may be observing could be due to a secondary change, which are a result
of methylation changes in upstream primary regulators. Third, we are looking at
animals that are 55 days old. While the majority of epigenetic modifications occur
early in life it is possible that a key change has occurred in a window after day
55. Subsequent studies should investigate methylation changes at a variety of time
points. It would also be beneficial to use another methylation technique to interrogate
more genes highlighted due to their gene expression profile or alternatively a genome-
wide methylation approach could be taken. A genome-wide approach might highlight
methylation changes in genes upstream of the genes found in this thesis, revealing a
cascade of changes in the affected pathways.
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Chapter 6
microRNA Expression Study
6.1 Introduction
The work presented in this chapter aimed to investigate the role of miRNAs in
gene expression regulation as a consequence of maternal undernutrition in the rat
model (see Chapter 3). We investigated miRNA expression changes in the liver
samples of 55 day old offspring of mothers that had been on a restricted diet or an
ad-libitum diet during pregnancy. This chapter begins with a review of microRNA
biogenesis and function. This background information is followed by a description of
experimental design, data quality and a presentation and discussion of the results.
6.1.1 microRNA
MicroRNAs (miRNAs) are small (18-25 nucleotide) noncoding RNAs that reg-
ulate gene expression in plants and animals by targeting mRNAs for cleavage or
translational repression. Recent studies have shown that miRNA regulation involves
a complex system of positive and negative post-transcriptional control that is only
just now being unravelled [184]. The miRNA target region (seed sequence) is located
at the 5’ end from bases 2 to 8. This region is important in identifying miRNAs. Com-
plex computational algorithms have been designed to predict miRNAs by looking for
these seed sequences. These algorithms predict that each miRNA can potentially
bind to 200 targets and estimate that miRNAs control the expression of one-third
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of human mRNAs. The official miRNA database (miRBase) currently lists over 600
human miRNAs [185]; however, computational prediction estimates there could be
over 1,000 [186]. Overall, miRNAs control the expression of hundreds or possibly
thousands of genes in a given cell type; therefore, they are likely to influence nearly
every genetic pathway [184]. Given this, it is not surprising that microRNA gene reg-
ulation has been shown to play a role in many biological functions including human
development, cellular differentiation, adaptation to environment, oncogenesis, host
cell interactions with pathogens, and has also been linked to human diseases such as
cancer, metabolic syndrome and aging [187, 184]. In addition, because of its tissue
specificity miRNAs are a potential target as biomarkers for human disease.
miRNA Biogenesis
The complex process of miRNA biogenesis in the human cell is shown in figure 6.1.
miRNA biogenesis involves two processing steps: the first takes place in the nucleus
and the next in the cytoplasm, where the final mature, single stranded miRNA is
produced. miRNA genes can be found in intergenic regions and in exons or introns
of other genes. These miRNA genes are transcribed by both RNA polymerase II
(most often) and III (occasionally) into primary transcripts (pri-miRNAs that are
100-1000s of nucleotides long) [188]. These pri-miRNAs contain Cap structures and
poly(A)-tails and can encode sequences for multiple miRNA genes. Two RNA type-
III endonucleases (Drosha and Dicer) coordinate the maturation of the miRNAs.
Drosha initiates the processing of the pri-miRNA by cleaving it at the stem loop.
It is then called pre-miRNA, and it is transported to the cytoplasm by Exportin-
5/Ran-GTP complex. There it is processed by Dicer into the short (≈22 nucleotide)
mature miRNA duplexes. These miRNA duplexes are then incorporated into the
miRNA-induced silencing complex (miRISC, also known as the miRNP complex),
where one strand is eliminated and one remains in the complex. There are occasions
where both sides of the miRNA-miRNA duplex are retained and associate with the
miRISC to target distinct subsets of mRNA for down-regulation [184]. miRNAs then
affect gene expression by annealing to the 3’-UTR (untranslated region) of target
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genes and cause mRNA degradation or repression of translation [189]. According to
the genomic region where a miRNA resides, miRNAs can be grouped into several
categories: intronic miRNAs in protein-coding genes; exonic miRNAs in non-coding
genes; intronic miRNAs in non-coding genes.
The Complexity of miRNA Transcription
Little detail is known on exactly how miRNAs are transcribed and what promoter
elements regulate their transcription. A few regulatory factors have been identified
that bind directly to miRNA promoter elements and control their expression. Specifi-
cally, the oncogene C-myc and the tumour-suppressor gene p53 are capable of positive
and negative control of miRNA transcription. In addition, subsets of miRNA genes
reside within CpG islands and are under epigenetic control. Transcription of miRNAs
miR-148a, miR-34b/c and let-7a-3 are dependent on their methylation status [184].
Recent studies estimate that 5-10% of mammalian miRNAs are epigenetically regu-
lated. In a study by Brueckner et al. [190], the let-7a-3 loci was hypomethylated in a
subset of patients with lung adenocarcinoma compared to patients with normal lung
tissue, suggesting that a lack of epigenetic control could contribute to the progres-
sion of cancer. Another layer of complexity is added with recent work indicating the
bidirectional transcription of miRNA genes. Drosophila mir-307 and the mammalian
mir-338 genes are both transcribed in the sense and anti-sense directions.
miRNAs and Methylation
In plants, small interfering RNAs have been known to direct methylation as a
mechanism of transcriptional control. Recent studies have provided evidence that
RNA-directed DNA methylation in mammals may also occur [191]. siRNAs and
miRNAs are considered to be closely related and many of the enzymes involved in
the RNA interference pathway (RNAi) are also processing pathways of siRNAs and
miRNAs[165]. Recent evidence also suggests that they affect histone modifications
[192]. Given that siRNAs and miRNAs are considered closely related miRNAs could
also be involved in controlling DNA methylation and histone modifications. A re-
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Figure 6.1: miRNA biogenesis. miRNAs are transcribed by polymerase II or poly-
merase III to primary transcripts (pri-miRNA). Two RNA type-III endonucleases,
Drosha and DGCR8, process pri-miRNA by cutting it at the bottom of its stem loop.
It is then exported, as pre-miRNA, to the cytoplasm by export factor-5 (exportin-5).
The pre-miRNA is then processed by Dicer to generate an approximately 22 nu-
cleotide long miRNA duplex. One strand of the now mature miRNA is then perma-
nently incorporated into the RNA-induced silencing complex (RINC) and will bind
to the 3’-UTR of a target mRNA. This can lead to silencing of the transcript via
mRNA degradation or translational repression. This figure has been adapted from
Poy et al. [189]
.
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cent study showed that miR-165 and miR-166 were required for the methylation of
the PHABULOSA (PHB) gene in Arabidopsis. These two miRNAs react with the
newly processed PHB gene to change chromatin of the gene’s template [193]. These
results present the mechanism that would allow miRNAs to control gene expression
in addition to the RNAi pathway. Similar findings in mammalian cells have yet to
be shown. MiRNAs may also regulate chromatin structure by regulating key histone
modifiers. A study in mice has shown that miR-140 can target histone deacetylase
4 [194]. There is still a lot to understand about miRNAs and their role in gene ex-
pression. The mounting evidence points to miRNAs as key players in the epigenetic
control of gene expression and it is worth investigating whether this is a mechanism
involved in the programming of the metabolic syndrome.
microRNAs in the Metabolic Syndrome
MicroRNAs have important regulatory roles in a variety of biological processes
including several related to metabolic processes including adipocyte differentiation,
metabolic integration, insulin resistance and appetite regulation. These are high-
lighted in figure 6.2 [185]. A role in energy metabolism was first shown in a drosophila
study that implicated miR-14 in fat metabolism. Subsequently, miRNAs have been
shown to have functional roles in all organs directly related to the metabolism of glu-
cose (pancreatic islet, liver, skeletal muscle, adipose tissue, and brain). All of these
tissues have a unique miRNA expression pattern; therefore, miRNA may contribute
to specific tissue functions by regulating a set of unique target genes [189]. The
liver miRNA expression profile is dominated by a single sequence, miR-122. This
miRNA has been implicated in cholesterol and lipid metabolism, and in hepatitis C
virus replication. This miRNA is expressed in human and rodent liver tissue with
estimates of 50,000-80,000 copies per cell [195]. Recent findings have identified miR-
NAs as having a principal role in the production and secretion of insulin [185, 189].
miR-375 is specific to pancreatic islet cells and has been shown to play a key role in
blood glucose homeostasis through its regulation of β-cell function. miR-124a, let-7b
and miR-30d are also found in pancreatic islet cells. The two former are important
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Figure 6.2: This figures summarises the known roles of particular miRNAs in specific
metabolically related tissues (brain, liver, muscle, adipocyte, and pancreatic islet).
This figure was adapted from Heneghan et al. [185].
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ribo-regulators of blood glucose and the latter has been shown to influence insulin
transcription [185]. In addition, a number of miRNAs (including miR-103, miR-143,
and miR-132) have been found in adipose tissue that are involved in adipocyte differ-
entiation, proliferation and growth, and insulin resistance [185]. Studies in Drosophila
flies have revealed two miRNAs (miR-14 and miR-278) that regulate lipid metabolism
in body fat [185] and another (miR-1) is essential for proper muscle function [195].
miRNAs as Biomarkers
miRNA offers the opportunity to locate unique biomarkers of metabolic health
and disease because of its tissue specific expression and association with clinicopatho-
logic variables. The recent discovery of their presence in circulation makes them a
potentially non-invasive biomarker option. Reasons for their release into circulation
need to be investigated thoroughly, in addition to their exact roles in gene expression.
However, they would be an excellent tool for diagnosing metabolic syndrome [185].
6.1.2 Study Design
In this study, the same samples were used as in Chapter 3. These samples in-
cluded eight biological replicates from the AD nutritional group and eight biological
replicates from the UN nutritional group. The samples are rat samples, but due to
the unavailability of rat miRNA expression arrays the samples were cross-hybridised
to mouse arrays. The Illumina miRNA Profiling Assay is similar to the BeadArray in
that there are 12 arrays on each chip, and 2 chips were used for this study. Each array
incorporates the mouse microRNA panel which contains 419 sequences. As miRNAs
are conserved between species it was reasonable to use the mouse array to interro-
gate rat RNA samples. The experimental design is the same as that illustrated in
figure 3.14. Some samples were run a second time to try and achieve a better quality
hybridisations.
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6.2 Results
Total RNA was extracted from the rat livers using a protocol to ensure that small
RNAs were not filtered out (see Chapter 2). Eight biological replicates for each of
the two treatment groups (AD and UN) were hybridised to the Illumina MicroRNA
Profiling Assay using the Mouse microRNA Panel. Amplifications and hybridisations
were randomised and were performed by Kerry Cline at Cambridge Genomic Services
in the Department of Pathology. Cross hybridisations of rat samples to mouse chips
resulted in the detection of an average of 64% of the features across all arrays. This
result was not as good as anticipated, but was reproducible when samples were re-
hybridised. Samples 4.0, 101.0, 106.0, and 102.1 were re-amplified and hybridised
a second time due to initially questionable quality control results (these repeated
sample are called 4.0.2, 101.0.2, 106.0.2, and 102.1.0). The second hybridisations for
each of these samples were remarkably consistent (as seen most clearly in the MA
plots). Ultimately only 4.0 and 4.0.2 were removed as outliers for the final differential
expression analysis. This resulted in a total of 18 arrays in the analysis.
6.2.1 Data Quality Control
The Illumina system incorporates a number of internal controls for estimating
hybridisation quality. Figure 6.3 shows the details of the eight graphs for the inter-
nal controls across all 20 arrays. The results of the quality control assessment are
not as good as recommended by Illumina, but this is most likely due to the cross-
hybridisation of rat RNA to a mouse array. Figure 6.3A shows the data for the
negative controls. The background and noise signals should be low. This data shows
values less than 700 for the noise, which is slightly higher than ideal. Figure 6.3B
shows the PAP controls comparing the housekeeping genes with all miRNA expres-
sion. The housekeeping genes should be much higher than the other genes as they
are always expressed. Here the values are quite similar with large error bars. Figure
6.3C compares the mismatches versus the perfect matches. As expected the perfect
matches are greater than mismatches. Figure 6.3D is a contamination control. The
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positive represents the high signals and the negative represents background. Figure
6.3E shows the overall miRNA intensity. Figure 6.3F shows the high, medium and
low annealing controls. Figure 6.3G shows the perfect match versus mismatch ex-
tension controls. Figure 6.3H shows the hybridisation controls, the expression levels
should be high. Some of the controls (particularly the PAP controls) gave less than
ideal results, but overall the quality is acceptable. In addition to the Illumina Inter-
nal Controls, an R library, arrayQualityMetrics [196], was used to assess the quality
of the data before and after normalisation. This programme produces a quality con-
trol report and a number of figures for data visualisation (MA plots, density plots,
boxplots, and a heatmap). The report includes information on which samples appear
to be outliers. The different metrics the program utilises are meant to assess indi-
vidual array quality (MA plot), homogeneity between arrays (density and boxplots),
between array comparison (heatmap) and variance mean dependency (plot of stan-
dard deviation versus rank of the mean). The images from this analysis are shown in
figures 6.4-6.11. A visual inspection of these images shows that sample 4.0 and 4.0.2
appear to be outliers. The array quality metrics program marked sample 4.0 as an
outlier in two metrics (heatmap and MA plot).
6.2.2 Normalisation
Following the quality control assessment, this data was normalised in much the
same way as the mRNA expression data in Chapter 3. The data was filtered for genes
present on at least one array. Data was then transformed with a variance stabilising
transformation and normalised with a quantile normalisation (as described in Chapter
2). This was all done using the Lumi library in R. The arrayQualityMetrics library
in R was also used post-normalisation to assess the quality of the data. At this
stage, the programme suggested the removal of one outlier (sample AD 4.0). This
sample failed in all three of the programmes metrics. Sample 4.0.2 failed in 2 out of 3
metrics (MA plot and heatmap) and samples 106.1 and 102.0 failed in 1 out of 3 of the
metrics (boxplot/density plot). Due to this assessment and the visual inspection of all
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Figure 6.3: Illumina BeadStudio Internal Controls. This figure shows the inter-
nal quality control tools for the Illumina platform. (A)Negative Controls. Arrays
should have low expression values for the negative controls (background and noise).
(B)PAP Controls. This represents the housekeeping genes and miRNA and expression
values should be positive. (C)Internal Single Mismatch Controls. Perfect matches
should be greater than mismatches. (D)Contamination Controls. Positive = High
Signal; Negative=Background (E)miRNA Intensity. The expression should be higher
than background. (F)Annealing Controls. The Higher Tm MSO > Lower Tm MSO
(G)Extension Controls. Perfect Match < Mismatch (H)Array Hybridization Con-
trols. Expression levels should be high.
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Figure 6.4: Hierarchical Clustering of Raw miRNA Data. This plot shows the hi-
erarchical clustering of the raw miRNA data. The AD and UN samples have not
separated clearly, which is likely to be due to the high level of variation between
replicates. The two samples 4.0 and 4.0.2 which cluster far away from the rest were
determined to be outliers and were removed from the final analysis.
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Figure 6.5: MA Plot of Raw miRNA Data. This plot shows MA plots for eight of the
samples before normalisation. MA is defined as M = log2I1 − log2I2; A=12(log2I1 +
log2I2). The mass of the distribution is expected to be concentrated along the M=0
axis, and there should be no trend in the mean of M as a function of A. You can see
that the majority of data is concentrated at the lower end of the A scale, which is
expected as smaller expression values are more common.
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Figure 6.6: MA Plot of Raw miRNA Data. This plot shows MA plots for eight of the
samples before normalisation. MA is defined as M = log2I1 − log2I2; A=12(log2I1 +
log2I2). The mass of the distribution is expected to be concentrated along the M=0
axis, and there should be no trend in the mean of M as a function of A. You can see
that the majority of data is concentrated at the lower end of the A scale, which is
expected as smaller expression values are more common.
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Figure 6.7: MA Plot of Raw Re-done miRNA Data. This plot shows MA plots for
four samples before normalisation that were re-amplified and re-hybridised. MA is
defined as M = log2I1− log2I2; A=12(log2I1 + log2I2). The mass of the distribution is
expected to be concentrated along the M=0 axis, and there should be no trend in the
mean of M as a function of A. You can see that the majority of data is concentrated
at the lower end of the A scale, which is expected as smaller expression values are
more common.
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Figure 6.8: Boxplot of Raw miRNA Data. This figure presents boxplots of the
log2(Intensities). Each box represents one array. Differences in box size and y position
indicate increased variation between arrays.
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Figure 6.9: Density Plot of Raw miRNA Data. This graph presents density estimates
(histograms) of the data. Each line represents a separate array. Lines that are very
different to the others should be investigated as outliers.
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Figure 6.10: Heatmap of Raw miRNA Data. This heatmap shows the distance be-
tween arrays based on hierarchical clustering. This plot can help to detect outlier
arrays.
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Figure 6.11: Mean SD of Raw miRNA Data. This plot shows the empirical standard
deviation of the intensities for each feature of all the arrays on the y-axis versus the
rank of the mean of intensities of the arrays on the x-axis. The red dots, connected by
lines, show the running median of the standard deviation. After VSN normalisation,
this should be approximately horizontal. There should be no substantial trend.
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plots samples 4.0 and 4.0.2 were removed from the analysis. Data was re-normalised
with data for the remaining 18 arrays before proceeding to the differential expression
analysis. Figures 6.12-6.16 show the normalised data. The Limma library in R was
used for pairwise comparison using a linear model to compute p-values and produce
a gene list. An FDR adjustment was computed and miRNA genes with a p-value <
0.05 were selected as statistically significant for further investigation.
6.2.3 Differential Expression
This study aimed to highlight miRNA that might be involved in the development
of the metabolic syndrome due to changes in nutrition during gestation. The results;
however, revealed no miRNAs that were significantly differentially expressed across
all eight biological replicates. Due to the cross hybridisation of rat RNA onto a
mouse miRNA array, only 64 % of the features were detected. Closer inspection of
the data revealed a significant amount of variation among these biological replicates.
In an effort to look at the data in more detail, two approaches to data analysis were
taken. The first involved a manual/candidate gene approach to look for the genes
implicated in pathways involved in the metabolic syndrome and determine if any of
them had potentially interesting expression profiles. The candidate miRNAs that
are used in this analysis were mentioned in the introduction to this chapter as being
metabolically relevant. Unfortunately, none of the miRNAs that were highlighted in
the literature had an interesting expression profile in this study. Overall, they all have
very small fold changes and very high p-values. As the candidate gene method did
not pull out any interesting results, a second method for analysing the data involved
filtering the data for those that were detected in at least 14 of the 18 samples. This
reduced the list from miRNAs to 213. Further filtering involved taking the p-value
before the FDR adjustment and selecting the samples with a p-value < 0.05. This
produced a filtered list of 44 miRNAs. Two of these miRNAs, mir-335-5p and 451,
have a two-fold change of increased expression. All 44 miRNAs are listed in table
6.1.
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Figure 6.12: Pairwise Comparison of AD Liver miRNA Samples After Normalisation.
This plot compares all seven AD liver biological replicates against each other after
normalisation and removal of outliers. These replicates should be very similar and
should be tightly distributed on the x=y axis, as these samples are. The correlation
for all comparisons ≥ 0.90.
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Figure 6.13: Pairwise Comparison of UN Liver miRNA Samples After Normalisation.
This plot compares all ten UN liver biological replicates and technical replicates
against each other after normalisation and removal of outliers. These replicates should
be very similar and should be tightly distributed on the x=y axis, as these samples
are. The correlation for all comparisons ≥ 0.93.
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Figure 6.14: Boxplot After Quantile Normalisation. This is a boxplot of the data
from each array. The plot compares the amplitude of all expression values on each
array. This shows that the majority of the signal is at lower expression levels. This
plot shows that there is no variability between the arrays. The normalisation has
effectively adjusted the expression values to remove the variability. This analysis was
done in Lumi.
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Figure 6.15: Density Plot Histogram of Density of Log2 Intensities for AD miRNA
Arrays After Quantile Normalisation. This is a histogram of each array showing the
density of intensities (log2). This plot shows that the majority of intensity values are
low and that there is no variation between samples. The normalisation has effectively
adjusted the expression values to remove the variability. This analysis was done in
Lumi.
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Figure 6.16: Density Plot Histogram of Density of Log2 Intensities for UN miRNA
Arrays After Quantile Normalisation. This is a histogram of each array showing the
density of intensities (log2). This plot shows that the majority of intensity values are
low and that there is no variation between samples. The normalisation has effectively
adjusted the expression values to remove the variability. This analysis was done in
Lumi.
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TargetID logFC P-Value Detect
mmu-miR-335-5p 0.97 0.00 18
mmu-miR-451 0.91 0.00 18
mmu-miR-203 0.66 0.00 18
mmu-miR-499 0.65 0.01 18
mmu-miR-200a 0.56 0.04 18
mmu-miR-194 0.55 0.01 18
mmu-miR-126-5p 0.53 0.03 18
mmu-miR-29c 0.52 0.00 18
mmu-miR-16 0.51 0.01 18
mmu-miR-223 0.50 0.03 18
mmu-miR-100 0.42 0.02 18
mmu-miR-182 0.42 0.03 14
mmu-miR-20a 0.40 0.01 18
mmu-miR-130a 0.40 0.03 18
mmu-miR101b:9.1 0.40 0.01 18
mmu-miR-30b 0.40 0.03 18
mmu-miR-7a 0.38 0.03 18
mmu-miR-142-5p 0.37 0.02 18
mmu-miR-26a 0.35 0.01 18
mmu-miR-350 0.32 0.03 18
mmu-miR-546 0.31 0.04 18
mmu-miR-450a-5p 0.30 0.03 18
mmu-miR-146a 0.27 0.05 18
mmu-miR-540-3p 0.27 0.05 14
mmu-miR-22 0.26 0.02 18
mmu-miR-190b 0.21 0.00 15
mmu-miR-293 0.20 0.00 15
mmu-miR-26b 0.20 0.01 18
mmu-let-7g 0.17 0.02 18
mmu-let-7c -0.14 0.04 18
mmu-miR-693-5p -0.15 0.01 18
mmu-miR-469 -0.24 0.03 18
mmu-miR-23a -0.30 0.02 18
mmu-miR-150 -0.32 0.01 18
mmu-miR-682 -0.33 0.04 18
mmu-let-7d* -0.41 0.05 18
1=1
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TargetID logFC P-Value Detect
mmu-let-7e -0.42 0.02 18
mmu-miR-669c -0.42 0.02 18
mmu-miR-381 -0.44 0.02 18
mmu-miR-92a -0.48 0.01 18
mmu-miR-18a -0.54 0.01 18
mmu-miR-326 -0.57 0.03 18
mmu-miR-207 -0.64 0.02 18
solexa-103-3961 -0.77 0.01 18
Table 6.1: Table of miRNA Results. This table shows the 44 miRNAs that had a
p-value < 0.05 and were detected in 14/18 arrays.
6.3 Discussion
This chapter aimed to highlight miRNAs that have been significantly differentially
expressed in the livers of male day 55 rats that were exposed to maternal undernutri-
tion during gestation. The study involved the cross hybridisation of rat samples to
a mouse array that resulted in the hybridisation of 64% of the features. In this type
of experiment, a multiple testing correction is recommended to eliminate a majority
of potential false positives. However, in this study the multiple testing correction re-
sulted in no significantly, differentially expressed genes. Therefore, out of interest, a
less stringent analysis was done by removing the multiple testing correction, but still
ensuring the feature was detected in at least 14/18 arrays. This analysis revealed 44
miRNAs with a p-value < 0.05. This represents 10% of the total number of features
on the array, which is less than would be expected by chance. The fact that only
two of these showed a nearly 2-fold upregulation in the UN livers (miR-335-5p and
miR-451) and both were found to be either directly or indirectly associated with the
metabolic syndrome in very recent literature makes further investigation into their
involvement worthwhile. In addition, miR-let-7e was shown by Ingenuity Pathways
Analysis to target Mapk4, which was highlighted as being down regulated in Chapter
4 and demethylated in Chapter 5. These results are not consistent and follow up
studies are important to elucidate exactly what s going on.
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6.3.1 miR-335 Implicated in Lipid Metabolism
A literature search revealed that miR-335 has been associated with lipid metabolism
in the livers of genetically obese mice [197]. Nakanishi et al. conducted a study using
63 day old male ob/ob (leptin deficient) mice, db/db (leptin-receptor deficient) mice,
and KKAy (lethal agouti gene) mice. They used a miRNA microarray similar to the
one used here but on a different platform (HOKKADO System) to compare db/db
mice to wild-type (WT). They found miR-335 to be significantly increased in the
db/db mice. They used real-time PCR to check the expression levels of miR-335 in
multiple tissues in WT mice and found high expression in brain, lung, heart, and
white adipose tissue (WAT). This figure is shown in figure 6.17. They then used real-
time PCR to check the liver expression levels in ob/ob, db/db, and KKAy mice. All
of these mice had significantly elevated body weight, liver weight, hepatic triglyceride
concentration, and hepatic cholesterol concentration compared to the WT. The PCR
revealed significant increase of liver miR-335 in the three obesity/diabetic mouse
models. These results are shown in figure6.18. The authors also investigated miR335
expression in white adipose tissue and miR-335 involvement in adipose differentiation
and hypothesised that miR-335 may have a role in regulating lipid metabolism. Li
et al. [198] also found miR-335 to be upregulated (4-fold) in ob/ob mice compared
to WT on another miRNA microarray platform (CapitalBio Mammalian miRNA Ar-
ray). This study used male and female ≈ 90 day old mice. Another study using a
human breast cancer cell line implicated miR-335 as a metastasis suppressor due to
significant down regulation [199]. This publication revealed that miR-335 suppresses
metastasis and migration through targeting of Sox4, the progenitor cell transcription
factor and tenascin C, extracellular matrix component. How exactly miRNA-335
functions in the metabolic syndrome is yet to be determined.
miR-335 Gene Homology to Mest
A more thorough investigation into miR-335 revealed significant homology to
two transcripts. One is involved in the inner ear and the other, Mest (also Peg1
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or Zpeg1), has been linked to fat storage. Mest (mesoderm-specific transcript) is a
paternally expressed imprinted transcript that is important during development. It is
a member of the α/β fold hydrolase superfamily (along with lipases, acyltransferases,
and esterases) [200] and is localised in the endoplasmic reticulum. A microarray
study by Takahashi et al. [201] found that Mest is significantly expressed in the white-
adipose tissue of obese mice. Additional experiments revealed that the expression was
related to adipocyte size rather than diabetes or increased body weight. These results
suggest that Mest is involved in the formation of adipose tissue and the determination
of adipose cell size. Later work by Nikonova et al. [202], has led to the hypothesis
that MEST controls developmental adipose tissue expansion at the onset of a positive
energy balance by regulating adipocyte hypertrophy. The work showed that adipose
tissue expansion always accompanies increased Mest expression, but increased Mest
expression is not always associated with increased fat in the diet. This suggests that
Mest is not triggered by the diet itself, but rather other cues that indicate the need
for increased lipid storage. A more detailed investigation into the control of Mest in
relation to miR-335 and the combined effects on the metabolic syndrome may offer
more insight into the mechanisms of the metabolic syndrome
6.3.2 miR-451 Expression in Human Cancer Cells and Pos-
sible Association with Adipocyte Differentiation
Zhu et al. [203] conducted an miRNA expression study using multidrug resistant
human cancer cell lines and found that miR-451 along with miR-27a were found to
be upregulated in the human ovarian cancer cell line and the cervix carcinoma cell
line compared to the respective parental cell lines. These miRNAs were shown to be
involved in activating the expression of P-glycoprotein, the MDR1 gene that has been
implicated in cancer cell resistance to a broad range of chemotherapeutics. Zhu et al.
hypothesised that miR-27a and miR-451 may be potential targets for a therapeutic
strategy to control multidrug resistance in cancer cells. In a very recent publication
by Sang Yun Kim et al. [204], miR-27a was shown to be a negative regulator of
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Figure 6.17: This figure was adapted from Nakanishi et al. [197] and shows the
expression of miRNA-335 in a variety of tissues in WT mice. This shows that highest
expression was observed in brain, lung, heart, and white adipose tissue (WAT).
Figure 6.18: This figure was adapted from Nakanishi et al. [197] and shows the
expression of miRNA in the livers of ob/ob (leptin deficient), db/db (leptin-receptor
deficient), and KKAy (lethal agouti gene) mice compared to the WT. * = p-value
<0.05; ** = p-value<0.01
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adipocyte differentiation by suppressing PPARγ expression. This study compared
expression of miRNAs in white adipose tissue of obese mice and lean mice. miR-27a
was downregulated in obese mice suggesting it might play a role in the suppression
of adipocyte differentiation through the control of PPARγ. As miR-27a was shown
to have a similar expression profile as miR-451 in human cancer cell lines, it would
be interesting to investigate whether it also plays a role in adipocyte differentiation
in white adipose tissue.
6.4 Summary
This study aimed to investigate the role of miRNA in metabolic syndrome by
comparing the expression profiles of livers of day 55 male rats exposed to maternal
undernutrition during gestation to those whose mothers had been fed normally. Two
of these miRNAs (miR-335 and miR-451) were up regulated by two-fold and were
found to be either directly or indirectly associated with the metabolic syndrome in
very recent literature. MiR-335 has been shown more than once, to be upregulated
in the livers of obese/diabetic mice. By association with miR-27a, miR-451 might be
involved in aspects of lipid metabolism in adipose tissue, but exactly what function
the upregulation found in this study might be associated with in the liver is unknown.
The next step in this investigation would be to use an alternative method to verify the
expression changes suggested by this miRNA study. Further work into the miRNA
expression in different tissues, at different time points would also be informative.
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Chapter 7
General Discussion and Future
Work
7.1 Conclusions
This thesis aimed to investigate the molecular mechanisms responsible for the de-
velopmental programming of the metabolic syndrome due to the exposure to maternal
nutritional insults. This was the first time that a global gene expression technique was
published in the DOHaD field [80]. Microarray technology was used to detect changes
in gene expression in target tissues, between offspring of control and undernourished
mothers, to obtain a broader picture of the cellular functions and genetic pathways
that may be implicated in the metabolic syndrome. Multiple studies have utilised
the candidate gene approach to look for gene expression changes and methylation dif-
ferences due to changes in maternal nutrition. However, a global approach makes it
possible to find novel genes that have not been implicated in the metabolic syndrome
previously. Preliminary analyses of methylation status and miRNA expression were
also performed in an effort to determine the mechanism of programming and the role
of miRNA in gene expression regulation, as related to the metabolic syndrome.
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7.1.1 Gene Expression Profiling Male 55 day old Rats Ex-
posed to Maternal Undernutrition in utero
The global gene expression approach was successful in revealing that at a young
age (day 55) and prior to the development of the metabolic syndrome phenotype,
the livers of male rats exposed to maternal undernutrition during gestation were al-
ready showing significant changes in metabolism compared to the control. The study
showed no differentially expressed genes in skeletal muscle and white adipose tissue,
which indicated the liver was being affected before changes in fat and muscle were oc-
curring. The hypothesis drawn from this was that the animals had been metabolically
programmed to favour fat as an energy source. This had resulted in mitochondrial
dysfunction, which initially affects hepatic function, but would potentially lead to
the development of the metabolic syndrome later in life. The phenotypic data was
compared to that of older male rats (day 110) that had developed the symptoms
of the metabolic syndrome. In a future study, an investigation into the expression
levels in the day 110 male rats would likely support this hypothesis and reveal more
information into the pathways being affected.
7.1.2 Gene Expression Profiling Female 170 day old Rats Ex-
posed to Maternal Undernutrition in utero, Postnatal
Leptin and postweaning High Fat Diet
In this thesis, a later time point (170 days) in female rats was investigated. Un-
fortunately, because of the difference in sex, a direct comparison could not be made
between the two studies; however, this second study involved a postnatal leptin treat-
ment and a postweaning high-fat diet. Phenotypic data from this study had indicated
that the postnatal leptin treatment resulted in a reversal of the metabolic syndrome
phenotype. Here, we aimed to find the molecular mechanism responsible for the re-
versal. Molecular evidence for a reversal of the developmental programming was not
revealed; however, it was clear that the interaction between treatments did result
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in significantly, differentially expressed genes. Intriguingly, the genes involved were
related to immune function, regulation of the circadian rhythm, and metabolism.
The interpretation was complex due to the interaction of the three treatments. A
follow up study would be useful to look into the highlighted genes in more detail,
and obtain a clearer picture of how the diet mismatch and the leptin treatment are
affecting the metabolism of these 170 day old female rats. In addition, a simplified
study design to observe immediate effects of leptin would help to separate the effects
of the post-natal diet.
7.1.3 Methylation Assay on Male 55 day old Rats Exposed
to Maternal Undernutrition in utero
In an effort to investigate the mechanism of fetal programming, a preliminary
study aimed to determine whether epigenetic mechanisms (specifically DNA methy-
lation) might be responsible for the observed transcriptional changes. This study was
conducted by a part II student during the preliminary stages of the analysis of the
Illumina BeadArray data set. For this reason, many of the genes that were anal-
ysed did not show up in the final analysis. Genes that were identified as significantly,
differentially expressed in the livers of 55 day old rats exposed to maternal undernour-
ishment during gestation were analysed to locate the promoter regions and to find
any nearby CpG islands. Primers were designed and methylation specific PCR was
used to look for methylation differences. Of the 87 genes analysed, only 26 were in the
final list of differentially expressed genes presented in Chapter 3. Of these 26, only
one showed a change in methylation. This gene was Zfand2a. Another 12 included
in the methylation analysis were genes that were found to be differentially expressed
on the MEEBO microarray platform. Of these 12, one showed a methylation change
in the McrBC assay. That gene was Mapk4. At least one potential transcription
factor binding site was found in the CpG islands of both of these genes. Further
investigation verifying the methylation differences and its effect on downstream gene
expression changes, would clarify the involvement in the metabolic syndrome. In
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addition, it would be of use to conduct a global methylation study on the day 55 or
day 170 samples or a similar study, to highlight methylation changes in other genes
that may be affecting the genes highlighted in this thesis, due to a cascade of events.
7.1.4 MiRNA Expression Profiling of Male 55 day old Rats
Exposed to Maternal Undernutrition in utero
The liver samples from this study were also used on a miRNA expression array to
highlight any miRNAs that might be involved in the differential regulation of gene
expression in the day 55 male offspring of undernourished mothers. Initially, this
study revealed no significant results. A closer look at the individual data points
revealed a large amount of variation between individuals that was over-shadowing
any potential differences between treatment groups. By using a less stringent sta-
tistical test (removing the multiple testing correction) and also, selecting for probes
that were detected on 14/18 arrays, 44 miRNAs were revealed as being differentially
expressed (p-value < 0.05). Two of these had a nearly 2-fold upregulation in the
UN livers. Both of these miRNAs were found to be either directly or indirectly as-
sociated with the metabolic syndrome in very recent literature. MiR-335 has been
shown, more than once to be upregulated in the livers of obese/diabetic mice and
has significant homology to a transcript that has been shown to be involved in lipid
storage (Mest). By association with miR-27a, miR-451 might be involved in aspects
of lipid metabolism in adipose tissue. However, the function of the miR-451 upreg-
ulation in the liver as found in this study is unknown. This data suggests, it would
be worthwhile to follow up on miR-335 and miR-451 to verify the expression changes
found in this study. In addition, if the variation between animals could be controlled,
a global miRNA study on a rat chip may reveal more candidate miRNAs that are
differentially expressed.
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7.2 Future Directions
These findings provide a number of interesting genes and pathways for further
studies and also highlight the need to conduct a thorough study in multiple tissues
at different time-points to pinpoint the window of developmental plasticity. Overall,
more investigation into the molecular mechanisms of the metabolic syndrome is nec-
essary to understand the pathways involved and to potentially reveal new treatments,
biomarkers, or preventive health advice. Studies designed to effectively highlight im-
portant developmental windows and studies in a variety of tissues (i.e. pancreas
and hypothalamus), in addition to those studied here, will also help to clarify our
understanding of the pathways involved.
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Appendix A
Primer Lists
Sequence Name Sequence 5′to3′
Tpi1 F Exp GCCCAGGAAGTACACGAGAA
Tpi1 R Exp CAGGCTACGCAGGAAGGTAG
Acad9 F Exp GGCCTCTCCAACACCATGTA
Acad9 R Exp GTGTTCCCCAGACGACAGTT
Slc37a4 F Exp GCTCCAGCAAAAATGAAAGC
Slc37a4 R Exp TGCAGCTAAACTACCCAGCA
GCK F Exp AGTATGACCGGATGGTGGAT
GCK R Exp CCGTGGAACAGAAGGTTCTC
HPRT F Exp CTCATGGACTGATTATGGACAGGAC
HPRT R Exp GCAGGTCAGCAAAGAACTTATAGCC
BETAACTIN F Exp GATTACTGCCCTGGCTCCTA
BETAACTIN R Exp TCATCGTACTCCTGCTTGCT
CA3 F Exp TTCTGAAGATAGGACGGGAG
CA3 R Exp ATGGGCTCTTTCAGTAGCAG
ORM1 F Exp TTTAACCTGACAGATGAGAACC
ORM1 R Exp GCACTTATCCTTTGTCCAGTC
PER2 exp F GATCCTGTACATCTCCAACCA
PER2 exp R CCTGAGTGAAAGAATCTAAGCC
Table A.1: Sequences of primers used for expression assays as described in chapter 3.
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Sequence Name Sequence 5′to3′
IGFBP2 exp F CCTCAAACAGTGCAAGATGTC
IGFBP2 exp R TGCTCGTTGTAGAAGAGATGG
IGFBP4 exp F CAGACCTCTGACAAGGATGAG
IGFBP4 exp R CCACAACCTTCATCTTGCTC
RT1-Ba exp F CTACCAACAAGGTTCCTGAG
RT1-Ba exp R TCGTTAGAAGGGATGAAGGTG
RT1-M6 2 exp F TTCTACCCTGCTGACATCAC
RT1-M6 2 exp R GTTGCTGGTTTCCATCTCAG
Ng22 exp F CACACTCCGTTATCACACTG
Ng22 exp R TGTAGGCATTACGGTTGAGG
RT1-149 exp F CTCCTTCATCCACTGATTCCA
RT1-149 exp R TGTCTTCATGCTTCACAATCTG
Table A.2: Sequences of primers used for expression assays as described in chapter 4.
Sequence Name Sequence 5′to3′
GR F EXP GGAGAATTATGACCACACTCAAC
GR R EXP GCAGTAGGTAAGGAGATTCTCAA
PPARa F EXP CTGGTCAAGCTCAGGACACA
PPARa R EXP AAACGGATTGCATTGTGTGA
PPARg F EXP TGCAGATTACAATGATGAC
PPARg R EXP TCGATATCACTGGAGATC
AOX F EXP CCAATCACGCAATAGTTCTGG
AOX R EXP CGCTGTATCGTATGGCGAT
11B-HSD2 F EXP TGGCCACTGTGTTGGATTT
11B-HSD2 R EXP ATCGGCCACTACCATGTTG
PPARa NEW F EXP CGGGTCATACTCGCAGGAAAG
PPARa NEW R EXP TGGCAGCAGTGGAAGAATCG
PEPCK F EXP AGCTGCATAATGGTCTGG
PEPCK R EXP GAACCTGGAGTTGAATGC
Cyclophilin F EXP TTCGGTCGCGTCTGCTTCGA
Cyclophilin R EXP GCCAGGACCTGTATGCTTCA
Table A.3: Sequences of primers used for expression assays as found in Lillycrop et
al. [82]. These assays are described in chapters 3 and 4.
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Sequence Name Sequence 5′to3′
Igfbp2 f m AGGGAGTGGTCTCCAAAAGG
Igfbp2 r m CCGCTGAGCTACGAGTTTCT
Serpinb6 f m GACTGAGTCGCCTTGTGGTC
Serpinb6 r m CAGGCACSCTGGACAAGAAA
LOC363151 f m CAGCCAACATGCAAACTGAG
LOC363151 r m CTCCTCCTCCAGCCTGACT
Gstp2 f m TGTTTTGTCCCCCAGAACTC
Gstp2 r m CCAAAAATGAACCCAGCACT
RGD1310991 f m TCAGCCTAGGCCAGAGATGT
RGD1310991 r m CAGCACTCCTGACCCTGTC
Adamts1 isl1 f m CACCGTCTGGAGGGTGAA
Adamts1 isl1 r m TTTCGGAGCTCTCAGTCTGC
Adamts1 isl2 f m CTGACCCCAAAGGGACTTCT
Adamts1 isl2 r m GGGCTCCAATGTGGCTATAA
Atf4 isl1 f m AACCTCTGGTGGCTCTTCC
Atf4 isl1 r m CAGGCTCTGCTGCCTCTAAT
Atf4 isl2 f m CATTTCTGCTTGCTCTGTGG
Atf4 isl2 r m TTGCACAAGATGGAGGCTTA
Galnt11 f m GACAACTCGGGCCTCACA
Galnt11 r m CTGGACCAACTACCAAACCTTC
Crlz1 isl1 f m TTCTCTGACCCCAGGACAAG
Crlz1 isl1 r m GGCTGAGACTAGCCTGGACA
Crlz1 isl2 f m CCGAGTGGAAGTTTGGTTGT
Crlz1 isl2 r m TGTTGGTGCTTGACCAATGT
Amd1 isl1 f m AAGCAGGCAAACCCTCCT
Amd1 isl1 r m CTTCGTACCATCCCAAGGTG
Amd1 isl2 f m ATTTTCCCGGCTATTTTCGT
Amd1 isl2 r m CTTCATCTGCAACCAAGCTG
Rbp1 f m TCTTTCTAGGCTGGGGAGGT
Rbp1 r m GCCCTCTAGTTGGCAGCA
Table A.4: Sequences of primers used for methylation assays described in chapter 5.
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Sequence Name Sequence 5′to3′
Tnfsf13 f m GACCACGACCAGCAGGAG
Tnfsf13 r m TGTGGGAGGGCTCAACATAC
Adra1b f m GACCAAGGCACCTCAGCTAC
Adra1b r m GGGTGTATGAACCCGGATG
Npm1 isl1 f m GGTAGGCCTCGCCTCACT
Npm1 isl1 r m ACTGACTGGAAGGGAGAGCTT
Npm1 isl2 f m TCCCTTCCAGTCAGTTACCG
Npm1 isl2 r m GCCTTCGAGCAAGTCAAATC
Cidea f m AGCCCCCAGAAGAGAAAAAC
Cidea r m AGGGGGACTATAGCCGTCTG
RGD1308082 f m GACCGACCGCAAAATAGAAA
RGD1308082 r m CTCACCCACTTCAGGGTCTC
Dhtkd1 f m CCATTCTTCCACGCGTCT
Dhtkd1 r m GAAGAGGCCCCTTTGGTC
Arhgef19 isl1 f m CATCTCCCATTTAGGGCTGA
Arhgef19 isl1 r m GTGCCTAGTGGGTCTTCCAC
Arhgef19 isl2 f m CATCCGAGACCCCTAAGTCA
Arhgef19 isl2 r m CCCGTGGAAAACTGGAGAC
Rpl10l f m TTTCTGCCAGCAAAGTCCTC
Rpl10l r m GTAGAGTGACCCGGAGGTTG
Usf2 isl1 f m CACCTTCCTGCAGCTCAAC
Usf2 isl1 r m CCCATGGACATGCTGGAC
Usf2 isl2 f m GCGCTGATTTTGGGACAA
Usf2 isl2 r m CCGAGGATCTGGGAAACAG
Rabepk f m TCCGCCACAGTCTTTTCTTC
Rabepk r m GGAGACCGAGCGAATTAGAA
Psip1 f m TCTTGGCGAAGATGAGGTCT
Psip1 r m AGCATCCCTGCCTCAGGT
Mapk4 isl1 f m AGCGGGCAGCTAGAGAAAA
Mapk4 isl1 r m ACGCAGGAGGTGCAGAAG
Table A.5: Sequences of primers used for methylation assays described in chapter 5
continued.
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Sequence Name Sequence 5′to3′
Mapk4 isl2 f m GGACAATATAAGCCACGCTGA
Mapk4 isl2 r m GACTGCATCGCCAGTGTCTA
XM 978865 f m AGCTGTGCTTGTAGGGGAAG
XM 978865 r m CAAGCACTCAGACCCCAGAT
Acad9 F Meth ACATTACATACAGCAATGCTTGG
Acad9 R Meth AAAGGTGGGAGCAGAGAACA
Tpi1 F Meth TGTCCCTAGGCCACCATCTA
Tpi1 R Meth TTGAAAAGGTGCCCTCAAAC
Slc37a4 F Meth GCAGGGAATATTTCTTTAGTTTTCTG
Slc37a4 R Meth GTAAGGCACCATGGCAAAAG
Table A.6: Sequences of primers used for methylation assays as described in chapter
5 continued.
Sequence Name Sequence 5′to3′
GR F METH CGTCTTGTTCCACCCACT
GR R METH CCTTGCAGTTGCCGACAG
PPARa F METH TGTGTCTCGTTCTGAACCG
PPARa R METH TCCACCCACCTCACTGTC
PPARg F METH CGACTGTGAGGAGCAAGG
PPARg R METH CCCAGGTCTCTTCTTCAG
Hexokinase F METH GAACCTGGACAGGTGTAGGAGAATC
Hexokinase R METH AGCACTAGTGTGTCCCACTGTCC
PPARg2 F METH GTCTCTGCTCTGGTAATTC
PPARg2 R METH AAGGCTTGTGGTCATTGAG
Table A.7: Sequences of primers designed for methylation assays as found in Lillycrop
et al. [82].
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Sequence Name Sequence 5′to3′
IGFBP2 F BISEQ TTGGTTTAGAAGGATTGAATTTTTT
IGFBP2 R BISEQ ACTTTACTCCCTTCAACCTAAAATC
ISL1 F BISEQ TGTTAGTTTTAGGAGATGTATTTTTTT
ISL1 R BISEQ AATTAAACAATTAATAAACAACCCACAA
EHMT2 F BISEQ GGGGGTAAAAATGTTTAAAAGGTT
EHMT2 R BISEQ ACAAACAACTAAAAAACCCAAAAC
MAPK4 F BISEQ GTGGAGTTTAGTTTTTTGGT
MAPK4 R BISEQ CTTTAAAAAAACCTCCAACCCTTAC
ATF4 F BISEQ TGGATTGATAGGATTGGATTAGGTA
ATF4 R BISEQ CTACCACAAAACAAACAAAAATAAC
TNFSF13 F BISEQ ATGTGTTTAGAAAGGGGTATGTTG
TNFSF13 R BISEQ TTCACTAACCCTCAAAAACCTTAAT
GCK1 F BISEQ GAATTTTATAGAAGAGTTTAGAATGTTTTGG
GCK1 R BISEQ CACACCTTATAATATCCATAACCATCTC
GCK2 F BISEQ GGGTGTTAGGGTAGTTAGAGGATTTG
GCK2 R BISEQ CCTAACTCCTAAAACCACCTATTAC
Crat biseq F TTTAGTAGGGAAATGAGTGTTGGTTT
Crat biseq R ATATCCAAATCTAACCAATATCCTTAAACA
Tpi biseq F TTAGTTATGTTTGTGAAATATTTGGGTT
Tpi biseq R AAACTCAAACATCCCACCTTAATAA
Table A.8: Sequences of primers designed for bisulphite sequencing assays as de-
scribed in chapter 5.
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Appendix B
Publications and Presentations
Publications
◦ T.J. Morris, M. Vickers, P. Gluckman, S. Gilmour and N. Affara (2009)
Transcriptional Profiling of Rats Subjected to Gestational Undernourishment: Impli-
cations for Developmental Variations in Metabolic Traits. PLoS ONE 4(9):e7271.
doi:10.1371/journal.pone.0007271
Presentations
◦ T. J. Morris, N. Affara, S. Gilmour, M. Vickers, and P. Gluckman.
Microarray Analysis to Investigate the Mechanisms of Metabolic Syndrome.
Poster presentation. 17th Annual International Conference on Intelligent Sys-
tems from Molecular Biology & 8th European Conference on Computational
Biology June 2009: Stockholm, Sweden.
◦ T. J. Morris, N. Affara, S. Gilmour, M. Vickers, and P. Gluckman.
A Global Approach to Epigenetic Change in an Undernourished Rat Model .
Poster presentation. 5th International Conference on Developmental Origins of
Health and Disease (Dohad) November 2007: Perth, Western Australia.
◦ T. J. Morris. A Gene Expression Study of Fetal Programming in Undernour-
ished Wistar Rats . Poster presentation. Sanger PhD Symposium April 2007:
Cambridge, UK.
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Appendix C
Supplementary Data
Supplementary Data including gene lists, tables, and trancription factor analysis
results as cited throughout this thesis are included on the accompanying DVD.
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